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S u m m a r y
The plasma disposition of albendazole, albendazole sulphoxide, 
and netob im in  were investiga ted  in goats fo llow ing  oral 
administration at the dose rate of 7.5 mg/kg. Netobimin and 
albendazole  were not detectable at any time following drug 
adm inistration. Plasma levels achieved by the anthelm intically 
active  m etabolite , albendazole sulphoxide (ABSO), were not 
s ignificantly  different following adm inistration of albendazole 
(AU C= 54.40 iig.h/ml; Cmax= 2.38 p.g/ml) and albendazole 
sulphoxide (AUC= 63.04 jag.h/ml; Cmax= 2.77 |ig/ml). Following 
administration of netobimin, thé AUC and Cmax for ABSO were 
29.76 fj.g.h/ml and 1,35 |ig/ml, respectively.
The effect of the m etabolic  inhib itor, p iperony l butoxide 
(adm inistered intramuscularly at 0.5 g/kg bodyweight), on the 
pharm acok ine tics  of albendazole (in sheep and goats) and 
fenbendazole (in goats) was studied. It was found that in sheep, 
pretreatm ent with piperonyl butoxide increased the area under 
the curve (AUC) and the mean residence time (MRT) of 
albendazole sulphoxide by 77% and 50%, respectively. The AUC 
and MRT of albendazole sulphone were also sign ifican tly  
increased with piperonyl butoxide pretreatm ent. In goats, the 
pharm acokinetic  param eters of ABSO were not significantly  
increased by piperonyl butoxide. Pretreatment of goats with the 
in h ib i to r  caused  more than th ree -fo ld  in c reases  in the 
b io a v a i la b i l i ty  o f fen b en d azo le  (FBZ) and fen b e n d az o le  
sulphoxide (FBSO).
The plasma disposition of piperonyl butoxide was determined in 
sheep and goats. Peak plasma concentrations were achieved 
between 10 and 15 hours. In sheep, the AUC and Cmax were 
132.96 |ig.h/ml and 2.92 p-g/ml, respectively. In goats, the AUC 
and Cmax am ounted  to 82.10 jig .h /m l and 1.17 jig/m l, 
re sp ec t iv e ly .
A pharm acokinetic  dose titration study was carried out with 
fenbendazole and piperonyl butoxide in sheep. Fenbendazole was
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given at a fixed dose (5 mg/kg) and piperonyl butoxide was 
administered orally at 0, 15, 31, 63, 125 and 250 mg/kg. The 
AUC of fenbendazole (FBZ) and fenbendazole sulphoxide (FBSO) 
increased significantly with dose rates of piperonyl butoxide 
equal to or higher than 31 mg/kg. Peak plasma concentrations 
(Cmax) and mean residence times (MRT) were also significantly 
increased  with the coadm in is tra tion  of fenbendazo le  and 
piperonyl butoxide.
Piperonyl butoxide given orally to two sheep was well absorbed 
resulting in an AUC of 761.2 }ig.h/ml (sheep 95) and 538.4 
Hg.h/ml (sheep96).
The efficacy of the combination fenbendazole-piperonyl butoxide 
(FBZ-PB) was assessed in sheep against benzimidazole-resistant 
O s te r t a g i a  c i r c u m c in c ta  and H a e m o n c h u s  contor tus .  T h e  
percentage reduction in the total number of O. c ircu m c in c ta  
worms was 7.90% (FBZ alone) and 97.8%  (FBZ-PB). For 
Haemonchus contortus,  the percentage reduction was 84.8% (FBZ 
alone) and 99.0% (FBZ-PB). Reduction in the faecal egg output, 7 
days after treatment was 93.7 % (FBZ alone) and 99.6 % (FBZ-PB). 
Piperonyl butoxide, given alone, had no effect against these two 
nematode species.
The in vitro  m e tab o lism  o f f e n b e n d a z o le ,  o x fe n d a z o le ,  
a lbendazole and triclabendazole was studied using microsomal 
preparations and cultured hepatocytes from rat liver. The extent 
of metabolism was found to be in the order triclabendazole > 
albendazole > fenbendazole and oxfendazole. Piperonyl butoxide 
inhibited the S-oxidation of all the benzimidazole drugs studied.
1-am inobenzotriazole inhibited significantly the metabolism  of 
triclabendazole in hepatocyte cultures.
The effect of the salicylanilide compound rafoxanide against 
im m ature  (4 w eek-old) stages of F a s c io l a  h e p a t i c a  was 
investigated in artificially infected sheep. Antipyrine clearance 
tests together with plasma glutamate dehydrogenase (GLDH) and 
gamma-glutamyl transferase (yGT) activities were used to follow 
the evolution of flukicidal therapy with rafoxanide. Glutamate
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but increased again at 12 weeks post-infection in the infected 
rafoxanide-treated sheep (group B). In the infected untreated 
sheep (group A), Antipyrine clearance decreased between 8 and 
14 weeks post-infection. In the infected treated sheep (group B), 
plasma clearance of antipyrine rem ained unchanged until 10 
weeks after rafoxanide treatment when it decreased from the 
pre-infection value of 5.09 to 3.90 ml/min.kg. Rafoxanide did not 
alter antipyrine disposition in uninfected sheep (group C).
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Chapter 1 
General  in troduct ion
The economic impact of parasitism is reflected in the capital invested for 
control and therapeutic measures. Every year, an estimated $ 1.7 billion 
worth of anthelm intics are administered to rum inants worldwide in 
order to minimise production losses caused by parasitic nematodes and 
trem atodes. It is not surprising, considering the large anthelm intic 
m arke t for l ives tock  that the m ost im portan t  advance  in the 
chem otherapy  of helm inthiasis, has come from the anim al health 
industry  (Horton, 1990). From the d iscovery  of the an thelm intic  
properties of phenothiazine in the 1940s to the recent exploration of the 
endectocide properties of the m ilbemycins, a considerable effort has 
been put to improve the potency, breadth of spectrum, efficacy and 
safety of antiparasitic compounds. This effort has been rewarded by two 
m ajor breakthroughs. The first was the discovery of thiabendazole 
(Brown et al., 1961) which stimulated extensive research leading to the 
design, by chemical manipulation of the benzimidazole ring, of many 
o ther  b road  spectrum  an the lm in tic  m olecu les . Second ly , it was 
d iscovered that the fermentation of the actinom ycete S r e p t o m y c e s  
a v e r m i t i l i s  produced compounds that were not only effective  at 
extremely low concentrations but also had a spectrum of activity that 
extended to ectoparasites (Miller et al., 1979). However, the launching of 
a novel product is always preceeded by long and increasingly prohibitive 
screening and testing processes. It has been estimated that it costs $ 230 
million to develop a new anthelmintic molecule from discovery to the 
market place (McKellar, 1993) which added to the the prospect of tough 
com petition  from existing products explains the paucity  o f newly 
developed anthelmintics. There is a rationale behind the search for novel 
strategies which extend the lifespan or improve the activity of existing 
antiparasitic drugs. This will only be achieved with a more complete 
understanding of the pharmacological properties of existing agents. The 
intim ate link between pharmacokinetics, pharmacodynamics and clinical 
efficacy is of primary importance for the understanding and possible 
manipulation of various factors that affect the therapeutic outcome of 
an thelm in tic  treatm ent.
1.1 F actors  a f fec t in g  the p h a r m a c o k in e t i c s  and e ff icacy  of  
a n t h e l m i n t i c  d rugs
Anthelmintics currently available belong to five major chemical families: 
(a) b e n z im id azo les  and p ro b en z im id azo les ;  (b) im id azo th iazo le s
(levamisole); (c) tetrahydropyrimidines (morantel); (d) salicylanilides; (e) 
macrocyclic lactones (avermectins and milbemycins).
Factors which affect the pharm acokinetics and, or, efficacy of these 
anthelm intics are numerous and could be classified into host-related 
factors, parasite-related factors and exogenous factors. The latter group
of fac tors refers to the effect of routes of adm inistra tion , drug
form ulation , delivery systems, feeding m anagem ent during treatm ent 
and drug combinations.
1.1.1 The host
The fate of most orally administered anthelm intics is determined in 
th ree  m ajo r body com p artm en ts  of the ru m in a n t  an im al: the
gastrointestinal (Gl) tract, the bloodstream and the liver.
1.1.1.1 Influence of  the gastrointestinal  tract
The complexity of the ruminant digestive tract in comparison with that
of monogastric animals creates unique problems and opportunities for 
the oral administration of drugs (Koritz, 1983). The rumen has indeed a 
remarkable influence on the absorption, distribution and metabolism of 
drugs administered by the oral route and may also contribute to the 
m etabolism  of parenterally administered drugs which diffuse from the 
plasm a across the rumen epithelium. The reticulo-rumen of the sheep 
makes up 20% of the body volume and may contain 5-10 kg of contents 
(Dobson, 1967; Hofmann, 1973). When a drug suspension is deposited in 
the rumen, solid particles mix and distribute through the large digesta 
volume. This slow mixing process not only delays further passage of the 
drug down the Gl tract but also prolongs the rate at which solubilised 
particles come into contact with the absorptive epithelial surface of the 
rumen (Koritz, 1983). The rumen can therefore act as a reservoir which 
lenghtens the duration of drug absorption and outflow down the Gl tract. 
This 'reservoir effect' of the forestom ach is strongly linked to the 
pharm acokinetics and the clinical efficacy of benzimidazole drugs in 
ruminants. Marriner and Bogan (1981b) found that oral administration of 
fenbendazole  (FBZ) resulted in higher and more sustained plasma 
concentrations of drug and metabolites than when the anthelmintic was 
given by the intraabomasal route. This provided an explanation for the 
observation that FBZ was more effective in removing benzimidazole- 
resistant H a e m o n c h u s  co n to r tu s  and T r ic h o s t r o n g y lu s  c o lu b r i fo rm is  
when given into the rumen then when given into the abomasum (Kelly et
a l . ,  1977). Hennessy (1993a) em phasised the role played by the 
adsorption of benzimidazoles (BZ) to ruminai particulate material in the 
extension of their bioavailability. It has been estimated that more than 
90% of oxfendazole  (OFZ) and m etabolites associate  with rumen 
particulate material. The period necessary for the desorption of OFZ and 
metabolites from particulate to fluid digesta, added to the time required 
for absorption extends the residence time of this benzimidazole drug in 
the plasma and throughout the rest of the GI tract. Drug and metabolites 
are re leased  from  particu la te  m ateria l p rog ress ive ly  as the drug 
concentra tion  in the ruminai fluid diminishes due to absorption or 
outflow to the lower GI tract. The physico-chemical nature of drug 
association  with particulate  material is likely to be by physical 
adsorption rather than specific chemical binding (Lees et a i ,  1988).
The oral adm inistration  of liquids or suspensions can som etim es 
stimulate the reflex of oesophageal groove closure causing a rumen 
bypass which diverts the drug preparation from the oesophagus to the 
abomasum. This reflex has been incriminated in instances of erratic 
anthelm intic  treatment failures. Prichard and Hennessy (1981) found 
that partial or complete oesophageal groove closure occured in 42% of the 
sheep treated with an oral OFZ preparation and caused a reduction in OFZ 
bioavailability and efficacy. In goats, a higher incidence of the rumen 
bypass reflex occurs following administration of an oral drench (Sangster 
et al., 1991). In cattle, failure to remove inhibited larvae of O s te r t a g i a  
o s te r ta g i  has also been linked to the rumen bypass reflex (Duncan et al., 
1977); this was later supported by McEwan & Oakley (1978). There is no 
unanimity, however, on whether the rumen bypass effect could alter the 
overall disposition of orally administered anthelmintic drugs in a manner 
that would be significant enough to compromise the therapeutic outcome. 
Ngomuo and coworkers (1984) did not find a significant difference in the 
area under the plasma concentrations-time curve (AUC) of OFZ and its 
metabolites following oral or intraruminal administration to cattle. Bogan 
& Marriner (1987) consider that the problem has been overrated. They 
argued that the reflex is more likely to occur with large volume drenches 
than with small volumes and even if the reflex occurs, most of the drug 
(in suspension) would remain spread along the oesophageal groove and 
would eventually be deposited in the rumen or the omasum rather than 
quickly directed to the abomasum. A biphasic pattern of absorption 
occurs and results in a typical early peak plasma concentration; this
initial onset cannot always be spotted on meaned values since it occurs at 
different times in different animals.
In order to minimise the risks of oesophageal groove closure, it is 
recommended that small volumes of drug preparation (less than 10ml) 
are administered and also that the drench is delivered on the back of the 
tongue rather than in the anterior part of the buccal cavity (Gibson, 1980; 
Hennessy, 1993b).
Absorption from the rumen, as from most body compartments, occurs by 
passive diffusion of the lipophilic unionized fraction of the drug. The 
extent of passage depends on the rumen/plasma pH gradient and the pKa 
of the drug and is somewhat restricted by the physical nature of the 
rumen wall which is composed of stratified squamous epithelium. To be 
absorbed, a drug needs first to be dissolved in the containing fluid; BZ are 
poorly soluble at ruminai pH (6.5) except for thiabendazole (TBZ) and 
cambendazole (CBZ) (McKellar & Scott, 1990). The rapid absorption and 
excretion of TBZ explains the relatively short residence time of this drug 
in the body and its lower efficacy in comparison to less soluble and, 
consequently longer residing BZs (Prichard et a l ,  1978; Prichard et a l ,
1981); FBZ, OFZ and also albendazole (ABZ) most likely owe their 
prolonged residence time to their low solubility in ruminai fluid and 
tendency to associate with digesta particulates. Diffusion also occurs from 
the b loodstream  into the rum en. This has been dem onstrated for 
levamisole administered subcutaneously (Bogan et a l ,  1982) but not for 
ivermectin given by the same route (Bogan & McKellar, 1988).
The role of the rumen as a metabolising com partm ent of foreign 
com pounds is well documented. The ruminai b iodégradation of the 
antibiotic chloromphenicol prohibits its oral administration to ruminants 
(Theodorides et a l ,  1968; Davis et a l ,  1972). There is in vivo and in vitro 
evidence that iverm ectin is degraded to some extent by the ruminai 
m icro flo ra . In sheep, the b ioava ilab ili ty  of iverm ectin  fo llow ing 
in tra rum inal adm in istra tion  is 75% lower than after intraabom asal 
administration and in vitro incubation of ivermectin in ruminai fluid was 
followed by its gradual disappearance from the incubate (Prichard et a l ,  
1985b). This may also exp la in  the absence  of subcu taneously  
administered iverm ectin from the ruminai fluid (Bogan & McKellar, 
1988). The nitro group of the flukicide nitroxynil is reduced by the 
rum inai m icro flo ra  and therefore  this drug is only active when 
administered parenterally  (Arundel, 1985). Nevertheless, bioconversion
by the rum inai flora can som etim es be benefic ia l in term s of 
bioavailability and efficacy of anthelmintics. The conversion of the 
probenzimidazole drug netobimin into its active form albendazole is 
determined by the ruminai microflora (Delatour et a l ,  1986). Also, the 
reduction in the rumen of albendazole sulphoxide (ABSO) (Lanusse et a l ,  
1992) and fenbendazole sulhpoxide (FBSO) (Marriner, 1980., Beretta et  
a l ,  1987) back to their respective parent compounds ABZ and FBZ, may 
enhance their antinematode action since the binding affinity to nematode 
tubulin  is higher with th ioether parent com pounds than with the 
sulphoxide metabolites (Lubega & Prichard, 1990).
O rally  adm in istered  anthelm in tics and m etabo lites  that reach  the 
abomasum originate from two sources; those in digesta that flows from 
the rumen and those in gastric secretion (H ennessy, 1993a). The 
plasm a/abom asum  pH gradient is larger than the p lasm a/rum en pH 
g rad ien t.  L ip o p h il ic  n o n io n ised  m olecu les  m ig ra te  dow n the ir  
concentration gradient to the side of the barrier membrane where higher 
ionisation occurs creating the so-called ion-trapping phenomenon. For 
exemple, the pKa of ABSO is 7.8; at plasma pH there will be a greater 
proportion of this molecule in the nonionised form which promotes its 
passage from plasma to different tissues (Lanusse & Prichard, 1993; 
1994). The greater plasma/abom asum  gradient creates a strong ionic 
trapping effect which explains the higher concentration of ABSO found in 
the abomasum in comparison with plasma and other GI compartments 
(Lanusse et a l ,  1993a). High concentrations of the parent compound ABZ 
and the sulfone metabolite were also found in the abomasal fluid. 
Hennessy (1993a) found 10-14% of an OFZ dose in the abomasal fluid and 
suggested that most of this fraction originated from gastric secretions 
rather than outflow from the rumen. It is surprising that no drug was 
found in the abomasal fluid o f sheep follow ing adm inistration of 
ivermectin even at 10 times the recommended dose (Bogan & McKellar, 
1988). It was however present in the abomasal mucus, which may 
account for the antiparasitic  action of this drug against abomasal 
ne m a to d e s .
In the intestine, distribution of BZ metabolites is highly dependent on 
biliary  secretion (Hennessy, 1993a) with re la tively  low proportions 
arriving from the upper GI tract or from the systemic circulation. Studies 
in cattle showed that only 28% of an orally administered FBZ dose flowed 
through the pylorus wheras 52% of the dose reached the ileocaecal
junction through biliary recycling (Prichard et a i ,  1981). In sheep, 63% of 
the dose was secreted as biliary metabolites following administration of 
OFZ (Hennessy et a i ,  1985). To quantify the enterohepatic recycling of 
FBZ metabolites, Hennessy and coworkers (1993d) infused unconjugated 
metabolites of FBZ into the duodenum. The rapid postinfusion appearance 
of free (unconjugated) metabolites in plasma and their resecretion in bile 
toghether with a rapid decline of biliary metabolite concentrations at the 
end of the infusion indicate the existence of metabolite reabsorption 
from the upper small intestine. This exchange could be crucial for the 
anthelmintic action against pathogenic nematodes located in the mucosal 
surface of the upper small in testine such as T r i c h o s t r o n g y l u s  
colubriformis .  Following infusion of conjugated biliary metabolites of OFZ, 
recirculation continued several hours after cessation of the infusion 
suggesting that conjugated biliary metabolites may be deconjugated and 
absorbed at sites distal to the upper small intestine. It is postulated that 
these  m etabolites , m ostly  hydroxy la ted , are deconjugated  by the 
intestinal microflora and then reabsorbed from this site contributing to 
the anthelmintic action of FBZ and OFZ against parasites of the large 
intestine. Hydroxylated metabolites have been shown to have a higher 
activity than the parent FBZ in binding to nematode tubulin (Lacey et al.,
1987).
Like the rumen, the ileum also contains a m icroflora that reduces 
sulfoxides into their parent compounds and converts netobimin into ABZ. 
Sulfoxidation also occurs to a minor extent in the ileum (Lanusse et al., 
1992).
Given the influence of the GI tract in the disposition of anthelmintics and 
considering the important structural and physiopathological changes that 
GI parasitism causes in this body compartment, researchers investigated 
the effect of GI parasitic burden on the pharmacokinetics of anthelmintic 
drugs. Prichard (1980) first reported  a decrease , in abomasal FBZ 
concentrations in treated sheep that were infected with O s t e r t a g i a  
c i r c u m c i n c t a  and T r ic h o s t r o n g y lu s  c o lu b r i fo rm is .  The decrease was 
proportional to the severity of the parasitic gastroenteritis. Marriner e t  
al. (1985) reported a lower abomasal and systemic availability of FBZ and 
metabolites in sheep infected with O. circumcincta.  Bogan et al. (1987) 
showed a 25% decrease in the bioavailability of OFZ in goats infected with 
the same nematode. Similarly, a 32% and 59% reduction in the systemic 
availability of OFZ was observed in sheep and goats respectively, after
8mixed infection with H. contortus and T. colubriformis (Hennessy et al., 
1993a) Debackere et al. (1993) have shown that, given at the same 
infection dose (50,000 Lg) to sheep, T. colubriformis  had a greater impact 
on the bioavailability of febantel metabolites than O. c ircum c inc ta  
although higher infection rates (100,000 Lg) of either parasite did not 
cause a greater decrease in bioavailability (Landuyt et al., unpublished 
data). Infection  with N e m a t o d i r u s  b a t t u s  had no effect on the 
pharm acokinetics of levamisole, iverm ectin, netobim in or albendazole 
(M cK ella r  et al., 1991; 1993b). Changes in abomasal pH, altered GI 
m otility  and digesta flow rate, leakage of p lasm a drug across the 
damaged GI mucosa are among the causes that have been implicated to 
explain the pharmacokinetic changes observed. M arriner et al. (1985) 
have shown an increase in the abomasal pH from 2.2 to 6.5 in sheep 
infected with 0.  circumcincta and suggested that elevated abomasal pH 
reduces the ion trapping effect and the degree of solubilisation of poorly 
soluble drugs thus reducing parasite exposure and drug absorption. 
However, in the study carried out by Hennessy et al. (1993a), the 
abomasal pH did not change but abomasal flow rate did tend to increase 
in both sheep and goats. It is likely that an increased fluid flow rate 
through the GI tract reduces the residence time of drug at the absorption 
sites and leads to impaired uptake. Gastroenteric plasma leakage may 
also contribute to reducing the systemic bioavailability of anthelmintic 
drugs. The absence of pharmacokinetic changes during N e m a t o d i r u s  
infection has been attributed to the low level of infection used in the 
s tu d ies .
These  changes in b ioavailab ili ty  are tr iv ia l  with regard  to the 
anthelm intic  efficacy against GI parasitism , since clinical trials are 
conducted on animals infected with GI parasites, however, they might be 
crucial when the animals are simultaneously infected with liver fluke 
and lungworm.
1.1.1.2 Effect o f  plasma protein binding
Following absorption, the blood serves as the tissue in which drug
m olecules are conveyed to various parts , of the body. W ithin the
bloodstream, a fraction of most drugs binds reversibly to protein, usually 
album in, and the rem ainder (unbound drug) undergoes simultaneous 
distribution, biotransformation and excretion processes (Baggot, 1977a). 
It is also the unbound fraction that is pharmacologically active. The
degree of protein binding of a drug may therefore be important in
determining its pharmacokinetic pattern as well as the duration and 
intensity of its action.
The majority of benzimidazole compounds show a plasma protein binding 
of less than 50% (Lanusse & Prichard, 1993). For ABZ metabolites, the 
proportion of bound drug amounted to 50.5% of the total plasma
metabolites for up to 26 hours after administration, and this proportion 
increased to 80-100% only after 34 hours postadministration at which 
time, the major plasma metabolite was the inactive sulphone (Hennessy, 
1985). However, two halogenated BZ have been shown to bind strongly to 
plasma protein ; triclabendazole (TCBZ) whose sulphoxide and sulphone 
metabolites are more than 99% bound to plasma albumin (Mohammed-
Ali et al., 1986; Hennessy et a l ,  1987); and luxabendazole (LBZ) which is
95% bound to plasma proteins (Steel and Duwel, 1987). The extensive
plasma protein binding of triclabendazole metabolites and luxabendazole 
reduces their distribution in the body and prolongs their elimination 
half-lives in comparison to other benzimidazoles. In sheep, the total TCBZ 
metabolite area under the plasma-concentration time curve is nearly 7 
and 20 times higher than that of the total ABZ and FBZ metabolites,
respectively (M arriner & Bogan, 1980; M arriner and Bogan, 1981b; 
Hennessy et a l ,  1987). This difference in the extent of plasma protein 
binding may account for the high flukicidal action of triclabendazole and 
luxabendazole against both immature and mature stages of F a s c i o l a  
hepatica  (Boray et a l ,  1983; Dorchies et a l ,  1983; Duwel, 1987). Hennessy 
(1985) demonstrated that flukes are unlikely to be exposed to the 
anthelmintic action of TCBZ metabolites via the bile since he failed to 
extract biliary m etabolites from the flukes recovered  from treated 
animals and also because flukes, like cestodes, are likely to lack enzymes 
that enable them to hydrolize conjugated biliary metabolites (Hennessy
et a l ,  1987). However, plasma TCBZ metabolites were extracted from 
liver flukes, showing that the haematophagous behaviour of F. hepatica  
determines the mechanism of drug uptake. The flukicidal activity of TCBZ 
and LBZ may be prom oted by their long residence  time in the
bloodstream but does not explain the specificity of the former to liver 
flukes and not to other blood-sucking helminths such as H a e m o n c h u s  
c o n to r tu s  from which plasma metabolites were also extracted following 
exposure (Hennessy, 1985). A likely explanation for the narrow spectrum 
of activity of TCBZ has recently emerged from a study on the structural 
and e lec tron ic  fea tu res  of the active  m etabo lite  tr ic labendazo le
sulphoxide (TCBSO) (Lipkowitz & McCraken, 1991). It appears that the
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shape of the substituent at position 2- of TCBSO is nonplanar, all other 
broad-spectrum BZ anthelmintics regardless of substituent at position 2- 
(m ethy l carbamate or thiazolyl) are flat. The second distinguishing 
feature is the net atomic charge on the substituent at position 2-; it is an 
order of magnitude larger than the net atomic charge on the other BZ 
a n th e lm in tic s .
O f  all anthelmintic products available, the salicylanilide  derivatives 
(rafoxanide, closantel, oxyclozanide) and also the nitrophenol flukicidal 
com pound nitroxynil, are probably the drugs with the longest residence 
tim e in the bloodstream. This is due to their strong plasma protein 
binding which is more than 99% for salicylanilides (Mohammed-Ali & 
Bogan, 1987), and 98% for nitroxynil (Alvinerie et al., 1991). It has been 
suggested that the long ' elimination halflife of some salicylanilides (2-3 
weeks) may reflect turnover of plasma albumin to which they are bound 
since the plasma albumin turnover is about 16.6 days (Holmes et al., 
1968). For these drugs, the plasma should therefore be considered more 
as a storage com partm ent than as a drug-vehicle  to other tissues 
(M ichiels et al., 1988). This creates an ideal situation for anthelmintic 
action  against blood sucking parasites whereby the cidal drug is 
concentrated in the parasite feeding source without the compromising 
consequence of high tissue residue levels. Indeed, the very high degree 
of plasma protein binding of salicylanilides may explain the observation 
that in well bled out carcasses relatively low tissue residues are found 
and standard withdrawal periods are generally shorter than might be 
pred ic ted  from their plasma pharm acokinetics (M oham m ed-Ali, 1985; 
Michiels et a l ,  1988; McKellar & Kinabo, 1991).
1.1.1.3  Effect of  hepatic drug-metabolism
Biotransformation tends to convert xenobiotics into less lipid soluble and 
more polar metabolites for easier and faster elim ination. A certain 
degree of lipid solubility is a prerequisite for drug transformation by the 
hepatic microsomal enzyme system (Baggot, 1977b); hydrophilic drugs 
and the majority of metabolite products are sufficiently polar to be 
elim inated. Classically, drug biotransformation is subdivided into two 
phases. In phase I (nonsynthetic) hydrophobic molecules are rendered 
more water soluble by the introduction of polar functional groups. Phase 
II (synthetic) reactions prim arily  consist of conjugation with water 
soluble substances, such as glucuronic acid, sulphate, etc. Phase I and II
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Figure 1.1 Primary substituent positions of the benzimidazole 
an th e lm in tic s .
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enzyme systems are predominantly localized in the liver and to a minor 
extent in other tissues. Metabolites formed through these reactions may
be inactive, less active or occasionnally more active or more toxic than 
the parent molecule
Overall, BZ anthelmintics are extensively metabolized in all mammalian 
species studied. As a common metabolic feature of BZ compounds, parent 
drugs are short-lived and metabolic products predominate in plasma and 
all tissues and excreta of the host as well as in parasites recovered from 
BZ-treated animals (Delatour & Parish, 1986; Lanusse & Prichard, 1994). 
The primary metabolites are usually the products of phase I oxidation or
hydrolysis and are more polar than the parent drug. Phase II conjugation
reactions  also take place whereby oxidized and/or hydrolized BZ 
metabolites are conjugated with glucuronide and/or sulphate to increase
their polarities and facilitate their biliary and urinary excretion.
The metabolism of BZ's usually involves the substituent on position 5- of 
the nucleus (Figure 1-1) which undergoes a variety of reactions catalyzed 
by hepatic mixed function oxidases. Phase I type reactions such as 
hydroxylation, S-oxidation, reduction have been shown to occur at this 
position. Hydrolytic decarboxylation of the carbamate group at position
2- to form aminoderivatives is also a common reaction (Gottschall et al., 
1990). However, metabolic reactions involving the BZ ring itself such as 
the 5-hydroxylation of TBZ are unusual. Following oral administration of 
this BZ to sheep, goats and cattle, the predom inant metabolite is 5- 
hydroxythiabendazole (Tocco et a l ,  1965; Weir & Bogan, 1985) which is 
anthelmintically inactive (Stone et a i ,  1965). Cambendazole (CBZ) is also 
oxidized to its phenolic metabolite, although this is unlikely to be a major 
pathw ay ( Van den Heuvel et al., 1978). BZ con ta in ing  5-keto  
substituents like mebendazole (MBZ) undergo a carbonyl reduction to 
give a secondary alcohol which in turn can be conjugated or undergo a 
carbam ate hydrolysis into an aminoalcohol (Van den Bossche et al.,
1982). As a general rule hydrolysis of the carbamate group eliminates 
both biological activity and toxicity (Delatour and Parish, 1986).
The presence of a sulphur atom in the 5-substituent ( e.g. FBZ, OFZ, ABZ, 
ABSO) or in the 2-substituent (e.g. TCBZ, TCBSO) group has a major 
in f lu e n ce  on m etabo lism . L iver m ic rosom al S -ox ida tion  of the 
thiosubstitu ted  BZ is a common metabolic pathway. FBZ, ABZ and 
probably  TCBZ are metabolised to their respective  sulphoxide and 
sulphone moieties by liver microsomal oxidation (Marriner, 1980; Galtier 
et a i ,  1986a; Hennessy et a l ,  1987; Souhaili-El Amri et al., 1987, 1988a,b;
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M urray  et al., 1992; Lanusse et al., 1993c). The su lphoxides of 
albendazole (albendazole sulphoxide) and fenbendazole (oxfendazole) are 
also commercially available as anthelmintics. Sulphoxidation is a rapid 
and reversible process which forms an equilibrium with the respective 
sulphide, although the equilibrium tends to favour metabolism towards 
the sulphoxide (Lanusse & Prichard, 1993; 1994). The sulphoxide
metabolites undergo a further oxidation into sulphones. In the rat and 
rum inants, pharmacokinetic and in vitro microsomal metabolism studies 
show  that sulphonation is a ra ther slow and irrevers ib le  reaction 
(Delatour and Parish, 1986; Souhaili-El Amri et al., 1988a,b; Short et al.,
1988). In vitro studies with ABZ showed that two microsomal enzymatic 
system s are involved in the two S-oxidations; the flavin-containing 
monooxygenase (FMO) and the cytochrome P450 enzyme system. It was 
initially beleived that the two systems were sequentially involved in the 
catalysis of the two successive reactions, i.e., the FMO is responsible for 
the sulphoxidation, and the cytochrom e P450 for the sulphonation 
(Fargetton et al., 1986; Souhaili-EL Amri et al., 1987, 1988a,b). Recent 
stereoselective studies have demonstrated that sulphoxidation does also 
involve cytochrome P450, however, FMO is the predominant catalyzing 
system in ruminants whereas in monogastrics, both systems are equally 
involved in this reaction (Delatour et a l ,  1994). The inducibility of the 
sulphonation has been shown following repeated treatments with ABZ 
and was corroborated by increased cytochrome P450c (also called P448 
and more recently P450 lA l)  activity in rat liver as a result of exposure 
to ABZ (Souhaili-El Amri et a l ,  1988a,b). In addition, in human hepatoma 
cell lines, ABSO, and to a lesser extent A B S02 induced the activity of 
cytochrome P450IA1 Similarly, the administration of OFZ to rabbits for 
10 consecutive days at a dosing regime of 4.5 or 22.5 mg/kg/d ay 
increased 1.54 and 2.36-fold the total liver microsomal cytochrome P450 
and more particularly the isozyme P450IA2 as demonstrated by western 
b lo tting  (G leizes et al., 1991a). The treatm ent of cultured rabbit 
hepatocytes with OFZ (lOmM) induced the isozymes P450IA1, IA2 and 
I I IA 6 (Gleizes et al., 1991b). This autoinduction of sulphoxide BZ 
m etabolism  could be detrim ental to the clinical efficacy of these 
compounds since the final metabolite product, the sulphone, is generally 
known to be anthelmintically inactive.
The aromatic ring p-hydroxylation that leads to the formation of OH-FBZ 
and OH-OFZ is also an important metabolic route (Short et al., 1987a,b, 
1988; Hennessy et al., 1993b). After administration of fenbendazole to
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sheep, hydroxylated oxfendazole (OH-OFZ) was the m ajor biliary 
metabolite contributing 66%, and hydroxyfenbendazole (OH-FBZ) 27%, of 
the total biliary metabolites characterized (Hennessy et aL, 1993d). 
Surprisingly, in vitro incubation of FBZ with subcellular fractions yielded 
OH-FBZ in all species studied except in sheep (Short et aL, 1988). 
Although OH-FBZ was detected in plasma of goats (Short., 1987), 
hydroxylated metabolites contribute very little to the FBZ metabolite 
profile in the bloodstream (Hennessy et aL, 1993d). They are excreted in 
bile and to a lesser extent, in urine, as free or as conjugated glucuronide 
and sulphate forms. Hennessy and co-workers (1993d) pointed out that 
because OH-OFZ was not measured in previous studies, faecal excretion of 
FBZ has been underestimated in sheep (Duwel, 1977), goats (Short et aL, 
1987a) and cattle (Short et aL, 1987b). P-hydroxylation and subsequent
conjugation is also an important metabolic process that preceedes biliary
excretion of TCBZ (Hennessy et aL, 1987).
The substitution of the BZ ring in position 5- has been particularly 
important in determining the metabolic fate of the modem BZ drugs. This 
position is metabolically labile; a feature that has been used to retard the 
biotransformation of 5 -substituted BZ anthelmintics (Lanusse & Prichard, 
1994). Alterations of the substituent radical in this position markedly 
change  the physico-chem ica l p roperties  o f the drug , hence its 
metabolism. Aromatic BZ derivatives such as FBZ, OFZ, MBZ and TCBZ 
re q u ire  m ore  ex tensive  m e tab o lism  than a l ip h a t ic  d e r iv a t iv e s  
(albendazole, parbendazole) to achieve sufficient polarity for excretion. 
This may account for the longer residence times and elimination half- 
lives of aromatic BZ and their metabolites compared to those of aliphatic 
derivatives. The aromatic substitution slows the oxidation of the sulphur 
(FBZ, OFZ) or reduction of the keto (MBZ) linkage; further hydroxylation 
and conjugation result in more polar excretory metabolites which are 
more extensively eliminated in bile (40-60% of the dose) than in urine 
(5-20% of the dose) (Lanusse & Prichard, 1994). Enterohepatic recycling 
is more important for aromatic substituted BZ than for aliphatic BZ 
derivatives. When oxidised, 5-aliphatic substituted BZ (ABZ, PBZ) are 
sufficiently polar to be mostly excreted in urine rather than undergo
conjugation and secretion in bile. Following ABZ administration to sheep 
only 8% of the dose was excreted in bile as free ABSO and 2 0 H -A B S 0  
m etabolites, and 6.3% as conjugated glucuronide and sulphate esters
mainly of 20H -A B S0 and 20H -A B S02  (Hennessy et aL, 1989); 59% of the
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dose was excreted in the urine of ABZ treated cattle, with ABSO being the 
major urinary metabolite (Gyurik et aL, 1981). The hydrolysis of the 
A B S 0 2  m ethy lca rb am ate  group form s a po la r  am ino deriv a tive ;  
N H 2A B S02. The 2-aminosulphone metabolite appears in plasma and in 
abomasal and ileal fluids after the A B S02 plasma peak (Lanusse et aL, 
1993a) and is the longest -residing free metabolite in tissue (Prichard & 
Parish, 1986).
R e ce n tly ,  the ch ira l  b ehav io u r  o f a lben d azo le  su lp hox ide  and 
fenbendazole sulphoxide have been described and an enantioselective 
biotransformation has been suggested (Delatour et aL, 1990a, b; 1991; 
1994; Benoit et aL, 1992). Two enantiomers of these sulphoxides have 
been identified and interestingly in sheep, goats and cattle, following 
administration of the parent sulphide, the plasma concentration of the 
isomers is never a racemate and as soon as the sulphoxide metabolite is 
de tec ted  there is predom inance of the (+) enantiom er. Follow ing 
adm inistra tion  of ABZ for instance, the ratio  +/- starts at 75/25 
(zerotime) and keeps changing in favour of the (+) isomer to reach a 
value of 95/5. The ratios were closer to a racemate after administration 
o f  a synthetic  racem ic m ixture  of the su lfoxide. The proposed 
ste reose lec tive  b io transform ation  suggests that sulfoxidation by the 
flavin monooxygenase enzyme system (FMO) produces more (+) than (-) 
whereas the sulfonating reaction, which is governed by the cytochrome 
P450 enzyme system, uses more of the (-) enantiomer as a substrate.
L iver metabolism of levamisole consists of a sulfoxidation, hydroxylation 
and sulphonation followed by a glucuronoconjugation. Metabolites are 
m ainly eliminated in the urine (Nielson & Rasmussen, 1983; Labourel,
1984). The metabolism of the (L) and (D) forms of tetramisole has also 
been shown to be enantioselective (Labourel, 1984).
Salicylanilides are not extensively metabolised. Following administration 
o f  closantel, 90% of the dose was excreted unchanged and 98% of the 
p lasm a concentration was attributed to the parent compound. Urinary 
excretion is negligable ( < 0.5%) and the only relatively efficient clearance 
route appears to be the excretion of mainly the unmetabolised drug in 
bile (Michiels et aL, 1987). The main metabolic pathway for closantel was 
reductive  monoiodination.
For ivermectin, the major liver metabolite in sheep, cattle and rat is 24- 
hydroxymethyl-H2B 1 a which is further conjugated to fatty acids and
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esters and deposited in the fat tissue. The major route of excretion is the 
bile (Shuet-Hing Lee Chiu & Lu, 1989).
Wide differences in metabolic capacities often exist, even among species 
phylogenetically  related ( Van't Klooster., 1992). Differences in the 
pharmacokinetic of BZ (Weir & Bogan, 1985; Bogan et aL, 1987; Sangster 
et aL, 1991; Hennessy et al., 1993a), levamisole (Gillham & Obendorf,
1985), closantel (Hennessy et aL, 1993b) and clorsulon (Sundlof et aL, 
1991; Sundlof & Whitlock, 1992) were found between sheep and goats 
and were attributed to a faster metabolism and, or, elimination in goats. 
Lower BZ bioavailability and faster elimination half-lives were also found 
in cattle in comparison to sheep (Weir & Bogan, 1985; Lanusse & 
Prichard, 1994).
Liver disease and parasite-mediated liver damage with alteration of the 
liver enzyme activities could affect biotransformation and bioavailability 
of anthelm intic drugs. Reduced enzymatic activity  of various liver 
microsomal oxidases have been reported in Fasciola  hepatica- in iQci^d  
rats (Galtier et aL, 1983; 1985a,b) and sheep (Galtier et aL, 1986b), which 
could lead to altered patterns of drug metabolism and clearance (Facino 
et aL, 1984; 1985; Tufenkji et aL, 1987; 1988; 1991) (See Chapter 6).
1.1.2 The parasite
The site of predilection, feeding habits and evolutive stage of a parasite, 
as well as its degree of susceptibility to the anthelmintic used are 
important factors which condition the clinical efficacy.
1.1.2.1 Location, feeding habits and stage
A primary condition for efficacy is the access of the antiparasitic moiety 
to the habitat of the parasite and this, at a sufficient concentration and 
for a sufficient length of time. Morantel is effective against most adult GI 
nematodes but since it is only distributed within the GI tract and is not 
systemically available, any possibility of action against adult lungworms 
is excluded. Oxibendazole is only active in its unchanged form and 
because it undergoes first-pass metabolism in the liver, it is active 
against GI helminths but not against D i c ty o c a u l u s  (Delatour & Benoit,
1987). Iverm ectin is effective against the m ajor GI nematodes and 
lungworms of sheep and cattle; depending on the nematode, however the 
dose of ivermectin required for high efficacy varies (Egerton et aL, 1981;
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Wescott & LeaMaster, 1982). In general abomasal parasites ( O. ostertagi, 
O. circumcincta and Trichostrongylus axei) are killed at a lower dose than 
are the small intestinal parasites ( Cooperia onchophora, C. curticei, T. 
colubriformis  and Nematodirus spp).  One explanation would be that, 
although phylogenetically related, nematodes of the abomasum have an 
inheren tly  higher susceptib ility  than the nem atodes of the small 
intestine. Another putative explanation supported by Bogan et al (1988b) 
and Bogan & McKellar (1988) relates the difference to a possible 
recovery and reestablishment of small intestinal parasites. Nematodes 
paralysed in proximal areas of the small intestine may recover before 
they have been expelled from the small intestine, and tend to reestablish 
dista lly , whereas for abomasal nem atodes, a shorter passage time 
through their predilection site precludes such a recovery. This could 
explain why the majority of adult C. curticei  recovered from ivermectin 
treated sheep were more distally located in the small intestine than 
those found in control animals (Bogan et aL, 1988b). Similar findings 
were reported in calves infected with C. onchophora  (Bogan & McKellar,
1988).
The feeding mechanism of a parasite is a crucial factor for the uptake of 
antiparasitic compounds. Anthelmintic drugs are taken in by the parasite 
e ither  orally or via the cuticle. The oral route is im portant in 
haematophageous helminths, and it is well documented that F. hepatica  
and H. contortus are particularly susceptible to anthelmintic drugs which 
strongly bind to plasma protein. The transcuticular pathway in parasite 
drug uptake is also very important and it is suggested that molecular size 
and lipophilicity are important criteria for anthelmintic compounds to 
cross the collagen matrix and the lipoid hypocuticular tissue (Verhoeven 
et aL, 1980; Ho et aL, 1990, 1992, 1994).
A nthelm intic  efficacy against both im m ature and m ature stages of 
nematodes and trematodes is highly desirable if an efficient control of 
helminthiasis is to be achieved. However, adult parasites are generally 
less refractory to anthelmintic treatment than tissue-dwelling immature 
parasites. A major drawback with the use of levamisole and morantel is 
their poor efficacy against developing and arrested larval stages of 
Ostertagia spp and Haemonchus spp in sheep, goats and cattle (Cornwell 
& Jones, 1970; Anderson & Marais, 1972; Gibson & Parfitt, 1973; 
Labourel, 1984; Prichard et aL, 1991; McKellar et aL, 1993c). Similarly, 
thiabendazole is ineffective against arrested larvae in cattle and in sheep; 
the dose has to be increased to kill hypobiotic stages. Oxibendazole and
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mebendazole are also ineffective against arrested larvae (McKellar & 
Scott, 1990).
Flukicidal action against immature F. hepatica  has been an intriguing 
problem until the introduction of triclabendazole which shows a highly 
satisfactory action against both early immature and mature flukes. The 
p h a rm a c o k in e t ic  p a t te rn  tha t c h a ra c te r is e s  the s a l ic y la n i l id e s  
complicates the assessment of their action against immature fluke; this 
will be discussed more extensively later (Chaper 6).
1.1 .2 .2  Res is tance
In the past three decades, the introduction of anthelmintic drugs and 
their subsequent routine use for control and treatm ent of parasitic 
deseases has been chronologically followed by the emergence of resistant 
strains of helminths. Reports have been published of resistance in 
nematode parasites to all the major groups of anthelmintics including the 
BZ, the levam iso le /m oran te l  group, the sa lic y la n i l id e s  and the 
avermectins. Resistance in a nematode population to one drug of the BZ 
group is likely to apply to all the BZ's (Donald, 1983). This is designated 
side-resistance and has been defined as resistance to a compound which 
is the result of a selection by another compound with a similar mode of 
action (Prichard et aL, 1980). Resistance across groups is not uncommon 
and is designated cross or multiple resistance. Resistance in sheep and 
goat nematodes to the effect of BZ and other anthelmintics is undeniably 
of great economic importance, and although the problem has long been 
considered to inflict almost exclusively the southern hemisphere, there is 
evidence to suggest that the incidence of anthelm intic resistance is 
increasing in livestock in countries throughout the world, including the 
UK (Jackson, 1993). The prevalence of resistance in cattle nematodes to 
the effect of anthelmintics is low but there have been reports of BZ 
resistance in T. axei from Australia (Eagleson and Bowie, 1986) and BZ 
resistance in C. onchophora  in New Zealand (Jackson et aL, 1987). It is not 
clear whether this low incidence results largely from host or parasite 
characteristics or simply reflects the bovine dosing regimes which may 
minimise the selection pressure.
For a proper understanding of the possible mechanisms involved in drug 
re s is tan ce , know ledge of the modes of action  of the d ifferen t 
an thelm in tic  c lasses is a prerequisite . Most available  anthelm intic 
compounds exert their antiparasitic effects by interference with energy 
m etabo lism , neurom uscular coordination  and m icro tubu la r  function.
/
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Benzimidazoles are known to affect parasite metabolism (Behm & Bryant, 
1979). Studies on a cambendazole-resistant strain of H. contortus (Rew et  
al., 1982) showed that, in the presence of BZ, adult parasites were able to 
increase their metabolism of glucose to volatile end-products, whereas 
catabolism of glucose was unaffected in a BZ-susceptible strain of H . 
c o n t o r t u s . Salicylanilides also interfere with energy m etabolism  as
uncouplers of oxidative phosphorilation at the mitochondrial membrane 
through interruption of fumarate reduction into succinate. H a e m o n c h u s  
c o n to r tu s  resistance to salicylanilides has been reported in South Africa 
(Van Wyk et al, 1980; 1982; 1987) and in Australia (Rolfe and Boray,
1990). H. contortus  resistant to salicylanilides may avoid the disruption 
of aerobic metabolism by some competitive m echanism which is still 
unclear (Rolfe, 1990).
The primary mode of action of the BZ is thought to consist of their 
b ind ing  to he lm inth  tubulin  causing a depo ly m eriza tion  of the 
microtubules and a general disruption of basic cell function (Borgers et  
al . ,  1975; Friedman & Platzer, 1978). It has been observed that when 
given to nematode-infected animals, BZ cause microtubules to disappear 
from intestinal cells of BZ-susceptible but not BZ-resistant nematodes 
(Sangster et al., 1985). Lacey and Prichard (1986) examined the total 
binding of ABZ, FBZ, MBZ, OFZ, and PBZ to tubulin extracts from BZ- 
resistant and BZ-susceptible parasites. It was found that extracts from 
BZ-resistant parasites bind less BZ than extracts from BZ-susceptible
p a ra s i te s .
Levamisole and morantel both act as cholinergic agonists which induce 
inflow of Na+ (Harrow and Oration, 1985), cause depolarisation of muscle 
membranes and muscle contraction (Aubry et al., 1970). Differences in 
the binding of levamisole have been observed between susceptible and
resistan t worms (Lewis et al., 1989). Resistance may be caused by a 
reduction in the number of cholinergic (levamisole) receptors or in the 
affinity of these receptors for levamisole.
Resistance to ivermectin appears to be developing rapidly throughout the 
world (Van Wyk & Malan., 1988; Echevarria & Trindade, 1989; Jackson et  
a l . ,  1992). Ivermectin exerts its anthelmintic action by irreversibly
opening chloride channels in muscle membranes (Turner & Schaeffer,
1989). To date, no evidence has been put forward to explain the 
m ech an ism  of res is tan ce  to iverm ec tin . The newly deve loped  
milbemycins have a similar mode of action to the avermectins. However, 
s tud ies  suggested  that paras ites  res is tan t to iverm ectin  are not
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necessarily resistant to the milbemycins (Craig et aL, 1992; Pankavich et  
aL,  1992). There is now evidence to contradict these suggestions; Shoop 
et al (1993) have found that 31 times and 9 times more moxidectin was 
required to achieve 95% clearance against ivermectin-resistant strains of 
0 .  c i r c u m c in c ta  and T. c o lu b r i fo rm is ,  re spec tive ly , than against
suscep tib le  stra ins . S im ilarly , Conder et al (1993) rev ea led  that 
moxidectin failed to clear more than 47.2% of an ivermectin-resistant 
strain of H. contortus  from jirds at a dose which invariably clears more 
than 98% of a susceptible strain. These workers consider therefore, that 
any ro ta tional dosing program m e should recognise  that m oxidectin ,
nemadectin and the avermectins belong to the same anthelmintic class.
Studies on the selection and genetics of resistance in nematode parasites 
suggest that resistance is polygenic and preadaptative ( i.e, it arises from 
within the normal phenotypic range), and that there are three phases in 
the selection process. An initial susceptible phase is followed by an 
in te rm ed ia te  one in which heterozygous re s is tan t  in d iv idua ls  are 
com m on w ith in  the population  and finally  hom ozygous res is tan t 
individuals predominate within the population (Martin, 1990; Jackson,
1993). A dm inistra tion  of subtherapeutic  doses favours surv ival of
h e te ro zy g o u s  re s is tan t  ind iv idu a ls  thus in c reas in g  the ra te  of
development of drug resistance (Waller & Prichard, 1986). The tendency 
to treat goats at the same dosage level as sheep may, because of 
p h a rm aco k in e tic  d iffe rences , resu lt  in a fa s te r  d ev e lo p m en t of 
anthelmintic resistance in goats herds. The frequency of treatments is
also a m ajor fac tor in the developm ent o f res is tance; frequent
anthelmintic interventions are likely to exert a strong selection pressure 
towards resistance (Waller & Prichard, 1986).
Reversion to susceptibility is a very slow process and is unlikely to occur 
through natural selection (Martin, 1990). In a field study carried out 
over a 4 year period, BZ resistance did not decrease significantly in the 
absence of chemotherapeutic control (natural selection). A parallel study 
which involved treatment with levamisole over the 4-year period did 
reduce BZ resistance but not to a level that would have allowed
réintroduction of the BZs (Martin et aL, 1988). Similarly, reversion to BZ 
susceptibility was not achieved after 6 years of counterselection with 
levamisole (Borgsteede & Duyn 1989).
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The rapid and widespread development of anthelmintic resistance, the 
slow pattern of reversion to susceptibility and the unlikely introduction 
of anthelmintic compounds which would display novel modes of action, 
have stimulated an interest in developing control strategies based on the 
use of existing anthelmintic products.
1.1.3 Exogenous Factors
These factors refer  to those param eters which are related to the
therapeutic intervention. It is through these factors that a beneficial 
manipulation of the pharmacokinetic properties of anthelmintic drugs is 
to be obtained. The route of administration or delivery system selected, 
the feeding management adopted during anthelmintic treatment and the 
use of drug com binations can significantly  alter the e fficacy  of
anthelm intic  compounds.
1.1.3.1 Feed Effect
The residence time of drugs in the rumen depends on the flow rate of 
digesta. Since the rumen volume is essentially constant, digesta residence 
time is inversely proportional to the quantity of food ingested (Kay,
1987). The level of food intake will therefore affect drug residence time; 
this is particularly  true for drugs that bind extensively to digesta
particulate. Following oral administration of OFZ to sheep fed a daily
ration of 400 or 800 gr lucerne/wheaten chaff, OFZ availability in sheep
on high compared to low intake was characterised by a more rapid rate 
o f absorption, an earlier maximum concentration in plasma, a faster rate 
o f  elimination and overall lower systemic availability (Hennessy & Ali, 
1993). The sheep on a higher daily ration had a faster digesta outflow 
and since OFZ associates extensively to rumen particulate material, the 
half-life of the drug in the rumen was similar to that of particulate
d igesta ; the faster passage rate reduced the time for dissociation,
absorption and recycling. This is in contrast with what has been found in 
m ono gas tr ics  were adm in istering  FBZ with food led to g rea ter
bioavailability (McKellar et aL, 1990, 1993a).
The type of food is also an important param eter that influences the 
residence time of anthelmintics in ruminants. Comparative studies on the 
pharmacokinetics of FBZ, TCBZ, rafoxanide and ivermectin in grazing
sheep and sheep fed hay and concentrate have shown that lower 
bioavailability of the drugs were obtained in the grazing animals. When 
sim ilar groups of lambs were dosed with the gastrointestinal transit
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marker chromium EDTA, a more rapid throughput of chromium by the 
grazing lambs and a more prolonged retention of chromium by the 
housed lambs, were observed (Taylor et aL, 1992, 1993).
These physiological and pharmacological aspects of the ruminant GIT 
could be exploited in order to enhance the residence time of anthelmintic 
drugs. Hennessy & Ali, (1993) reported that halving the feed intake for 
36 hours prior to treatment significantly increased the efficacy of OFZ 
and ABZ against BZ-resistant H. contortus and T. colubriformis.  Increase 
in the bioavailability of ivermectin was also obtained by reducing the 
feed intake.
3.2 R ou te  of a d m in is t r a t io n ,  fo rm u la t io n  and  d e live ry  system s 
Benzimidazoles and probenzimidazoles available, with the exception of 
netobimin, are poorly soluble in water and are therefore administered 
orally, generally as suspensions to ruminants.
N etobim in is a nitrophenylguanidine, with a sulphonic acid in its 
structure; a feature which enhances its water solubility and permits a
flexibility of administration (Prichard et aL, 1991). It is formulated either 
as a soluble zwitterion suspension for oral administration or as an 
aqueous trisamine salt solution for subcutaneous injection. However, 
following oral or intraruminal administration in both sheep (Lanusse & 
P r ic h a rd ,  1990) and cattle  (L anusse  et aL,  1990; 1991) the
pharm acokinetic  profiles of the main plasma m etabolites, ABSO and 
A B S 0 2 ,  were s ig n if ican tly  h igher than fo llo w ing  subcu taneous 
administration; this is due to a more efficient conversion of the prodrug 
follow ing adminstration by the former route. These pharm acokinetic 
differences are reflected in clinical efficacy; a higher dose rate being 
required  when netobim in is administered parenterally , to achieve a
satisfactory removal of parasites (Duncan et aL, 1985; Prichard, 1987).
The aqueous solubility of netobimin has also permitted its administration 
via drinking water to cattle (Downey, 1987; Prichard, 1987; Jacobs et aL,
1988). The clinical response to drinking water treatment administered 
over a period of 7 days was reported to be better than the response to a 
single oral treatment in cattle infected with D ic ty o c a u lu s  v iv ipa ru s  
(Jacobs et aL, 1988).
Selfm edication has however advantages and disadvantages. It avoids 
gathering and handling of animals and it also allows the spreading of
anthelmintic intake over a number of days thus exposing parasites for a
prolonged length of time. The use of BZ in feed blocks may be suitable for
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reducing the periparturient rise in faecal egg output near the lambing 
period (Bogan & Marriner, 1983; McKellar, 1988). However, considerable 
individual variation in feed block intake often occurs and the risk of drug 
resistance inherent in subtherapeutic intake is not to be underestimated 
(Bogan & Marriner, 1983; Donald, 1985).
Differences in the persistence and efficacy of ivermectin given orally or 
subcutaneously  have also been investigated  (M arriner et aL, 19 8 7 ;  
McKellar and Marriner., 1987; Borgsteede, 1993). It has been shown that 
fo llow ing subcutaneous adm inistration of iverm ectin  to periparturient 
ewes, the plasma concentrations of the drug were more persistent than 
when the drug was administered as an oral drench and that the period of 
reduced faecal egg output was extended by at least one week. This has 
been confirm ed recently  by Borgsteede (1993) who found a 100% 
persisten t effect against reinfections with H. contortus  and C. curticei  
during a period of at least 10 days when the injectable formulation was 
used. Zajac et al. (1992) suggested that a more frequent treatment 
regime is necessary when the oral formulation is used.
The bioavailability and efficacy of levamisole has also been shown to be 
higher following subcutaneous or intramuscular injection than following 
oral administration (Galtier et aL, 1981; Bogan et aL, 1982). Levamisole 
has a relatively narrow safety margin and signs of toxicity are more 
likely to appear after subcutaneous injection than after drenching since 
plasma concentrations are higher by the former route (Prichard et aL,
1991).
Iv e rm e c t in  and lev am iso le  are c u rre n t ly  av a i lab le  as pour-on  
form ulations for cattle. Following pour-on administration , plasma and 
gastro in tes tina l concentra tions of levam isole  were low er than those 
observed following administration by other routes (Forsyth et aL, 1983). 
The percuteneous route has been envisaged as an alternative easy and 
non-invasive route for ivermectin administration in goats (Scott et aL,
1990); a lower bioavailability but a longer persistence of the drug were 
observed in comparison to the oral route. Recently, a topical formulation 
of ivermectin has been tested in sheep but only against blow-fly strike 
and lice (Eagleson et aL, 1993; Cramer et aL, 1993).
A lth o u g h  the in tro d u c tio n  o f  c o n tro l le d  d e liv e ry  sys tem s for 
anthelm intics has revolutionised the control of internal parasites in 
cattle , there have been, until recently , no com m ercially  available 
anthelmintic products which could be administered to sheep in a slow
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release manner. The observation that small amounts of BZ delivered over 
an extended period of time by infusion were more efficacious than the 
single dosing regime has been reported by Prichard et al (1978) and 
Kwan et al (1988). An experimental controlled release capsule (CRC) was 
designed for sheep to release continuous low levels of OFZ (Anderson et  
al., 1980) and was found effective in reducing the worm egg output over 
extended periods. This effect is epidem iologically  beneficial since it 
reduces considerably the larval contam ination of pastures. A similar 
experim ental CRC was successfully  tested against BZ resistan t H . 
contortus, 0 .  circumcincta and T. colubriformis  (Le J ambre et al., 1981). A 
commercial albendazole CRC is now available for sheep. Similar to the OFZ 
CRC, it is based on the Laby design which relies upon small wings 
extruding from the barrel of the bolus when it reaches the rumen thus 
preventing regurgitation or further passage of the bolus. The capsule 
contains 3.85 gr of albendazole in the form of tablets pushed by a spring 
against an orifice through which they diffuse continuously in the rumen 
until exhaustion for 90-100 days. The daily delivery rate is 0.5 mg/kg in 
a 65 kg sheep. The plasma kinetics of the ABZ metabolites were studied 
following the administration of the bolus and it was found that in sheep, 
there was more of the anthelmintically inactive A B S 0 2  than suphoxide 
and in cattle more sulphoxide than sulphone (Delatour et al., 1990c). This 
was explained by an enzyme inducing  effect of ABZ in sheep. 
Nevertheless, the bolus does confer parasitological control and production 
b e n e f i t  in sheep  ind ica ting  adequa te  c o n ce n tra t io n s  o f  ac tive  
an the lm in tic s  (B arton  et al., 1990; Barger et al., 1992). It is also 
suggested that the ABZ slow release bolus may confer activity against the 
establishm ent of incoming BZ-resistant larvae (Fisher et al., 1992).; 
however the impact of a routine use of the CRC on the incidence of BZ 
resistance is still to be evaluated.
The use of liposomes and lipid-protein matrices has been investigated 
with the aim of improving the efficacy of BZ's. Liposomes are small 
ph o sp h o lip id  ves ic le s  used as c a rr ie rs  o f  th e rap eu tic  agen ts . 
In co rp o ra tio n  of a lb e n d az o le -p o ly v in y l  p y rro l id o n e  in to  lec ith in
cholesterol liposomes followed by intraperitoneal administration to goats 
in fec ted  with F. hep a t ica  p roved more e ffec tive  than an oral
administration of albendazole suspension in reducing faecal egg counts. It 
was suggested that the liposome formulation conferred greater efficacy
on albendazole and that it could be administered more precisely and at
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lower dosage rates (Yang & Fung, 1991). The use of lipid-protein 
matrices has recently been assessed for the administration of ABZ in a 
formulation which has improved efficacy. The aim of the preparation is 
to deliver parent ABZ which has high affinity for target nematode
tu b u lin ,  to the abom asum  or sm all in te s t in e  fo llo w in g  oral
administration. This is not normally possible since ABZ is absorbed 
mainly from the rumen and oxidised in the liver before it diffuses back 
to the abomasum. The matrix preparations have been shown to resist
rum en incubation for a period  of 24 hours but to re lease  the
encapsulated ABZ rapidly in the abomasum and upper small intestine. 
M atrix  form ulations result in 3-4 fold increase  of ABZ abomasal 
concentrations compared to conventional oral suspensions (Hennessy,
1992).
1.1.3.3 Drug combinations and potentiation
The purpose of anthelmintic combinations is to broaden the spectrum of 
activity and, or, increase the efficacy of anthelmintic preparations. For 
instance, flukicidal drugs have been combined with nematodicidal drugs 
for sim ultaneous treatm ent of fluke and worm  in fes ta tions. The 
prelambing dose often given to ewes to reduce or remove inhibited or 
recently ingested nematodes and chronic fluke burdens is an appropriate 
time for such combination products to be used (McKellar & Kinabo,
1991). Nevertheless, the perceived advantage of these com binations 
should take into account the epidem iological d ifferences that exist 
between nematodes and flukes; often throughout the year one of the 
components is unnecessary when the other is essential (McKellar, 1993). 
In countries were H. contortus  and T. colubr i formis  are predom inant 
parasites, a control scheme termed 'Wormkill' has been dcvelopped to
contend with a drug resistance problem and reduce the frequency of 
treatm ent, using a com bination of c losantel and a broadspectrum  
anthelmintic (Dash, 1986). There is a concern however about risks of
resistance development as a result of persistent declining concentrations 
of closantel which probably discriminate the incoming larvae in favour of 
closantel resistant genes (Martin, 1990).
C om bina tions of an the lm in tics  to which nem atode  res is tance  is
genetically unrelated and which have similar persistence in the host, e.g. 
levamisole and a BZ, have also been successfully used to counter the
development of resistance to the individual components (Anderson et a l ,  
1991a, b). The exposure of parasites to both drugs is thought to increase
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the po lygen ic ity  of res is tance  and there fo re  to slow down its 
developm ent (Martin, 1990).
Combination products have also been investigated which potentiate the 
effects  o f the incorporated anthelm intics. The coadm inistra tion  of 
p a rb endazo le  with oxfendazole  has been shown to increase  the 
anthelmintic activity of the OFZ and to confer activity against BZ-resistant 
nematodes (Hennessy et a i ,  1985; 1992). This effect is believed to be due 
to reduced  hepatic b iotransform ation and biliary  secretion of OFZ 
together with increased extrabiliary secretion of the drug. Parbendazole 
has been shown to cause a transient, dose related reduction in bile flow 
rate which explains the slower excretion of OFZ given in combination 
with parbendazole.
It has also been shown that the coadministration of hepatic oxidation- 
inh ib iting  compounds with netobim in alter the d isposition  of the 
m etabolites ABZ, ABSO and A B S 0 2  (Lanusse & Prichard , 1991). 
M ethimazole is a substrate for the flavine monooxygenase system and 
competes with ABZ sulphoxidation (Galtier et aL, 1986); metyrapone is an 
inhibitor of cytochrome P450 and inhibits the sulphonation reaction. Both 
inhibitors have been shown to improve the pharmacokinetic profiles of 
netobimin metabolites in ruminants (Lanusse & Prichard, 1991; 1992a,b) 
and have been suggested as possible potentiators for the anthelmintic 
a c t iv i ty  of ne tob im in . Im proved  b io av a ila b il i ty  o f  an the lm in tic  
metabolites were also obtained when FBZ and OFZ were coadministered 
with m ethim azole (Lanusse et aL, 1993b). A new anthelmintic drug 
(AB763) based on the combination of ABZ with another parasiticide
(A B762) has been recently developed and it is believed that the 
com bination enhances the bioavailability of albendazole (Page et aL,
1 9 9 3 )
1.2 Study objectives
The aims of the studies described in this thesis were:
(1) To determine the pharm acokinetics of albendazole and related
compounds in goats;
(2) To explore the effects of piperonyl butoxide (PB), an inhibitor of 
h e p a t ic -d ru g  o x id a tiv e  m etabo lism  (cy to ch ro m e  P 4 5 0 ) ,  on the 
pharm acokinetics of fenbendazole and albendazole and to assess the 
efficacy  of a combination fenbendazole-p iperonyl butoxide on BZ- 
resistant strains of nematodes in sheep;
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(3) To study the in vitro metabolism of ABZ, FBZ and TCBZ using rat liver 
m icrosom es and primary culture of rat hepatocytes. The effects of 
piperonyl butoxide on the in vitro S-oxidations of these benzimidazole 
drugs were also studied.
(4) To reach a better understanding of the flukicidal action of the 
salicylanilides against immature F. hepatica using rafoxanide as a model. 
A novel methodology based on the use of a pharmacokinetic marker of 
liver function, antipyrine, was used to assess efficacy against different 
stages of liver fluke.
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C h a p te r  2
P h a r m a c o k in e t ic s  o f  a lb e n d a z o le ,  a lb e n d a z o le  su lp h o x id e
and  n e to b im in  in goa ts
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2.1 In troduct ion
Albendazole, a lbendazole sulphoxide and netobim in are related 
broad spectrum anthelm intics widely used in sheep and cattle 
(Campbell, 1990). In goats, the efficacy of albendazole has been 
assessed against gastrointestinal nematodes (M cKenna & Watson, 
1987; Charles et aL, 1989), the lungworm Mullerius capillaris  (Helle,
1986) and the liver fluke Fascio la  hepatica  (Misra et al, 1 9 8 9 ) .  
Recently, netobimin has been shown to be efficacious against mixed 
in fec tion  with M. c a p i l la r i s  and  B e n z im id a z o le - r e s i s t a n t  
gastrointestinal nematodes when administered orally at 7.5 mg/kg 
on three successive occasions or at 10 mg/kg on two successive 
occasions (Cabaret, 1991). Very little information has however 
been provided on the pharm acokinetic  behaviour o f  the three 
anthelmintics in goats (Delatour et aL, 1991; Hennessy et aL, 1993). 
Dosage regimens have not been clearly established in this species 
and often are based on knowledge acquired from studies carried 
out in sheep and cattle.
In the present bioequivalence study, the plasma disposition of 
albendazole in goats is compared to that of its synthetic metabolite 
(albendazole sulphoxide) and precursor (netobimin).
2.2 Materials and Methods
2.2.1 Anim als
Seven (07) mixed-breed healthy goats (identification numbers G I, 
G3, G7, GIG, G l l ,  G12 and G13) weighing 11.5 to 30.0 kg at the 
beginning of the experiment were randomly allocated to two groups 
of two animals and one group of three animals. They were 
maintained indoors with hay and water provided ad libitum  and 
were given concentrate pellets (Lamb W eaner, Stewarts, Larbert, 
UK) twice a day.
2.2.2 Drug administration and sampling procedure
A nim als in each group were dosed orally  with a lbendazole  
(Valbazen 2.5%; Smith Kline Animal Health Ltd.), albendazole 
sulphoxide (R icobendazole  2.5%; R ycovet Ltd.) or netobim in 
(Hapadex 2.5%; Kirby Warrick Ltd.) in a three-way crossover design 
protocol. A 1-2 week washout period was allowed between 
crossovers. The three drug products were given at a dose rate of 7.5 
mg/kg bodyweight which corresponds to 2.83 X  10"5, 2.66 X  10-5
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and 1.78 X 10-5 moles of active metabolite (albendazole sulphoxide) 
per kilogram bodyweight for albendazole, albendazole sulphoxide 
and netobimin, respectively. Drug suspensions were adminstered 
with plastic syringes (Becton Dickinson, Dublin, Ireland) placed on 
the back of the tongue. Blood samples were collected in lithium 
heparin syringes (10 ml Monovette, Sarstedt Lim ited, Leicester, 
England) by jugular venepuncture prior to drug administration and 
0.25, 0.5, 1, 2, 4, 8 , 12, 24, 32, 48, 72 and 96 hours thereafter. 
Samples were centrifuged at 1700 g for 10 minutes, the plasma was 
removed and stored at -20 ° C until analysis.
2.2 .3 Drug analysis
Plasm a samples were analysed by High P erfo rm ance  Liquid 
Chromatography following liquid phase extraction (samples from 
animals treated with albendazole and albendazole sulphoxide) and 
so lid  phase ex trac tion  (sam ples from  an im als trea ted  with 
ne tob im in ) .
2 .2 .3 .1  S ta n d a rd  p r e p a r a t io n
Stock solutions (100 |ig/ml) of pure standard netobimin (Sobering 
P lough  Ltd., UK ), a lbendazo le , a lbendazo le  su lphox ide  and 
albendazole sulphone (Robert Young Ltd., UK) were prepared using 
methanol (Rathburn Chemicals Ltd., UK) as a solvent. These were 
diluted to give 20, 10, 5, 2, 1 pg/m l standard solutions for 
ca lib ra tion  and for adding to d rug-free  p lasm a sam ples to 
determine the recovery.
2.2 .3 .2  Liquid phase  extract ion
This procedure enabled the extraction of albendazole and its two 
metabolites albendazole sulphoxide and albendazole sulphone but 
was not suitable for the extraction of netobimin.
The method was adapted from the procedure  described by 
Marriner and Bogan (1980). To 2 ml of plasma sample contained in 
a 50 ml ground glass tube were added 200 p i  of am m onium  
hydroxide (NH4 OH, O.IN), 0.2 grams of sodium chloride and 20 ml 
of diethyl ether (Rathburn Chemicals Ltd.). Sample tubes were 
stoppered and shaken for 15 minutes on a a slow rotary mixer. 
Fifteen ml of the ether was then transfered from the sample tube to 
a 50 ml thin-walled glass tube. A further 20 ml of ether were 
added to the sample tube, the shaking procedure repeated and 20
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ml of the solvent phase removed and added to the 15 ml ether 
from the first extraction step. The ether was evaporated under a 
stream of air at 50 ° C until the remaining volume was 8-10 ml. It 
was then transfered to a 15 ml conical tube and evaporated to 
dryness. the residue was reconstituted in 0.30 to 0.60 ml of 
methanol (depending on the amount of drug expected), placed in an 
ultrasonic water bath for 1 minute and finally injected onto the 
c h ro m a to g rap h .
2.2.3.3 Solid phase extraction
This procedure enabled the extraction of netobimin, albendazole, 
albendazole sulphoxide and albendazole sulphone and was used for 
plasma samples collected from goats treated with netobimin.
Samples were processed according to the method developed by 
Allan et al. (1980) and modified by Hennessy et al. (1985). C18 Sep 
Pak cartridges (Waters Chromatography Division, Milfort, USA) 
were used. Each cartridge was prewashed with 5 ml of methanol 
followed by 5.0 ml of 0.017M ammonium dihydrogen phosphate 
buffer (pH 5.5). Plasma (1 ml) was then applied and the cartridge 
was washed successively with 20 ml of distilled water, 0.5 ml of 
40% methanol and 0.4 ml of 100% methanol. Netobim in and 
metabolites were finally eluted with 2.5 ml of 100% methanol and 
the elution product evaporated to a volume of 0.4 ml for analysis.
2.2.3.4 HPLC system
This comprised a solvent delivery pump (Gilson Model 802; Scotlab 
instrument Sales Ltd., Glasgow, UK) connected to an ODS-Hypersil 
(5p) column (16 cm X 5 mm) (Shandon Southern, Cheshire, UK) and 
a UV detector (Model SPlOO or model SP 8450, Burke Electronics 
Ltd, Glasgow, UK). For the quantification of albendazole, the mobile 
phase was a mixture methanol:0.05M ammonium carbonate (70:30, 
v/v) running at a flow rate of 1 ml/minute, whereas for the elution 
of the sulphoxide and the sulphone metabolites a mixture methanol: 
water (80:20) to which perchloric acid was added (1 |il of 1.1 % 
w/v perchloric acid per ml of solvent mixture), was used at the 
same flow rate. A mobile phase similar in composition (but not in 
proportion) to the latter was used for the elution of netobimin 
(47:53 methanol:water to which perchloric acid 1.1% was added at a 
proportion of 7 |ii per ml of solvent), this solvent was run at 1.6 
ml/minute. Albendazole and its two metabolites were analysed in
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two separate systems and, where netobimin was to be measured, 
the HPLC system in which the sulphoxide and sulphone metabolites 
were analysed was used after washing with methanol for 20 
m inutes and running the appropriate  solvent for 30 minutes. 
Absorbance was set at 0.01 AUFS (ABSO and ABS02), 0.05 AUFS 
(ABZ) and 0.005 AUFS (netobimin). Wavelenghts were 292 nm for 
ABZ, ABSO and ABS02, and 347 nm for netobimin. Retention times 
were 2.7 minutes (ABZ), 3.2 minutes (ABSO), 2.2 minutes (ABS02) 
and 2.4 minutes (netobimin).
2 .2 .3 .5  R ecovery  a n d  p rec is io n
Recovery of the four compounds from plasma to which the drugs 
had been added was evaluated by reference  to peak heights 
resulting from direct injection of standard solutions. The precision 
of extractions and chromatographic procedures was assessed by 
the coefficients of variation of replicate plasma samples to which 
known amount of drug had been added and analysed. Recoveries 
and coefficient of inter-assay variations are reported in Appendix 
A-1 and A-2. Limits of detection as assessed by a peak height of 
one unit were 0.01 |ig/ml for ABZ and A B S02, 0.025 jig/ml for 
ABSO and 0.04 jig/ml for netobimin.
The concentrations of drug (and metabolites) in unknown samples 
were calculated by reference to plasma samples to which known 
amounts of drug (and m etabolites) had been added and taken 
through the analytical procedure.
2 .2 .4  P h a rm a c o k in e t ic  a n d  s ta t i s t ic a l  a n a ly s is  
The maximum plasma concentration (Cmax) and time to maximum 
concentration (tmax) were determined from observed values. The 
area under the plasma concentration-time curve (AUCobs) and the 
area under the first-m om ent curve (AUM Cobs) were calculated 
from  observed values using the trapezo idal rule. The mean 
residence time (MRT) was calculated as the ratio AUMCobs/AUCobs.
A non-parametric statistical test (W ilcoxon signed rank-test) was 
used  to com pare  pharm acok inetic  p a ram eters  ob ta ined  with 
different drug preparations and a value of P< 0.05 was considered 
significant.
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2.3 Results
Following its oral administration netobimin was not detectable in 
p lasm a at any time; ne ither  was its su lph ide  m etabo lite  
albendazole. Albendazole was also below the limit of analytical 
detection when given as the parent drug or when the sulphoxide 
form was administered. Albendazole sulphoxide and albendazole 
sulphone were present in the plasma, following administration of 
each moiety, for 32 to 48 hours (Tables 2-1 and 2-3). Fifteen 
minutes after drug administration, ABSO appeared in the plasma of 
most animals (6 out of 7) treated with albendazole sulphoxide 
(Table 2-1; Appendix A-7). When albendazole and netobimin were 
administered, albendazole sulphoxide was first detectable in only 
one goat ( G l l )  at 15 minutes (albendazole) (Appendix A-3) and 30 
minutes (netobimin) (Appendix A -11) po'stadministration, with the 
remaining goats showing initial detectable levels at 0.5 to 1 hour 
(a lb e n d a z o le )  and 1 hour (n e to b im in )  p o s ta d m in is t ra t io n .  
Ind iv idua l concen tra tions  of a lbendazo le  su lphone  fo llow ing  
a d m in is t ra t io n  of a lbendazo le ,  a lb en d azo le  su lp hox ide  and 
ne tob im in  are given in A ppendices A-5, A-9 and A-13,
respectively. The plasma concentration versus time profiles of the 
two metabolites albendazole sulphoxide and albendazole sulphone 
following administration of the three anthelmintic preparations are 
show n in F igu re  2-1 and F igure  2-2 , re sp ec t iv e ly .  The 
pharmacokinetic parameters of both metabolites (Table 2-2 and 
2-4; Appendices A-4, A-6 , A -8 , A-10) were not significantly  
d ifferent when the albendazole and the albendazole sulphoxide 
treatments were compared. However, the areas under the plasma 
concentra tion  time curves (AUG) and m axim um  concentrations 
(Cm ax) were significantly  lower (P<0.05) follow ing netobim in 
administration (Tables 2-2 and 2-4; Appendices A-12 and A-14). 
The m ean res id en ce  tim e (M RT) and tim e to m axim um  
concentration (tmax) were similar for the three formulations. The 
ratios AUG (ABS02)/AUG (ABSO) were 0.55, 0.51 and 0.56 for 
albendazole, albendazole sulphoxide and netobimin, respectively.
2.4 Discussion
The anthelm intic  activity of netobimin is conditioned by the 
bioconversion of the prodrug into albendazole (Figure 2-3). The 
biotransformation is exerted by the gastrointestinal microflora and 
consists of a reduction and a secondary cyclization to form the
3 4
Table 2-1. Plasm a concentrations of albendazole sulphoxide (ABSO) 
(mean ± SEM) following administration of albendazole, albendazole 
sulphoxide and netobimin to goats at a dose rate of 7.5 mg/kg 
b o d y w e ig h t.
Mean ± SEM (n=7).
T im e A lbendazo le A lbendazo le N e tob im in
(h o u rs ) su lph ox ide
0 0.00  ± 0.00 0.00  ± 0.00 0.00  ± 0.00
0 .25 0.01 ± 0.01 0.04 ± 0.01 0.00  ± 0.00
0.5 0.07 ± 0.02 0.16 ± 0.01 0.00  ± 0.00
1 0.20 ± 0.02 0.45 ± 0.05 0.13 ± 0.02
2 0.49 ± 0.05 1.00 ± 0.09 0.46 ± 0.06
4 0.94 ± 0.09 1.89 ± 0.21 0.89 ± 0.09
8 2.01 ± 0.16 2.59 ± 0.23 1.28 ± 0.13
12 2.37 ± 0.15 2.70 ± 0.20 1.30 ± 0.13
2 4 1.54 ± 0.17 1.55 ± 0.21 0.77 ± 0.11
3 2 0.67 ± 0.20 0.64 ± 0.20 0.26 ± 0.08
4 8 0.01 ± 0.01 0.02  ± 0.02 0.00  ± 0.00
7 2 0.00  ± 0.00 0.00  ± 0.00 0.00  ±  0.00
96 0.00  ± 0.00 0.00  ± 0.00 0.00  ± 0.00
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Figure  2-1. P lasm a concentrations of albendazole sulphoxide 
(mean ± SEM) following oral adm inistration of albendazole, 
albendazole sulphoxide and netobimin to goats (n=7) at a dose 
rate of 7.5 mg/kg bodyweight.
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Table 2-2. Pharmacokinetic parameters for albendazole sulphoxide (ABSO) 
(mean ± SEM) following adm inistration  of albendazole , albendazole 
sulphoxide and netobim in to goats at a dose rate  of 7.5 mg/kg 
b o d y w e ig h t.
Mean ± SEM (n=7)
ABSO
A lbendazo le  a lb en d azo le  N etob im in
su lphox ide
AUCobs (M-g.h/ml) 
AUMCobsCM-g-h^/ml) 
MRT (h)
Cmax (jig/ml) 
tmax (h)
54.41 ± 5.96 63.06 ± 7.16 29.75 ± 3.14* 
943.3 ± 145.5 1003.8 ± 163.0 459.49 ± 62.87 
16.96 ± 0.63 15.43 ± 0.87 15.15 ± 0.83 
2.29 ± 0.12 2.77 ± 0.20 1.36 ± 0.13* 
11.43 ± 0.57 11.43 ± 0.57 12.57 ± 2.03
Significantly different (P<0.05)
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Table 2-3. Plasma concentrations of albendazole sulphone (A B S02) 
(mean ± SEM) following administration of albendazole, albendazole 
sulphoxide and netobimin to goats at a dose rate of 7.5 mg/kg 
b o d y w e ig h t.
Mean ± SEM (n=7)
T im e A lbendazo le A lbendazo le N etob im in
(h o u rs ) su lp h o x id e
0 0.00  ± 0.00 0.00  ± 0.00 0.00  ± 0.00
0 .25 0.00  ± 0.00 0.00  ± 0.00 0.00  ± 0.00
0.5 0.00  ± 0.00 0.00  ± 0.00 0.00  ± 0.00
1 0.01 ± 0.00 0.02  ± 0.01 0.00  ± 0.00
2 0.03 ± 0.01 0.07 ± 0.01 0.02  ± 0.01
4 0.08 ± 0.01 0.18 ± 0.02 0.08 ± 0.01
8 0.25 ± 0.02 0.41 ± 0.03 0.19 ± 0.01
1 2 0.50 ± 0.05 0.62 ± 0.04 0.34 ± 0.02
2 4 0.97 ± 0.07 1.08 ± 0.06 0.61 ± 0.03
3 2 1.04 ± 0.10 0.94 ± 0.13 0.49 ± 0.09
4 8 0.12 ± 0.11 0.10 ± 0.09 0.00 ± 0.00
7 2 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
9 6 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
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Figure 2-2. Plasma concentrations of albendazole sulphone (mean ± SEM) 
following oral administration of albendazole, albendazole sulphoxide 
and netobimin to goats at a dose rate of 7.5 mg/kg bodyweight (n=7).
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Table  2-4. Pharm acokinetic  param eters  for a lbendazo le  su lphone 
(A B S 0 2 )  (mean ± SEM) follow ing adm inistra tion  of albendazole , 
albendazole sulphoxide and netobimin to goats at a dose rate of 7.5 
mg/kg bodyweight.
Mean ± SEM (n=7)
ABS02
A lbendazole  A lben dazo le  N e tob im in  
su lph ox ide
AUCobs (|ig.h/ml) 
AUMCobs(M-g.h2/ml) 
MRT (h)
Cmax (|ig/ml) 
tmax (h)
29.85 ± 3.03 31.26 ± 2.22 15.75 ± 0.99* 
803.1 ± 122.9 787.67 ± 93.06 374.28 ± 31.18 
26.34 ± 1.32 24.78 ± 1.23 23.54 ± 0.74
1.08 ± 0.07 1.13 ± 0.05 0.63 ± 0.03*
30.86 ± 1.14 28.57 ± 1.62 26.29 ± 1.48
* Significantly different (P<0.05)
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active drug (Delatour et al., 1986). Absorption of netobimin from 
the gastro intestinal tract has been reported in sheep following 
intraruminal administration of the prodrug at a dose rate of 20  
mg/kg (Lanusse and Prichard, 1990). However, in the same species 
only trace amounts of the prodrug were detected when the dose 
was reduced to 7.5 mg/kg (Lanusse and Prichard, 1992) and in 
cattle even at 20 mg/kg, netobimin was not detectable following 
oral adm inistration (Lanusse et a i ,  1991). In the present study, 
netobimin was not detected in the plasma and this suggests an 
efficient conversion of the prodrug into the active form.
Albendazole was not detectable in the jugular blood and this is 
similar to results obtained in sheep and cattle (Marriner and Bogan 
1980, Prichard et a i ,  1985a; Hennessy et a i ,  1989). Considering the 
rapid formation of the sulphoxide metabolite, a first-pass oxidation 
in the liver, and possibly  in the gut mucosa, is the likely 
exp lanation  for the absence of a lbendazole  in the system ic 
circu la tion .
A delay in the appearence of the sulphoxide m etabolite  was 
observed when albendazole or netobimin were adm inistered in 
com parison to the direct administration of the sulphoxide. This 
delay reflects the time required for the metabolic processes to 
occur; this was clearly shown with netobim in when the first 
detection of albendazole sulphoxide was observed 45 minutes later 
than the f irs t  appearance  when the su lphox ide  i ts e l f  was 
a d m in is te re d .
Albendazole sulphone appeared more slowly than the sulphoxide as 
evidenced by the difference in the tmax of the two metabolites and 
this is in accordance with the slow nature of sulphonation 
(Souhaili-El Amri et al., 1988a,b). The ratio AUC (A B S02)/A U C  
(ABSO) ranging between 0.51 and 0.56 for the three drug products 
is consistent with that reported in goats by Delatour et al. (1991) 
(ratio= 0.56) and Benoit et al. (1992) (ratio= 0.59) after treatment 
with albendazole.
There was bioequivalence between albendazole and albendazole 
su lphox ide  since no m ajor d ifferences were noted in the 
pharm acokinetic  parameters of the two compounds given at the 
same dose rate. Tiberghien & Bogan (1987) have shown a similar 
equipotency in sheep and cattle. The rapid  su lphoxidation of 
a lbendazole  in the liver together with the reduction of the 
sulphoxide drug into the sulphide form by the ruminai microflora
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Figure 2-3. Biotransformation of netobimin
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are the two phenomenon that make the fate of the two compounds 
indistinguishible and help to explain the similar plasma disposition 
observed between the parent drug and the metabolite.
The systemic availability of ABSO and A B S 0 2  was lower with 
netobimin than with the sulphide and the sulphoxide drugs. Since
the molecular weight of the prodrug is higher than that of the
sulphide and the sulphoxide metabolites (Figure 2-3), the dosage 
rate should be adjusted on the molar basis for bioequivalence. 
Netobimin is recommended at the same dose rate (7.5 mg/kg) as 
albendazole for the treatment and control of lungworm and adult 
gastrointestinal nematode infections in cattle but to achieve efficacy 
against type-II ostertagiasis in this species, the dose rate  of 
netobimin has to be increased to 20 mg/kg bodyweight.
In co nc lu s io n  a lb endazo le  and a lben dazo le  su lpho x id e  are
bioequivalent. However, if a dose rate of 7.5 mg/kg is adopted for 
the use of these two compounds in goats, the adequate equivalent 
dosage for netobimin would be 58.9% higher (i. e. 11.9 mg/kg).
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C h a p te r  3
E ffec t  o f p ip e ro n y l  bu tox ide  on the  p h a rm a c o k in e t ic s  of 
a lb e n d az o le  an d  fen b en d azo le  in sheep  a n d  goats
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3.1 In troduct ion
Benzimidazole thioether anthelmintics are extensively metabolised 
into their sulphoxides which in turn are Oxidized into the more
polar and less anthelmintically active sulphone metabolites. Slowing 
down the sulphoxidation and, or, the su lphonation  of these
compounds could be a useful means of prolonging the residence 
time of the active moieties (sulphide and, or sulphoxide) in the 
host’s body thus optimizing the exposure of parasites to their lethal 
action.
P ip e ro n y l  b u to x id e  (PB ) (F ig u re  3 -1 )  is a sy n th e t ic
m ethylenedioxy  phenyl de riva tive  w idely used as a pyrethrin  
synergist (O'Brian, 1967; Haley, 1978; Wayne Ivie & Rowe, 1986) 
and has been shown to inhibit mixed function oxidase activity in 
insects as well as in mammalians (Franklin, 1977; Haley, 1978). 
Inhibition of the cytochrom e P450 activ ity  was observed in
microsomal preparations from goats treated for three consecutive 
days with piperonyl butoxide (Burley & Bray, 1983).
The present study was carried out in order to investigate the effect 
of p ip e ro n y l  bu tox ide  as a m etab o lic  in h ib i to r  on the 
pharm acokinetics of fenbendazole in goats and albendazole in 
sheep and goats.
3.2 Materials and Methods
3.2.1  Anim als
Six mixed breed goats and five Scottish Balckface sheep were used. 
They were kept indoors throughout the experimental period with 
hay and water provided ad libitum and concentrate twice a day.
3.2.2 Experim enta l  design
3 .2 .2 .1 Goats
Each goat received fenbendazole and albendazole alone or with 
piperonyl butoxide in a 4-phase randomized crossover study. A 4- 
week washout period was allowed between phases.
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Figure 3-1. Chemical structure of piperonyl butoxide.
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3.2 .2 .2  Sheep
Sheep were allocated to two groups ( one group of three animals 
and another group of two animals) and were administered the 
drugs in a two-way crossover design protocol, i.e, in the first phase 
one group received albendazole alone while the second group 
received both albendazole and p iperonyl butoxide and in the 
second phase each group received the alternative treatment in such 
a way that at the end of the experiment both treatments had been 
given sequentially to every animal used. A 4-week washout period 
was allowed between the experimental phases.
3.2.3 Drug administration and sampling procedure
Oral drenches of albendazole (Valbazen 2.5%) and fenbendazole 
(Panacur 2.5%) were given at a dose rate of 7.5 mg/kg bodyweight. 
P ip e ro n y l  b u tox ide  (A ld r ich  C h em ica ls )  was ad m in is te re d  
intramuscularly at a dose rate of 0.5 g/kg bodyweight, one hour 
prior to anthelmintic administration.
Blood samples were taken as previously described at 0, 0.25, 0.5, 1, 
2, 4, 8, 12, 24, 32, 48, 72 and 96 hours following administration of 
albendazole and fenbendazole. For the m easurm ent of piperonyl 
butoxide concentrations in plasma, two additional samples were 
taken 0.25 and 0.5 hours after piperonyl butoxide administration. 
Samples were stored at -20 ° C and analysed for the measurement 
of ABZ/FBZ metabolites and piperonyl butoxide concentrations.
3.2.4 Drug analysis
3.2 .4 .1  Standard preparation
Standards of ABZ m etabolites (Robert Young Ltd., UK), FBZ 
m etabolites (H oechst Ltd., Gebaude, G erm any) and piperonyl 
butoxide (Aldrich Chemicals Ltd., UK) were prepared as described 
previously (see Section 2.2.3.1).
3.2 .4 .2  Extraction
In order to extract sim ultaneously piperonyl butoxide and BZ 
m etabolites, an extraction method involving plasma precipitation 
was developed. Half a ml of plasma was precipitated with 1ml of 
acetonitrile and vortexed for 30 secondes, 4 ml of chloroform were 
added and the tube was shaken on a slow rotary mixer for 10
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minutes. After centrifugation at 1700 g,  4 mi of the organic phase 
were transferee! to a thin-walled 10 ml conical glass tube and 
evaporated to dryness at 50 ° C under air. The residue was 
reconstitu ted  with 150 p.1 of methanol, placed in an ultrasonic 
water bath for 1 minute and finally injected.
3.2 .4.3 HPLC system
HPLC conditions were similar to those described in Chapter 2 
(Section 2.2.3.4) except for the solvent mixture used for the elution 
of ABSO, A B S 02  and piperonyl butoxide. This was a mixture 
methanol:water (87:13) to which 160 p.1 of 1.1% perchloric acid per 
100ml of solvent were added; the flow rate was 0.6 ml/min. The 
retention times were 2.50, 3.10 and 5.00 minutes for albendazole 
su lp h o n e ,  p ip e ro n y l  b u to x id e  and a lb e n d a z o le  su lp h o x id e  
respectively (Figure 3-2). Recoveries and precision of the method 
are reported in Appendices B-1 and B-2.
3.2 .5  P harm acok in et ic  and sta t is t ica l  ana lys is
P h a rm a c o k in e t ic  p a ra m e te rs  w ere e s t im a te d  as p re v io u s ly  
described (see Section 2.2.4).
D ifferences between treatm ents were analysed  by a W ilcoxon 
signed rank test for data obtained in goats. Pharmacokinetic data 
obtained in sheep were investigated for normality using normal 
probability plots and correlation analysis and were then analysed 
by a paired Student-t test. Comparisons between sheep and goats 
were carried out using a Mann-Witney U-test. Differences were 
judged significant when P < 0 .0 5 .
3.3 Results
3.3.1  Fenbendazole  and a lbendazole  m etabol ites  in goats
Plasma concentrations of fenbendazole (Table 3-1, Appendix B-3 
and B-5), fenbendazole sulphoxide (Table 3-3, Appendices B-7 and 
B-9) and fenbendazole sulphone (Table 3-5, Appendix B -11 and B- 
13) are plotted in Figures 3-3, 3-4 and 3-5, respectively. Mean 
pharm acokinetic  parameters of these m etabolites are shown on 
Tables 3-2, 3-4 and 3-6 (see Appendix B for individual values). 
M ean m axim um  co n cen tra tio n s  (C m ax) ach ieved  fo llo w in g  
adm in is tra t io n  of fenbendazo le  alone were 0 .19 , 0.25 and
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Table 3-1. Plasma concentrations of fenbendazole (FBZ) (|ig/ml) in goats 
following administration of fenbendazole (7.5 mg/kg) either alone or in 
combination with piperonyl butoxide (0.5 g/kg).
Mean ±- SEM (n=6)
T im e F enbendazo le Fenbendazole with
(ho u rs) alone Piperonyl butoxide
0 0.00 ± 0.00 0.00 ± 0.00
0 .25 0.00 ± 0.00 0.00 ± 0.00
0 .5 0 0.00 ± 0.00 0.00 ± 0.00
1 0.00 ± 0.00 0.01 ± 0.00
2 0.02 ± 0.01 0.05 ± 0.02
4 0.09 ± 0.02 0.14 ± 0.04
8 0.19 ± 0.03 0.32 ± 0.05
1 2 0.18 ± 0.02 0.37 ± 0.05
2 4 0.13 ± 0.02 0.40 ± 0.08
3 2 0.07 ± 0.02 0.31 ± 0.05
4 8 0.01 ± 0.01 0.14 ± 0.04
7 2 0.00 ± 0.00 0.02 ± 0.01
9 6 0.00 ± 0.00 0.00 ± 0.00
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Figure 3-3. Plasma concentrations of fenbendazole (mean ± SEM) 
following administration of fenbendazole alone (n=6) or with 
piperonyl butoxide (n=6) in goats.
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Table 3-2. Pharmacokinetic parameters of fenbendazole (FBZ) in goats 
following administration of fenbendazole (7.5 mg/kg) either alone or in 
combination with piperonyl butoxide (0.5 g/kg).
Mean ± SEM (n=6)
FBZ
F enben dazo le
a lone
Fenbendazole with 
p iperonyl butoxide
AUCobs (lag.h/ml) 4.76 ± 0.65 15.59 ± 2.52*
AUMCobs(p.g.h^/ml) 88.83 ± 15.99 422.68 ± 89.74*
MRT (h) 18.42 ± 1.03 25.85 ± 1.85*
Cmax (jig/ml) 0.19 ± 0.02 0.45 ± 0.07
tmax (h) 9.00 ± 0.02 16.33 ± 2.75
* Significantly different from fenbendazole alone (P< 0.05)
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Table 3-3. Plasma concentrations of fenbendazole sulphoxide (FBSO) 
(p.g/ml) in goats following administration of fenbendazole (7.5 mg/kg) 
either alone or in combination with piperonyl butoxide (0.5 g/kg).
Mean ± SEM (n=6)
T im e F enben dazo le Fenbendazole with
(hou rs) alone Piperonyl butoxide
0 0.00 ± 0.00 0.00 ± 0.00
0 .25 0.00 ± 0.00 0.00 ± 0.00
0 .5 0 0.00 ± 0.00 0.00 ± 0.00
1 0.00 ± 0.00 0.00 ± 0.00
2 0.00 ± 0.00 0.00 ± 0.00
4 0.02 ± 0.01 0.03 ± 0.01
8 0.14 ± 0.02 0.21 ± 0.04
1 2 0.22 ± 0.03 0.44 ± 0.08
2 4 0.25 ± 0.03 0.58 ± 0.08
3 2 0.19 ± 0.03 0.60 ± 0.08
4 8 0.03 ± 0.01 0.31 ± 0.08
7 2 0.00 ± 0.00 0.03 ± 0.02
9 6 0.00 ± 0.00 0.00 ± 0.00
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F igure  3-4. P lasm a  c o n cen tra t io n s  of fenbendazo le  
sulphoxide (mean ± SEM) follow ing adm inistration of 
fenbendazole alone (n=6) or with piperonyl butoxide (n=6) 
in goats
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Table 3-4. Pharmacokinetic parameters of fenbendazole sulphoxide 
(FBSO) (|ig/ml) in goats following administration of fenbendazole 
(7.5 mg/kg) either alone or in combination with piperonyl butoxide 
(0.5 g/kg).
Mean ± SEM (n=6)
FBSO
F en b endazo le  Fenbendazole with 
a lone  piperonyl butoxide
AUCobs (fig.h/ml) 
AUMCobs( | ig .h2/ml)  
MRT (h)
Cmax (jig/ml) 
tmax (h)
7.72 ± 0.99 24.40 ± 3.45* 
186.44 ± 28.48 772.99 ± 142.76* 
23.95 ± 1.01 30.70 ± 2.02* 
0.25 ± 0.03 0.65 ± 0.08* 
23.00 ± 1.00 26.67 ± 1.33
* Significantly different from fenbendazole alone (P< 0.05)
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Table 3-5. Plasma concentrations of fenbendazole sulphone (FB S 02) 
(p.g/ml) in goats following administration of fenbendazole (7.5 mg/kg) 
either alone or in combination with piperonyl butoxide (0.5 g/kg).
Mean ± SEM (n=6)
T im e F en b end azo le Fenbendazole with
(hou rs) a lone Piperonyl butoxide
0 0.00 ± 0.00 0.00 ± 0.00
0 .25 0.00 ± 0.00 0.00 ± 0.00
0 .5 0 0.00 ± 0.00 0.00 ± 0.00
1 0.00 ± 0.00 0.00 ± 0.00
2 0.00 ± 0.00 0.00 ± 0.00
4 0.00 ± 0.00 0.01 ± 0.01
8 0.02 ± 0.00 0.04 ± 0.01
12 0.04 ± 0.01 0.06 ± 0.02
2 4 0.09 ± 0.01 0.08 ± 0.02
3 2 0.09 ± 0,01 0.09 ± 0.01
4 8 0.03 ± 0.01 0.11 ± 0.01
7 2 0.00 ± 0.00 0.05 ± 0.01
9 6 0.00 ± 0.00 0.01 ± 0.00
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Figure 3-5. Plasma concentrations of fenbendazole sulphone 
(mean ± SEM) following administration of fenbendazole alone 
(n=6) or with piperonyl butoxide (n=6) in goats.
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Table 3-6. Pharmacokinetic param eters of fenbendazole sulphone 
(FB S02) (pig/ml) in goats following administration of fenbendazole 
(7.5 mg/kg) either alone or in combination with piperonyl butoxide 
(0.5 g/kg).
Mean ± SEM (n=6)
FBS02
F enbendazo le  Fenbendazole with 
a lone  piperonyl butoxide
AUCobs (lig.h/ml) 
AUMCobs(|J-g.h2/ml) 
MRT (h)
Cmax (p,g/ml) 
tmax (h)
3.02 ± 0.40 6.03 ± 0.68* 
104.17 ± 15.93 262.36 ± 29.22* 
34.37 ± 1.52 43.90 ± 3.20* 
0.08 ± 0.01 0.12 ± 0.01 
29.33 ± 1.33 34.00 ± 5.82
Significantly different from fenbendazole alone (P< 0.05).
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0.08 |ig/m l for FBZ, FBSO and F B S 0 2 ,  respectively ; when 
fenbendazole was given after piperonyl butoxide administration, 
the Cmax values for each of these metabolites were increased 
by 137%, 160% and 50%, respectively. Areas under the plasma 
concentrations versus time curves and mean residence times were 
significantly increased (P < 0.05) for FBZ and metabolites when
piperonyl butoxide was given prior to fenbendazole administration. 
The concentrations of albendazole were under the limit of detection 
when adm inistered  alone or in com bina tion  with p iperonyl 
butoxide. Albendazole sulphoxide and albendazole sulphone plasma 
concentrations are shown in Tables 3-7 and 3-9, Appedices B-15, 
B-17, B-19 and B-21 and Figures 3-6 and 3-7. Large interindividual 
variations were observed and although a 93% increase in the AUC 
of A B S 02  occured after pretreatm ent with piperonyl butoxide, 
there were no sta tistically  significant changes in the kinetic 
variables of albendazole metabolites (Tables 3-8 and 3-10, 
Appendices B-16, B-18, B-20 and B-22).
3.3.2 Albendazole  metabolites  in sheep
Given alone or in combination with piperonyl butoxide, albendazole 
was not detected in p lasm a at any sam pling time. Plasm a 
concentrations of the sulphoxide and the sulphone metabolites are 
reported in Tables 3-11 and 3-13, Appendices B-23, B-25, B-27 and 
B-29 and plotted in Figures 3-8 and 3-9. The AUC of the sulphoxide 
metabolite (ABSO) was increased from 25.61 |ig.h/ml (albendazole 
a lo n e )  to 45.41 p .g .h/m l (a lb e n d a z o le  w ith  p ip e ro n y l  
butoxide)(Table 3-12; Appendices B-24 and B-26). The MRT and 
the tmax of the same metabolite were prolonged by 4.86 and 6.00 
hours, respectively, when the combination ABZ-PB was given. 
Increases in the AUC and MRT of A BS02 were also observed with 
the combination (Table3-14; Appendices B-28 and B-30).
3.3.3 Piperonyl butoxide in sheep and goats
Piperonyl butoxide was slowly absorbed following in tram uscular 
administration. It reached plasma levels of 0.26 p-g/ml in goats and 
0.45 |ig/ml in sheep 10 minutes after injection and peak plasma 
concentrations occured 10 hours (sheep) and 15 hours (goats) after 
drug administration and were significantly higher in sheep than in 
goats (Tables 3-15 and 3-16; Appendices B-31, B-32, B-33 and
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Table 3-7. Plasma concentrations of albendazole sulphoxide (ABSO) 
(jig/ml) in goats following administration of albendazole (7.5 mg/kg) 
either alone or in combination with piperonyl butoxide (0.5 g/kg).
Mean ± SEM (n=6)
T im e albend azo le albendazole with
(h o u rs) alone Piperonyl butoxide
0 0.00 ± 0.00 0.00 ± 0.00
0 .25 0.02 ± 0.01 0.01 ± 0.01
0.5 0.09 ± 0.01 0.10 ± 0.03
1 0.29 ± 0.08 0.26 ± 0.07
2 0.72 ± 0.22 0.74 ± 0.17
4 1.37 ± 0.30 1.58 ± 0.36
8 1.74 ± 0.28 1.54 ± 0.17
1 2 1.65 ± 0.28 1.33 ± 0.13
2 4 0.37 ± 0.19 0.69 ± 0.41
3 2 0.03 ± 0.03 0.34 ± 0.43
4 8 0.00 ± 0.00 0.09 ± 0.09
7 2 0.00 ± 0.00 0.01 ± 0.01
9 6 0.00 ± 0.00 0.00 ± 0.00
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Figure 3-6. Plasma concentrations of albendazole sulphoxide 
(mean ± SEM) following administration of albendazole alone 
(n=6) or with piperonyl butoxide (n=6) in goats.
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Table 3-8. Pharm acokinetic param eters for albendazole sulphoxide 
(ABSO) in goats following administration of albendazole at 7.5 mg/kg 
either alone or in combination with piperonyl butoxide (0.5 g/kg)
Mean ± SEM (n=6)
ABSO
alben dazo le  albendazole with 
a lone  piperonyl butoxide
A U C obs (M-g.h/ml) 
A U M C o b s( |ig .h ^ /m ) 
MRT (h)
Cmax (|ig/ml) 
tmax (h)
29.63 ± 3.77 35.82 ± 9.13 
333.85 ± 69.78 593.51 ± 324.05 
10.92 ± 1.29 12.94 ± 2.94 
2.00 ± 0.27 2.11 ± 0.22 
8.67 ± 1.61 10.00 ± 3.06
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Table 3-9. P lasm a concen tra tions of a lbendazo le  su lphone 
(A BS02) (jig/ml) in goats following administration of albendazole 
(7.5 mg/kg) e ither alone or in com bination with p iperonyl 
butoxide (0.5 g/kg).
Mean ± SEM (n=6)
Tim e a lben d azo le albendazole with
(hou rs) a lone Piperonyl butoxide
0 0.00 ± 0.00 0.00 ± 0.00
0 .25 0.00 ± 0.00 0.00 ± 0.00
0 .5 0 0.00 ± 0.00 0.00 ± 0.00
1 0.01 ± 0.01 0.00 ± 0.00
2 0.04 ± 0.02 0.04 ± 0.02
4 0.15 ± 0.04 0.20 ± 0.05
8 0.34 ± 0.07 0.49 ± 0.09
1 2 0.57 ± 0.09 0.72 ± 0.11
2 4 0.56 ± 0.20 0.95 ± 0.24
3 2 0.13 ± 0.08 0.32 ± 0.17
4 8 0.00 ± 0.00 0.22 ± 0.22
7 2 0.00 ± 0.00 0.00 ± 0.00
9 6 0.00 ± 0.00 0.00 ± 0.00
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Figure 3-7. Plasma concentrations of albendazole sulphone
(mean ± SEM) following administration of albendazole alone
(n=6) or with piperonyl butoxide (n=6) in goats.
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Table 3-10. Pharmacokinetic parameters for albendazole sulphone 
(ABS02) in goats following administration of albendazole at 
7.5 mg/kg either alone or in combination with piperonyl butoxide 
(0.5 g/kg).
Mean ± SEM (n=6)
ABS02
alben dazo le  albendazole with 
a lone  piperonyl butoxide
A U C obs (lig.h/ml)
A U M C obs(K g.h^/m ) 
MRT (h)
Cmax (|ag/ml) 
tmax (h)
13.57 ± 2.20 26.17 ± 5.26 
250.77 ± 58.78 651.36 ± 260.12 
16.19 ± 1.81 21.13 ± 3.83 
0.78 ± 0.14 1.19 ± 0.14 
18.00 ± 2.68 26.00 ± 4.82
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Table 3-11. Plasma concentrations of albendazole sulphoxide (ABSO) 
(jig/ml) in sheep following administration of albendazole (7.5 mg/kg) 
either alone or in combination with piperonyl butoxide (0.5 g/kg).
Mean ± SEM (n=5)
T im e a lbendazo le albendazole with
(h o u rs ) alone Piperonyl butoxide
0 0.00 ± 0.00 0.00 ± 0.00
0 .25 0.08 ± 0.02 0.00 ± 0.00
0 .5 0 0.30 ± 0.07 0.08 ± 0.03
1 0.66 ± 0.16 0.25 ± 0.06
2 1.40 ± 0.25 0.59 ± 0.14
4 1.95 ± 0.34 1.10 ± 0.25
8 1.47 ± 0.16 2.43 ± 0.38
12 1.05 ± 0.06 2.20 ± 0.32
2 4 0.26 ± 0.06 0.94 ± 0.14
3 2 0.02 ± 0.01 0.35 ± 0.08
4 8 0.00 ± 0.00 0.00 ± 0.00
7 2 0.00 ± 0.00 0.00 ± 0.00
9 6 0.00 ± 0.00 0.00 ± 0.00
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Figure 3-8. Plasma concentrations of albendazole sulphoxide
(mean ± SEM) following administration of albendazole alone (n=5)
or with piperonyl butoxide (n=5) in sheep.
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Table 3-12. Pharmacokinetic parameters of albendazole sulphoxide 
(ABSO) in sheep following administration of albendazole at 7.5 
mg/kg either alone or in combination with piperonyl butoxide
Mean ± SEM (n=5)
ABSO
A lbendazo le  Albendazole with 
a lone  piperonyl butoxide
AUCobs (P-g.h/ml) 
AUMCobs(M.g.h2/ml) 
MRT (h)
Cmax (jig/ml) 
tmax (h)
25.61 ± 2.24 45.41 ± 4.29* 
244.19 ± 21.04 665.57 ± 84.32** 
9.66 ± 0.81 14.52 ± 0.96* 
2.01 ± 0.30 2.35 ± 0.29 
4.40 ± 0.98 10.40 ± 0.98**
'(P<0.05); **(P<0.01) Significantly different from albendazole alone.
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Table 3-13. Plasma concentrations of albendazole sulphone (A B S02) 
(|ig /m l) in sheep following administration of albendazole (7.5 mg/kg) 
either alone or in combination with piperonyl butoxide (0.5 g/kg).
Mean ± SEM (n=5)
T im e a lben dazo le albendazole with
(hou rs) a lone Piperonyl butoxide
0 0.00 ± 0.00 0.00 ± 0.00
0 .25 0.00 ± 0.00 0.00 ± 0.00
0 .5 0 0.00 ± 0.00 0.00 ± 0.00
1 0.02 ± 0.01 0.00 ± 0.00
2 0.06 ± 0.02 0.04 ± 0.02
4 0.16 ± 0.03 0.14 ± 0.06
8 0.28 ± 0.03 0.37 ± 0.06
1 2 0.34 ± 0.03 0.61 ± 0.08
2 4 0.33 ± 0.03 0.77 ± 0.06
3 2 0.07 ± 0.04 0.45 ± 0.15
4 8 0.00 ± 0.00 0.11 ± 0.06
7 2 0.00 ± 0.00 0.00 ± 0.00
9 6 0.00 ± 0.00 0.00 ± 0.00
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Figure 3-9. Plasma concentrations of albendazole sulphone
(mean ± SEM) following administration of albendazole alone
(n=5) or with piperonyl butoxide (n=5) in sheep.
7 0
Table 3-14. Pharmacokinetic parameters for albendazole sulphone 
(A B S02) in sheep following administration of albendazole at 7.5 
mg/kg either alone or in combination with piperonyl butoxide.
Mean ± SEM (n=5)
ABS02
a lb endazo le  albendazole with 
a lone  piperonyl butoxide
AUCobs (Hg.h/ml) 
AUMCobs(M-g.h2/ml) 
MRT (h)
Cmax (pg/ml) 
tmax (h)
8.22 ± 0 .76t 22.32 ± 2.23** 
133.95 ± 17.86 541.96 ± 99.97* 
16.12 ± 0.74 23.52 ± 2.54* 
0.36 ± 0 .0 3 t t  0.80 ± 0.05** 
14.40 ± 2.40 26.00 ± 2.68**
* (P<0.05); ** (P<0.01) Significantly different from albendazole alone,
t  (P<0.05); f t  (P<0.01) Significantly different from corresponding 
values in goats.
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Table 3-15. Plasma concentrations of piperonyl butoxide (|ig/ml) in 
sheep and goats follow ing in tram uscular injection of piperonyl 
butoxide at 0.5 g/kg bodyweight.
Mean ± SEM
Time (h) Goats (n=6) Sheep (n=5)
0 0.00 ± 0.00 0.00 ± 0.00
0 .16 7 0.26 ± 0.04 0.45 ± 0.08
0 .5 0 0.38 ± 0.09 0.67 ± 0.10
1 0.36 ± 0.11 1.07 ± 0.26
2 0.59 ± 0.08 1.55 ± 0.39
3 0.68 ± 0.08 2.01 ± 0.44
5 0.87 ± 0.08 2.14 ± 0.41
9 1.11 ± 0.15 2.19 ± 0.26
1 3 1.32 ± 0.16 2.67 ± 0.41
25 1.06 ± 0.18 2.49 ± 0.39
33 0.92 ± 0.17 1.52 ± 0.28
4 9 0.83 ± 0.15 0.82 ± 0.12
7 3 0.70 ± 0.09 0.83 ± 0.13
9 7 0.63 ± 0.07 0.93 ± 0.27
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Figure 3-10. Plasma concentrations of piperonyl butoxide 
(mean ± SEM) following intramuscular administration 
to sheep (n=5) and goats (n=6).
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Table  3-16. Pharm acokinetic  param eters o f p iperonyl butoxide 
administered intramuscularly to sheep and goats at a dose rate of 
0.5 g/kg bodyweight.
Mean ± SEM
Sheep (n=5) Goats (n=6)
AUCobs (lig.h/ml) 
AUMCobs(Kg.h2/ml) 
MRT (h)
Cmax (jig/ml) 
tmax (h)
132.96 ± 18.93 82.10 ± 10.99 
4969.3 ± 835.45 3588.7 ± 454.26 
37.04 ± 1.67 44.01 ± 0.83** 
2.92 ± 0.40 1.17 ± 0.20* 
10.20 ± 1.50 15.00 ± 2.00*
* (P<0.05); ** (P<0.01) Significantly different from sheep.
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B-34; Figure 3-10). The AUC of piperonyl butoxide was 62% higher 
in sheep.
3.4 Di scuss ion
The alteration of liver drug oxidative metabolism by pretreatment 
with piperonyl butoxide resulted  in significant changes in the 
pharm acokinetic  patterns of the two benzim idazole  com pounds 
studied. These changes were mainly expressed as increases in the 
bioavailability of the two metabolites measured and also, in the
case of fenbendazole, of the parent compound. Previous studies
carried out in vitro and in vivo have shown that the rate of
sulphoxidation and sulphonation of the benzimidazole drugs could 
be altered by m etabolic inh ib ito rs  which in te rfere  with the 
m icrosom al flavine m onooxygenase and, or, cy tochrom e P450- 
dependent activities (Fargetton et a i ,  1986; Galtier et al., 1 9 8 6 a ;  
Lanusse et al., 1991; Murray et a l ,  1992; Lanusse et al., 1993c). 
Piperonyl butoxide is a substrate for cytochrome P450-dependent 
oxidative m etabolism  and its b io transform ation by this system
results in the formation of metabolic interm ediates which bind 
covalently to cytochrome P450 enzymes; the complex thus formed 
results in an inhibition of the enzymatic activity of the system 
(Franklin, 1977). In this study, the absence of albendazole parent 
drug from the plasm a of both p iperonyl bu tox ide-p re trea ted  
anim als and control (albendazole  alone) anim als supports the 
suggestion that, in ruminants, albendazole sulphoxidation is far 
more predominantly catalysed by the flavine monooxygenase than 
by the cytochrome P450-dependent monooxygenase (Galtier et al., 
1986a; Delatour et al., 1994). On the other hand, the increased area 
under the plasma concentration-tim e curve, mean residence time 
and the delayed peak p lasm a concentra tion  of a lbendazole  
su lphoxide  observed in sheep when a lbendazo le  was given 
fo llow ing p iperonyl butoxide adm in istra tion , dem onstra tes  the 
inhibition of the cytochrome P450-dependent sulphonating reaction 
(Souhaili-El Amri et al., 1988b) by this metabolic inhibitor. There 
was also a significant increase in the AUC, MRT and tmax of the 
sulphone metabolite which was due, at least partly, to a slower rate 
of sulphone formation. Another reason for the increase in the 
b ioavailability  of the sulphone stems from the nature of the 
metabolism that this compound undergoes. According to Gyurik et 
a l  (1981), albendazole sulphone is hydroxylated in aromatic or
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alkyl positions with possible further conjugation; the hydroxylation 
could be catalysed by a cytochrome P450-enzyme system which 
was inhibited in the present study by piperonyl butoxide resulting 
in increased albendazole sulphone. Infection of lambs with F a sc io la  
h e p a t i c a ,  which also decreases hepatic mixed function oxidase 
activity (Galtier et al., 1983; 1985a; 1986b), has been shown to 
result in a dramatic increase of albendazole  sulphone plasma 
concentrations (Galtier et a i ,  1991).
More than 3-fold increases in the AUC of fenbendazole and 
fenbendazole sulphoxide were observed when fenbendazole was 
given following metabolic inhibition with piperonyl butoxide. There 
is evidence from in vitro inhibition studies that the sulphoxidation 
of fenbendazole involves both the flavine-monooxygenase and the 
cytochrome P450 enzyme systems whereas for the sulphonation 
and hydroxylation of fenbendazole sulphoxide, evidence only exists 
to implicate the cytochrome P450-monoxygenase system (Murray 
et al., 1992). Although, this provides an explanation of the changes 
caused by piperonyl butoxide to the kinetic disposition of both FEZ 
and FBSO, there is also a possiblity that the increase in the 
b ioavailab ility  of the paren t com pound is a consequence  of 
increased sulphoxide concentra tions; since d istribution  of this 
metabolite  into the gastrointestinal tract, its reduction into the 
sulphide by the gut m icroflora  (M arriner, 1980) follow ed by 
reabsorption would indeed increase the systemic availability of FEZ. 
The AUC and MRT of fenbendazole sulphone were also increased, as 
a result of a retarded sulphonation and may be also, as a 
consequence of an inhibition of FES0 2  hydroxylation.
Overall, there was a difference in the extent to which piperonyl 
butoxide affected the pharmacokinetics of the two benzimidazole 
drugs in goats. It could be that different isozymes of cytochrome 
P450 are involved in the metabolic pa thw ays of the two 
anthelmintics and that these isozymes are differently affected by 
the m etabolic  inhibitor used. Isozyme specificity  of piperonyl 
butoxide has been previously shown in rats using different probe 
drugs for hepatic drug-m etabolizing activity  (Eachmann, 1989). 
W hile the c learance o f  antipyrine, used as a probe for the 
cytochrome P450 IIE l and P450 IIE2 isoforms, was decreased by 
50% fo llo w in g  p re tre a tm e n t  with p ip e ro n y l  bu tox ide , the 
disposition of quinidine, expressing the activity of the cytochrome 
P450 IIIA subfamily, was unaffected by this inhibitor. Another
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factor may be the relative importance of hydroxylation for the
metabolites of the two benzimidazoles studied. Hennessy (1985)
has shown that the total (free and conjugated) hydroxylated 
albendazole sulphoxide accounted for 3% of the total dose of 
a lb e n d a z o le  a d m in is te re d  to sheep w h e rea s  h y d ro x y la te d  
fenbendazole sulphoxide represented nearly 26% of the dose of 
fenbendazole given; On the other hand, 3% of the total dose of
albendazole was converted to hydroxylated albendazole sulphone 
when only 0.6% of the total dose of fenbendazole was metabolised 
into hydroxylated sulphone. The extent of hydroxylation and the 
possible effect of piperonyl butoxide inhibition on hydroxylating
reactions, may help to explain why at the same dosage rate of
p iperonyl bu toxide , d iffe ren t changes in the d isposition  of 
' albendazole and fenbendazole metabolites were observed.
There was also a difference between the two animal species used, 
in the effect of PB on albendazole pharmacokinetics. Although the 
AUC of A B S 0 2  was doubled in PB-pretreated goats, inhibition did 
not affect markedly the plasma kinetics of ABSO in this animal
species w hereas in sheep , the p lasm a d isp osit io n  of both 
metabolites was significantly affected by metabolic inhibition. This 
in terspecies d ifference could be due to the re la tive ly  higher 
b ioavailability  of piperonyl butoxide observed in sheep in the
present study; the plasma concentrations achieved in the goats,
although high enough to alter the metabolism of fenbendazole, 
might not have been sufficient to cause significant changes in the 
metabolism of albendazole.
C om para tive  studies have revea led  c o n s id e ra b le  d if fe rences  
betw een rum inan t species regard ing  the ph arm acok ine tics  of 
an the lm in tic  drugs. M ost of these s tud ies  em phasised  the 
d ifferences encountered between sheep and goats. It has been 
reported that thiabendazole was metabolised faster in goats than in 
sheep (W eir & Bogan, 1985). Lower p lasm a concentrations of 
oxfendazole and metabolites were also observed in goats compared 
to sheep (Bogan et a i ,  1987; Sangster et al., 1991; Hennessy et al., 
1993a). This lower bioavailability may account for the poor efficacy 
of oxfendazole in goats when administered at the dosage rate 
recommended for sheep (Kettle et al., 1983). A similar suggestion 
has been made by Gillham & Obendorf (1985) to explain the poor 
efficacy of levamisole in goats. These d ifferences extend to
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fasciolicide drugs; the AUC of clorsulon after oral adminstration in 
goats was 60 % of that in sheep (Sundlof et a i ,  1991; Sundlof & 
Whitlock, 1992) and the rate of closantel elimination was 2 to 3- 
times greater in goats than in sheep (Hennessy et al., 1993b). It has 
been reported by Hennessy et al. (1993c) that the AUC of ABSO 
following administration of albendazole was lower in goats than in 
sheep, though no major difference in the elimination rate was 
observed, but the AUC and elimination half-life of A B S 0 2  were 
similar between the two species. These authors suggested that the 
difference in the systemic availability of ABSO was unlikely to be 
due to a difference in the metabolic rate and that it could be related 
to a greater sequestration of ABSO in the liver of goats. In the 
present study, the only difference found between sheep and goats 
regarding the pharmacokinetics of ABSO following administration of 
albendazole was the longer tmax (P=0.05) observed in the latter 
species. This could be due to a slower digesta flow rate in the goat 
(Hennessy et al., 1993c). Regarding the kinetics of the sulphone 
metabolite (ABS02) it is not clear why higher AUC and Cmax were 
found in goats .
A substantial difference was observed between the albendazole 
pharm acokinetic  values found in the present study and those 
reported in a previous experiment (see Chapter 2). Because the two 
experiments were conducted two years apart and four of the goats 
were used in both experiments, the difference could well be due to 
age. Some drug-metabolising enzyme activities have indeed been 
shown to increase with age (Kaddouri et al., 1990; Kawalek and El 
Said, 1990). However, McKellar et al (1993b) did not demonstrate 
any d iffe ren ces  in the ph a rm aco k in e t ic s  o f ne tob im in  or 
albendazole metabolites between 3 and 9 month old lambs.
In conclusion, this study shows that p iperonyl butoxide has 
increased  s ign if ican tly  the b ioavailab ili ty  o f abendazo le  and 
fenbendazole metabolites and this could be exploited in increasing 
the efficacy of benzimidazole drugs.
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C h a p te r  4
Dose t i t r a t io n  and  efficacy s tud ies  w ith  the  co m b in a t io n  
f e n b e n d a z o le - p ip e r o n y l  b u to x id e  in  sh eep
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4.1 I n t r o d u c t io n
The systemic availability of fenbendazole m etabolites has been 
shown to increase dram atically following pretreatm ent of goats 
with piperonyl butoxide (see Chapter 3).
The present study was undertaken in order to determine the effect 
of the combination in sheep, at various oral dose rates of piperonyl 
butoxide and to evaluate the efficacy of the drug mixture against 
benzim idazole-resistant gastric nematodes.
4.2 M a te r ia ls  and  M ethods
4 .2 .1  A n im a ls
All animals were maintained indoors under conditions described 
previously (Section 2.2.1).
4 .2 .2  E x p e r im e n ta l  des ign
4.2.2 .1 O ra l  b io av a ila b il i ty  of p ip e ro n y l  b u to x id e
Two (02) 1 year-old Scottish Blackface sheep were given piperonyl 
butoxide orally at a dose rate of 0.5 g/kg bodyweight. Blood 
samples were taken prior to drug administration and 0.25, 0.5, 
0.75, 1, 2, 3, 4, 6, 8, 12, 24, 32, 48, 72, 96, 120, 144 and 319 hours 
th e re a f te r .
4.2 .2 .2 Dose t i t r a t io n  s tudy
Six (06) Scottish Blackface sheep were used in a 6-way crossover 
design study (Table 4-1) whereby a fixed dose of fenbendazole 
(Panacur 2.5% at 5 mg/kg bodyweight) was co-administered with 0, 
15, 31, 63, 125 and 250 mg/kg bodyweight of piperonyl butoxide. 
4 -w eek  w ashout periods were observed betw een crossovers . 
Because of the risk of piperonyl butoxide aspiration during oral 
dosing it was decided for the present study, to administer the drugs 
by stomach tube. Immediately after drug administration, the tube 
(10 mm X 2 m. Vet Drug Company pic, Falkirk, UK) was flushed with 
20 ml of water. Blood samples were taken and stored as previously 
described (Section 2.2.2) and were analysed by HPLC for the 
quantification of FEZ metabolites.
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Table 4-1. Piperonyl butoxide dosing schedule adopted during 
the dose titration study (dose rates are in mg/kg).
Animal num ber
76 77 78 97 98 9 9
Crossover 1 0 2 5 0 125 63 125 2 5 0
Crossover 2 15 0 2 5 0 3 1 63 125
Crossover 3 3 1 1 5 0 1 5 3 1 63
Crossover 4 63 3 1 15 0 15 3 1
Crossover 5 125 63 3 1 2 5 0 0 1 5
Crossover 6 2 5 0 125 63 125 2 5 0 0
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4.2.2.3  E fficacy  t r ia l
This was carried out in comformity with the World Association for 
the Advancement of Veterinary Parasitology (WAAVP) guidelines 
(Powers et al., 1982).
Twenty-four (24) parasite-naive Suffolk cross lambs were allocated 
into four groups (A, B, C and D) of six animals each. Each lamb 
received  an oral dose of 6 ,000 in fec tive  larvae  (L3) of
b ez im idazo le -re  sis tan t Ostertagia  c ircum cinc ta  and 2,400 (L3) 
b e n z im id a z o le - re s is ta n t  H aemonchus  contor tus  (both  parasite  
strains were purchased from the Moredun Institute, Edinburgh, 
UK). Twenty-eight days after infection, group B was treated with 
fenbendazole at the recommended dose rate, group C received
piperonyl butoxide at the selected dose ra te  of 63 mg/kg 
b o d yw eig h t,  g roup D was trea ted  w ith  the com b ina tio n
fenbendazole:piperonyl butoxide (5 mg/kg: 63 mg/kg) and animals 
in group A were left untreated as controls. Seven days after 
treatment, faecal samples were taken, all animals were killed and
their abomasa collected for parasite counting.
4.2.3 D rug  ana ly s is
4 .2 .3 .1  E x t r a c t io n
The extraction of piperonyl butoxide was identical to that described 
previously (Section 3.2.4.2).
For the extraction of FBZ metabolites, a solvent extraction using 
chloroform was performed. To 1 ml of plasma were added 200 |xl 
of ammonium chloride, 0.2 g of sodium chloride and 6 ml of 
chloroform. After shaking for 10 minutes on a slow rotary mixer, 
the samples were centrifuged for 20 minutes at 1700 g .  The 
supernatant was carefully removed and discarded and 4 ml of the 
organic phase were transfered to a 10ml thin-walled tube. Samples 
were evaporated to dryness under nitrogen, reconstituted in 150 
|il methanol then processed on the HPLC system.
4.2.3.2 H P L C  system
The HPLC conditions for the analysis of piperonyl butoxide were as 
previously described (Section 3.2.4.3).
A computerised (PC 1000, Spectra-Physics Analytical Inc., UK) HPLC 
system comprising a gradient pump (model P 4000), a UV-detector 
(model Spectra-Focus), an autosampler (model AS 3000) and a
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controller (model SN 4000), was used for the analysis of FBZ, FBSO 
and FB S02. The mobile phase was a mixture acetonitrile-water to 
which glacial acetic acid (BDH Ltd., Pool, UK) was added (0.5 %, v/v). 
It was pumped through the column (CIS Nucleosil 5, 10 cm X 4.6 
mm, HPLC Technology Ltd., Cheshire, UK) in a linear gradient 
fashion changing from 35:65 (acetonitrile:water) to 82:18 for 8 
m inutes, 82:18 to 35:65 for 1 minute and the last ratio was 
maintained for 3 minutes. The flow rate was 1.5 ml/minute. The 
detection was at 292 nm. The retention times were 1.60 minutes 
(FBSO), 2.60 minutes (FBS02) and 5 minutes (FBZ).
Recovery and precision of the extraction and HPLC detection are 
reported in Appendix C-1.
4.2.4 Faecal egg n u m b e rs  and  p a ra s i te  co u n tin g
4.2.4.1 Faeca l egg coun ts
These were carried out using the McMaster technique modified by 
G ordon and W hitlock  (1939). Three gram s of feces were 
homogenized in 42 ml of water and the suspension passed through 
a 250 |i sieve (Endecotts Ltd, London, England). Fifteen ml of the 
filtrate were collected in a glass tube and centrifuged for 3 minutes 
at 1500 g .  The supernatant was discarded and the pellet was 
resuspended in a saturated salt (NaCl) solution, both chambers of 
the M cM aste r  s lide  (G e lm an  H aw ksley  L td , H arro w d en , 
Northampton) were filled with the suspension (0.15 ml) and the 
number of eggs counted. The result was multiplied by a factor of 50 
to give the number of eggs per gram (epg) of faeces.
4 .2 .4 .2  W o rm  co u n tin g
After opening the abomasum along its greater curvature, the 
mucosal surface was washed under slow running water and the 
contents made up to 2 litres. Duplicate samples of 200 ml were 
taken and 1ml of iodine (45% solution) was added to each sample. 
In order to count possible immature or arrested larvae, the mucosa 
was scraped off and incubated for 6 hours with a pepsin- 
hydrochloric acid mixture at 42^C. The digest was made up to 2 
litres and again duplicate samples of 200 ml were taken and iodine 
was added to each sample.
After thorough mixing, 2 ml of abomasal content or digesta sample 
was transfered to a lined petri dish. The sample was decolourised 
with a sodium thiosulphate solution, the parasites were identified 
and counted. The procedure was repeated ten times so that 20 ml
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of each sample were screened and results for each parasite species 
multiplied by 100 to give the total number of worms in each 
abomasal sample.
4.2.5 P h a rm a c o k in e t ic  a n d  s ta t i s t ic a l  a n a ly s is
P h a rm ac o k in e t ic  v a r ia b le s  were d e te rm in e d  as p rev io u s ly  
described (Section 2.2.4).
Data from the dose titration study were analysed using the 
Wilcoxon signed rank-test and a P<0.05 was considered significant. 
Data from the efficacy trial were com pared using the Mann- 
Whitney U-test with P<0.01 as a level of significance. Geometric 
means were determined after Log^o (x + 1) transformation where
X is the worm or faecal egg number:
Geometric mean = Antilog [1/n Z Log (x; +1)]
Percentage efficacy was calculated as follows:
[Mean(control) - mean (treated)/mean (control)] x 100
4.3 R esu lts
4.3 .1  P ip e ro n y l  b u to x id e
P la sm a  lev e ls  of p ip e ro n y l  b u to x id e  and the re la te d  
pharm acokinetic  data  are d isp layed  on Tables 4-2 and 4-3 
resp ec tiv e ly . F ifteen  m inutes after ad m in is tra t ion , p iperonyl 
butoxide reached a mean plasma concentration of 4.53 |ig/ml. The 
peak  c o n c e n tra t io n  was re a c h e d  at 12 to 24 hours  
postadministration and the drug was not detectable after 13 days 
(Figure 4-1).
4 .3 .2  F e n b e n d a z o le  m e ta b o l i te s
Mean plasma concentrations (Figures 4-2, 4-3 and 4-4) and mean 
pharm acok inetic  param eters  of FBZ m etabo lites  ob tained  at 
different dose rates of piperonyl butoxide, are shown in Tables 4-4 
to 4-15. The corresponding individual values are shown in 
Appendices C-2 to C-37. The AUC of fenbendazole, fenbendazole 
sulphoxide and fenbendazole  sulphone increased  linearly  with 
increasing doses of piperonyl butoxide (r2=0.98 for FBZ, r2 = 0 .93  
for FBSO and r2=0.95 for FBS02) (Figure 4-5). However, when the
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Table 4-2. Plasma concentrations of piperonyl butoxide (jig/ml) in 
sheep following oral administration at 0.5 g/kg bodyweight.
Animal number
Time (hours) 95 9 6 M ean
0 0 .00 0 .0 0 0 .0 0
0.25 6.76 2 .29 4 .53
0.5 7 .22 2 .2 4 4 .73
0.75 7 .20 2 .98 5 .0 9
1 8.28 2.91 5 .6 0
2 9.85 5 .1 0 7 .4 8
3 8.69 6.33 7 .51
4 8.80 6 .46 7 .63
6 8.23 6.05 7 .1 4
8 9 .34 8 .10 8 .7 2
1 2 9 .72 8.75 9 .2 4
2 4 11.68 7 .3 4 9.51
3 2 11.47 8.65 10 .06
4 8 11.67 8 .09 9 .8 8
7 2 2 .70 1.45 2 .0 8
9 6 0 .52 0 .59 0 .5 6
120 0 .24 0 .26 0 .2 5
144 0 .26 0 .13 0 .2 0
3 1 9 0 .00 0 .0 0 0 .0 0
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Figure 4-1. Plasma concentrations of  piperonyl butoxide
administered orally to sheep (n=2) at 0.5 g/kg bodyweight.
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Table 4-3. Pharmacokinetic parameters of piperonyl butoxide in sheep 
following oral administration at 0.5 g/kg bodyweight.
Animal number
Sheep 95 Sheep 96 M ean
AU Cobs (|ig.h/ml) 7 6 1 .2 5 3 8 .4 64 9 .8
AUMCobs(M-g.h2/ml) 3 0 0 5 3 2 0 5 0 3 2 5 2 7 8
MRT (h) 3 9 .48 3 8 .0 8 38 .78
Cmax (|ig/ml) 11.67 8.75 10.21
tmax (h) 24 12 1 8
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Table 4-4. Plasma concentrations of FBZ metabolites (mean ± SEM) 
following administration of fenbendazole (5 mg/kg) alone.
Mean ± SEM (n=6)
Time (h) FBZ FBSO FBSO2
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0.25 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0.5 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
1 0.01 ± 0.01 0.00 ± 0.00 0.00 ± 0.00
2 0.08 ± 0.03 0.01 ± 0.01 0.00 ± 0.00
4 0.18 ± 0.03 0.07 ± 0.02 0.00 ± 0.00
8 0.20 ± 0.03 0.18 ± 0.02 0.02 ± 0.00
1 2 0.19 ± 0.04 0.23 ± 0.03 0.04 ± 0.01
2 4 0.16 ± 0.02 0.25 ± 0.04 0.09 ± 0.01
3 2 0.11 ± 0.01 0.22 ± 0.04 0.09 ± 0.01
4 8 0.06 ± 0.01 0.11 ± 0.02 0.10 ± 0.01
7 2 0.02 ± 0.00 0.02 ± 0.01 0.06 ± 0.01
9 6 0.00 ± 0.00 0.00 ± 0.00 0.03 ± 0.01
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Table 4-5. Plasma concentrations of FBZ metabolites (mean ± SEM) 
following administration of fenbendazole (5 mg/kg) in combination 
with piperonyl butoxide (15 mg/kg).
Mean ± SEM (n=6)
Time (h) FBZ FBSO FBSO2
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0 .25 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0.5 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
1 0.02 ± 0.01 0.00 ± 0.00 0.00 ± 0.00
2 0.05 ± 0.03 0.01 ± 0.01 0.00 ± 0.00
4 0.11 ± 0.01 0.04 ± 0.02 0.01 ± 0.00
8 0.18 ± 0.01 0.14 ± 0.02 0.02 ± 0.00
1 2 0.17 ± 0.01 0.21 ± 0.02 0.04 ± 0.01
2 4 0.17 ± 0.01 0.25 ± 0.02 0.08 ± 0.01
3 2 0.14 ± 0.02 0.24 ± 0.02 0.09 ± 0.01
4 8 0.09 ± 0.02 0.14 ± 0.02 0.10 ± 0.01
7 2 0.02 ± 0.00 0.03 ± 0.00 0.07 ± 0.01
9 6 0.00 ± 0.00 0.00 ± 0.00 0.04 ± 0.00
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Table 4-6. Plasma concentrations of FBZ metabolites (mean ± SEM) 
following administration of fenbendazole (5 mg/kg) in combination 
with piperonyl butoxide (31 mg/kg).
Mean ± SEM (n=6)
Time (h) FBZ FBSO FBSO]
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0.25 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0 .50 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
1 0.02 ± 0.01 0.00 ± 0.00 0.00 ± 0.00
2 0.07 ± 0.03 0.01 ± 0.00 0.00 ± 0.00
4 0.20 ± 0.05 0.06 ± 0.02 0.00 ± 0.00
8 0.29 ± 0.06 0.21 ± 0.04 0.02 ± 0.00
1 2 0.28 ± 0.04 0.30 ± 0.04 0.04 ± 0.01
2 4 0.27 ± 0.02 0.39 ± 0.05 0.09 ± 0.01
3 2 0.20 ± 0.02 0.37 ± 0.04 0.12 ± 0.01
4 8 0.16 ± 0.06 0.23 ± 0.05 0.12 ± 0.02
7 2 0.03 ± 0.00 0.06 ± 0.01 0.08 ± 0.01
9 6 0.01 ± 0.00 0.01 ± 0.00 0.05 ± 0.00
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Table 4-7. Plasma concentrations of FBZ metabolites (mean ± SEM) 
following administration of fenbendazole (5 mg/kg) in combination 
with piperonyl butoxide (63 mg/kg).
Mean ± SEM (n=6)
Time (h) FBZ FBSO FBSO2
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0 .25 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0.5 0.02 ± 0.01 0.01 ± 0.01 0.00 ± 0.00
1 0.05 ± 0.03 0.02 ± 0.02 0.00 ± 0.00
2 0.12 ± 0.06 0.06 ± 0.05 0.00 ± 0.00
4 0.25 ± 0.04 0.14 ± 0.07 0.00 ± 0.00
8 0.31 ± 0.03 0.27 ± 0.04 0.02 ± 0.00
1 2 0.26 ± 0.04 0.34 ± 0.04 0.03 ± 0.00
2 4 0.28 ± 0.05 0.46 ± 0.09 0.08 ± 0.01
3 2 0.20 ± 0.05 0.42 ± 0.09 0.11 ± 0.01
4 8 0.11 ± 0.03 0.22 ± 0.05 0.13 ± 0.02
7 2 0.05 ± 0.01 0.06 ± 0.02 0.09 ± 0.01
9 6 0.01 ± 0.01 0.01 ± 0.01 0.05 ± 0.01
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Table 4-8. Plasma concentrations of FBZ metabolites (mean ± SEM) 
following administration of fenbendazole (5 mg/kg) in combination 
with piperonyl butoxide (125 mg/kg).
Mean ± SEM (n=6)
Time (h) FBZ FBSO FBSO2
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0.25 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0.5 0.02 ± 0.01 0.00 ± 0.00 0.00 ± 0.00
1 0.07 ± 0.03 0.01 ± 0.00 0.00 ± 0.00
2 0.16 ± 0.05 0.03 ± 0.01 0.00 ± 0.00
4 0.34 ± 0.07 0.13 ± 0.04 0.00 ± 0.00
8 0.47 ± 0.07 0.36 ± 0.07 0.01 ± 0.00
1 2 0.55 ± 0.10 0.58 ± 0.12 0.03 ± 0.01
2 4 0.52 ± 0.05 0.79 ± 0.10 0.09 ± 0.02
3 2 0.39 ± 0.04 0.69 ± 0.07 0.13 ± 0.02
4 8 0.21 ± 0.02 0.38 ± 0.04 0.17 ± 0.02
7 2 0.06 ± 0.02 0.11 ± 0.03 0.13 ± 0.01
9 6 0.02 ± 0.01 0.03 ± 0.01 0.08 ± 0.01
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Table 4-9. Plasma concentrations of FBZ metabolites (mean ± SEM) 
following administration of fenbendazole (5 mg/kg) in combination 
with piperonyl butoxide (250 mg/kg).
Mean ± SEM (n=6)
Time (h) FBZ FBSO FBSO2
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0 .25 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
0.5 0.01 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
1 0.04 ± 0.01 0.01 ± 0.00 0.00 ± 0.00
2 0.13 ± 0.04 0.03 ± 0.01 0.00 ± 0.00
4 0.29 ± 0.04 0.11 ± 0.03 0.00 ± 0.00
8 0.38 ± 0.03 0.28 ± 0.05 0.01 ± 0.00
1 2 0.48 ± 0.05 0.47 ± 0.07 0.02 ± 0.01
2 4 0.63 ± 0.05 0.74 ± 0.07 0.08 ± 0.02
3 2 0.62 ± 0.05 0.78 ± 0.08 0.12 ± 0.02
4 8 0.54 ± 0.04 0.61 ± 0.03 0.18 ± 0.03
7 2 0.17 ± 0.03 0.24 ± 0.03 0.18 ± 0.02
9 6 0.05 ± 0.01 0.06 ± 0.01 0.12 ± 0.01
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Figure 4-2. Plasma concentrations of fenbendazole (mean ± SEM) 
following administration of fenbendazole in combination with 
various dose rates of piperonyl butoxide in sheep (n=6).
9 4
FBSO (no PB)
FBSO (15 mg/kg PB)
FBSO (31 mg/kg PB)
0 . 7 5 -
FBSO (63 mg/kg PB)co
FBSO (125 mg/kg PB)
V 0 .5 -
oV
FBSO (250 mg/kg PB)
eg
J  0 . 2 5 -
0 8 1 6 2 4 3 2 4 0 4 8 5 6 6 4 7 2 8 0 8 8 9 6
T im e (hou rs)
Figure 4-3. Plasma concentrations of fenbendazole sulphoxide 
(mean ± SEM) following administration of fenbendazole in 
combination with various dose rates of piperonyl butoxide 
in sheep (n=6).
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Figure 4-4. Plasma concentrations of fenbendazole sulphone 
(mean ± SEM) following administration of fenbendazole in 
combination with various dose rates of piperonyl butoxide 
in sheep (n=6)
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Table 4-10. Pharm acokinetic param eters of FBZ metabolites following 
administration of fenbendazole (5 mg/kg) alone.
Mean ± SEM (n==6)
FBZ FBSO FBSO2
AUCobs (|lg.h/ml) 7.54 ± 0.79 10.62 ± 1.59 5.94 ± 0.60
AUMCobsCP-g-h^/ml) 194.79 ± 25.05 313.18 ± 55.34 281.25 ± 34.80
MRT (h) 25.52 ± 2.02 28.72 ± 1.61 46.72 ± 1.74
Cmax (jig/ml) 0.24 ± 0.02 0.27 ± 0.03 0.11 ± 0.01
tmax (h) 10.00 ± 3.01 20.67 ± 3.64 34.67 ± 4.46
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Table 4-11. Pharm acokinetic  param eters of FBZ m etabolites following 
administration of fenbendazole (5 mg/kg) in combination with piperonyl 
butoxide (15 mg/kg).
Mean ± SEM (n:=6)
FBZ FBSO FBSO2
AUCobs (p-g.h/ml) 8.09 ± 0.63 11.26 ± 0.60 6.29 ± 0.54
AUMCobs(M-g.h2/ml) 240.27 ± 29.78 365.98 ± 23.91 310.58 ± 27.03
MRT (h) 29.21 ± 1.36 32.47 ± 1.10* 49.62 ± 2.35
Cmax (|ig/ml) 0.20 ± 0.00 0.26 ± 0.02 0.11 ± 0.01
tmax (h) 14.33 ± 4.63 22.33 ± 2.75 46.67 ± 5.63
* Significantly different (P< 0.05) from corresponding value in control 
(see Table 4-10)
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Table 4-12. Pharmacokinetic  parameters of FBZ metabolites following 
administration of fenbendazole (5 mg/kg) in combination with piperonyl 
butoxide (31 mg/kg).
Mean ± SEM (n==6)
FBZ FBSO FBSO2
AUCobs (lig.h/ml) 12.91 ± 1.57* 18.07 ± 2.03* 7.55 ± 0.90
AUMCobs(p.g.h^/ml) 379.32 ± 61.68* 611.38 ± 73.14* 374.13 ± 42.95*
MRT (h) 29.26 ± 1.92 33.78 ± 0.85* 49.75 ± 0.98
Cmax (pg/ml) 0.35 ± 0.05 0.42 ± 0.05* 0.13 ± 0.02
tmax (h) 20.67 ± 6.23 30.67 ± 3.68 37.33 ± 2.67
* Significantly different (P< 0.05) from corresponding value in control 
(see Table 4-10).
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Table 4-13. Pharmacokinetic parameters of FBZ metabolites following 
administration of fenbendazole (5 mg/kg) in combination with piperonyl 
butoxide (63 mg/kg).
Mean ± SEM (n==6)
FBZ FBSO FBSO2
AUCobs (|lg.h/ml) 12.80 ± 1.92* 19.78 ± 3.05* 7.61 ± 0.82
AUMCobsC^g-h^/ml) 372.84 ± 79.14* 636.41 ±131.93 396.13 ± 50.52*
MRT (h) 27.62 ± 2.56 29.38 ± 4.03 51.28 ± 2.14
Cmax (jig/ml) 0.35 ± 0.03* 0.53 ± 0.04* 0.13 ± 0.01
tmax (h) 12.67 ± 3.64 23.33 ± 4.18 42.67 ± 3.96
* Significantly different (P< 0.05) from corresponding value in control 
(see Table 4-10).
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Table  4-14. Pharm acokine t ic  parameters  of FBZ m etabol i tes  follow 
administrat ion of fenbendazole (5 mg/kg) in combination with piperc 
butoxide (125 mg/kg).
Mean ± SEM (n=6 )
FBZ FBSO FBSO]
AUCobs (M.g.h/ml) 
AUMCobs(M<g-h2/ml) 
MRT (h)
Cmax (jig/ml) 
tmax (h)
23.39 ± 1.59* 33.32 ± 2.68* 9.97 ± 0.77 
673.61 ± 40.2 0 n i  14.63 ± 82.94* 540.77 ± 39.85* 
29.29 ± 2.14 33.83 ± 2.11* 54.43 ± 1.87* 
0.57 ± 0.09* 0.79 ± 0.10* 0.17 ± 0.02* 
20.00 ± 2.53 25.33 ± 1.33 47.33 ± 3.64
* Significantly different (P< 0.05) from corresponding value in control 
(see Table 4-10).
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Table  4-15. Pharmacokinet ic  parameters  of FBZ metaboli tes  
following administration of fenbendazole (5 mg/kg) in combination 
with piperonyl butoxide (250 mg/kg).
Mean ± SEM (n=6)
FBZ FBSO FBSO2
AUCobs (lig.h/ml) 
AUMCobs(M-g-h2/ml) 
MRT (h)
Cmax (|ig/ml) 
tmax (h)
35.58 ± 1.60* 40.73 ± 2.03* 11.73 ± 1.28 
312.97 ± 75.81*1604.93 ± 53.26* 683.80 ± 65.06* 
36.97 ± 1.71* 39.71 ± 1.60* 58.79 ± 1.19* 
0.66 ± 0.05* 0.79 ± 0.08* 0.20 ± 0.02 
32.00 ± 3.58* 28.05 ± 6.40 64.00 ± 5.06
* Significantly different (P< 0.05) from corresponding value in control 
(see Table 4-10).
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Figure 4-5. Area under the plasma concentra tion-time curve 
(AUC) values of fenbendazole metabolites at various dose rates 
of piperonyl butoxide.
* Significantly different from control values (P O .0 5 )
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dose of piperonyl butoxide administered was 250 mg/kg, the AUC 
of FBZ and FBSO showed a 4-fold increase from the control value, 
while that of the sulphone metabolite only doubled (figure 4-5) 
therefore decreasing the ratio AUC (FBS02)/  AUC (FBZ) from the 
control value of 0.79 to 0.33 and the ratio AUC(FBS02)/AUC(FBS0) 
from 0.56 to 0.29. The mean residence time (MRT) of fenbendazole 
sulphoxide increased significantly from the control value (P< 0.05), 
with  four  of the f e n b e n d a z o le - p ip e r o n y l  b u to x id e  dose  
combinations. Mean maximum concentrations (Cmax), particularly 
those of FBZ and FBSO, also tended to increase with the combination. 
The time until maximum concentration was also prolonged for all 
metabolites but statistical significance was only reached with FBZ 
when the highest dose of piperonyl butoxide was given.
4 . 3 . 3  A n t h e l m i n t i c  e f f i c a c y  o f  the  c o m b i n a t i o n  
f e n b e n d a z o l e - p i p e r o n y l  bu tox ide
The results of the efficacy trial are shown on Tables 4-16, 4-17, 4- 
18 and Appendix C-38. Piperonyl butoxide, given on its own had no 
effect  on parasitism. While fenbendazole given alone was not 
effective (less than 8% efficacy) in reducing the number of BZ- 
resistant O. circumcincta,  the administration of the combination 
FBZiPB showed a 98% efficacy against this parasite strain. The 
combination was also more effect ive against  BZ-resis tant  H . 
c o n to r tu s  (99% reduction) than the conventional treatment (85% 
reduction). Only one animal showed a positive faecal egg count after 
treatment with the combination.
4.4 Discussion
A sustained plasma level of piperonyl butoxide was obtained 
following oral administration and concentrations higher than those 
measured following in tramuscular  injection of the drug were 
achieved (see Chapter 3). However, considering the very high dose 
given, relatively low plasma levels were attained which could be 
due to poor absorption, first-pass effect or vast tissue distribution. 
There is no published information on the disposition of piperonyl 
butoxide in ruminants and in rats oral administration resulted in 
poor gastrointestinal absorption and rapid excretion in the urine 
and faeces  (H a ley ,  1978). A l th o u g h  it wou ld  be an 
oversimplificat ion to predict the inhibitory effect of piperonyl 
butoxide when given orally or intramuscularly simply from the
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Table  4-16. Mean worm counts  and pe rcen tage  reduc t ions  
(Ostertagia circumcincta)  in different treatment groups.
A r i thm etic  
mean (± SD)
Geometric
m e a n
% reduction 
(a r i th m e t ic )
%reduction
(geom etr ic)
Group A 
(n = 6 )
2985 ± 654 2 9 1 1 - -
Group B 
(n = 6 )
2875 ± 1308 2 68 1 3.7 7.9
Group C 
( n = 6 )
3783 ± 441 3 7 6 0 - -
Group D 
(n = 6 )
450 ± 565* 64.5 84.9 97.8
Group A (control)
Group B (fenbendazole alone)
Group C (piperonyl butoxide alone)
Group D (fenbendazole + piperonyl butoxide)
* Significantly different (P< 0.01) from group A, B and C.
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T able  4-17. Mean worm counts  and pe rcen tage  reduc t ions  
(Haemonchus contortus)  in different treatment groups.
* A ri thm etic  
mean (± SD)
Geometric
m e a n
% reduction 
(a r i th m e t ic )
%reduction
(geom etr ic )
Group A 
(n = 6 )
345 ± 67 3 4 0 - -
Group B 
(n = 6 )
58 ± 29* 51.7 83.0 84.8
Group C 
(n = 6 )
320 ± 133 2 9 7 - -
Group D 
(n = 6 )
7 ±  8**>t 3.5 98 .0 99 .0
Group A (control)
Group B (fenbendazole alone)
Group C (piperonyl butoxide alone)
Group D (fenbendazole + piperonyl butoxide)
* Significantly different (P<0.01) from group A and C 
** Significantly different (P<0.005) from group A and C 
t  Significantly different (P<0.01) from group B
1 0 6
Table 4-18. Mean faecal egg counts (epg) and percentage reductions 
in different treatment groups.
A r i thm e t ic  
mean (± SD)
Geometric
m e a n
% reduction 
(a r i thm e t ic )
%reduction
(geometr ic)
Group A 
(n = 6 )
492 ± 267 4 3 8 - -
Group B 
(n = 6 )
100 ± 84** 27 .7 79.7 93.7
Group C 
( n = 6 )
483 ± 342 3 7 3 - -
Group D 
( n = 6 )
8 ± 2 0** 1.9 98 .4 99.6
Group A (control)
Group B (fenbendazole alone)
Group C (piperonyl butoxide alone)
Group D (fenbendazole + piperonyl butoxide)
** Significantly different (P<0.005) from group A and C
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plasma disposition of the drug, it is at least evident that, since it is 
present in the general circulation, the drug has reached the target 
organ (liver). Since it is the metabolites of piperonyl butoxide that 
bind to and inhibi t  m icrosom al  ox idases ,  m easu rem en t  of 
metabolite products in blood but also in liver tissue would give a 
better estimate of the inhibitory activity, this was however beyond 
the scope of this thesis.
The pharmacokinetic behaviour of fenbendazole was similar to that 
described by Marriner  & Bogan (1981b) with fenbendazole  
sulphoxide being the main metabolite detected in plasma. A direct 
comparison of FBZ disposition in sheep with that described in goats 
(chapter 3) was not possible since the dose rates used were 
different; it is of interest, however, to note that with a 33% higher 
dose given to goats the AUC of FBZ and FBSO were lower than in 
sheep by 37% and 27%, respectively. Lower bioavailability was also 
found in goats as compared  to sheep when fenbendazole  
sulphoxide was given (Bogan et al., 1987; Sangster et al., 1991; 
Hennessy et al., 1993a). The response to metabolic inhibition, 
expressed in the alteration of FBZ metabolites disposition, increased 
with increasing doses of piperonyl butoxide. The linear increase 
pattern observed with the AUC of FBZ, FBSO and FB S02  resembles 
that described by Hennessy et al (1985) when oxfendazole was co­
administered with increasing doses of parbendazole.  Parbendazole 
is a potent inhibitor of the polymerization of mammalian tubulin 
(Friedman & Platzer, 1978), and it has been suggested that by 
binding temporarily to liver tubulin, PBZ may reduce the rate of 
metabolism and excretion of co-administered oxfendazole; there is 
however evidence that benzimidazoles and their metabolites can 
act as inhibitors of microsomal cytochrome P450 (Murray et al., 
1992). A declining ratio F B S 0 2 /F B S 0  was observed with the 
coadm in is t ra t ion  of increas ing  doses of p iperonyl  butoxide  
indicating a slower rate of sulphonation. The delay in the tmax and 
the prolonged mean residence times observed also reflect a slower 
clearance of the benzimidazole metabolites.
The results of the efficacy study give fur ther  support to the 
hypothesis that anthelmintic efficacy parallels the concentration of 
active metaboli tes in the bloodstream (Prichard et al., 1978; 
Hennessy et al., 1985; Kwan et al., 1988). The increased AUC of
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both fenbendazole  and its active metabolite  (FBSO) following 
concomitant administration of fenbendazole and piperonyl butoxide 
markedly improved the efficacy of the benzimidazole anthelmintic 
against BZ-resistant strains of O. circumcincta.  Indeed, whereas this 
strain was almost totally refractory to fenbendazole given alone, it 
was highly susceptible to the combination (P<0.01). The strain of 
H a e m o n c h u s  con tor tus  did not show a high degree of resistance 
since fenbendazole given alone at the therapeutic dosage rate 
significantly removed this parasite (P<0.01). Nevertheless ,  the 
c o a d m in is t r a t io n  of p ip e ro n y l  bu tox ide  with fen b en d azo le  
significantly improved the removal of adult H. contortus (P < 0 .0 1 ) .  
The faecal  egg counts were s ignif icant ly  reduced by both 
fenbendazole  and fenbendazole  with piperonyl  butoxide;  the 
reduc t ion ,  a l though h igher  with the co m b in a t io n  was not
signif icant ly  d ifferent  (P=0.062) from that att r ibuted to the 
benzimidazole given alone. Taking into account the much higher 
fecundity of H. contortus in comparison to O. circumcincta,  a higher 
difference in terms of faecal egg production would have been 
expected between the group that received fenbendazole alone and 
the one that received the drug combination,  had the level of 
resistance of the H. contortus strain been higher.
Piperonyl butoxide given alone had no effect on worm burden or
faecal  egg excret ion and therefore  the in te rac t ion  between 
fenbendazole and piperonyl butoxide is not an additive one. Also, 
the potentiation is unlikely to occur at the parasite level since 
knowledge so far acquired on drug metabolism in helminths 
suggests that nematodes, unlike insects are not equipped with a 
microsomal cytochrome system that would enable them to detoxify 
xenobiotics (Barrett, 1981). The synergism observed here is most 
likely due to an improvment of the pharmacokinetic profile of the 
potentiated drug in the animal host and not in the parasite, as it is 
the case for the synergistic action of piperonyl butoxide towards 
pyrethrins (O'Brien, 1969; Haley, 1978).
In conclusion ,  p iperonyl  butoxide  adm in is te red  oral ly  with 
fenbendazole and at much lower doses than in the preliminary 
studies (chapter 3 ), significantly increased the systemic availability 
of the two anthelmintically active moieties (FBZ and FBSO). This was 
reflected in a high efficacy of the drug combination against 
benzimidazol e-res is tant nematodes.
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Chapter 5
Metabol i sm (S-oxidat ion)  of  benz imidazol e  anthelmintics;
in ntro  studies
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5.1 Introduct ion
The metabolism of benzimidazole anthelmintics occurs mainly in 
the hepatic cells (see Chapter 1). Oxidation of ABZ into ABSO in vitro 
has been demonstrated in rat (Fargetton et a i ,  1986; Souhaili-El 
Amri et aL, 1988a,b), pig (Souhaili-El Amri et al., 1987), sheep 
(Galtier et al., 1986a; Lanusse et aL, 1993c), cattle (Lanusse et al., 
1993b) and human (Rolin et al., 1989) liver microsomes. Initially, it 
was p roposed  that su lphox ida t ion  of ABZ was a f lavin-  
monooxygenase (FMO) dependent reaction, while the oxidation of 
ABSO into A BS02  (sulphonation) was cytochrome P450-dependent. 
There is now evidence to suggest that the enzymatic  systems 
involved in the sulphoxidation of ABZ are species-dependent, i.e, 
both cytochrome P450 and FMO systems act equally in rats and 
probably in dogs and man, while FMO is the predominant system in 
ruminants (Delatour et al., 1994). Both systems are also involved in 
the sulphoxidation of fenbendazole (FBZ) in rats (Murray et al.,
1992). There are no reports on the in vitro  metabolism of
triclabendazole (TCBZ).
Hepatic subcellular fractions (microsomes) or intact hepatocytes 
maintained in culture are useful in vitro models for studies on the 
biotransformation of benzimidazole drugs. In vitro models may 
help understand aspects of BZ pharmacokinetic  behaviour (e.g. 
first-pass effect), and also help assess effects of various factors that 
can alter their metabolism.
The aim of the present  study, was to compare  the in vitro  
su lp h o x id a t io n  and su lp h o n a t io n  o f  th ree  th io s u b s t i tu t e d
benzimidazoles- fenbendazole, triclabendazole and albendazole - 
and to de termine the effect  of p iperonyl  butoxide on the 
metabolism of each of these benzimidazole drugs, using microsomal 
preparations and primary culture of hepatocytes isolated from rat 
l ive rs .  The  in v o lv e m en t  of  c y to c h ro m e  P450  in the 
biotransformation of t r ic labendazole  was investigated using 1-
aminobenzotr iazole  (1-ABT) as inhibitor  of cy tochrome P450 
(Mugford et aL, 1992).
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5.2 Materials  and methods
5.2 .1  Microsomal  prepara t ions
5.2 .1 .1  Chemica ls
Nicotinamide adenosine dinucleotide phosphate (NADP), isocitrate 
d e h y d ro g e n a s e ,  t r i sod ium  iso c i t ra te ,  T r iz m a  base ,  T r izm a  
hydrochloride and glycerol were all purchased from Sigma Chemical 
Co.(St Louis, MO, USA). All other chemicals were obtained from BDH 
Chemicals Ltd (Poole, UK). Standard drugs were obtained from 
sources mentioned earl ier  (Chapter 3) with the exception of
triclabendazole metabolites (Ciba Geigy AG, Basel, Switzerland).
5 .2 .1 .2  I so la t ion
Four (04) female Sprague-Dawley rats weighing 300-400 grams 
were used for the preparation of liver microsomes. They were
killed by decapitation, the abdomen was opened and the liver 
perfused with ice-cold saline (0.9% NaCl solution) through the portal 
vein. The liver was excised, drained of excess moisture  and 
weighed. All procedures were carried out at 0-4° C. The organ was 
collected in 3 volumes of 1.15% KCl and finely chopped before 
homogenization. This was carried out using a Potter-Elvehjem 
homogenizer;  three to four passages of the teflon pestle were
usually sufficient to disrupt the liver tissue. The liver homogenate 
was centrifuged for 20 minutes at 9000 g in a Beckman J2-21
(California . ,  USA) refr igerated centr ifuge.  This centr ifugat ion  
allowed the removal of cell debris, nuclei and mitochondria. After 
removing the floating fat layer with a spatula, the supernatant was 
decanted in 4 or 6 Beckman Ultra-Clear tubes (California, USA) and 
centr ifuged at 105000 g for 75 minutes in a Beckman L8-55 
refrigerated ultracentrifuge. The cytosolic  fraction (supernatant)  
was discarded and, using an ultra-turrax (Janke & Kunkel GmbH & 
Co., Germany) the microsomal pellet was resuspended in 6 ml of 0.1 
M Tris-phosphate buffer (pH 7.4) containing 20% (v/v) glycerol. 
The suspensions were frozen in liquid nitrogen and stored at -80°C 
until used for incubation assays . Fifty to one hundred microliters of 
the microsomal suspension were used for the determination of total 
protein and cytochrome P450 concentrations. Microsomal protein 
concentrations were measured using a commercial ly available kit 
(Sigma Chemical Co., St Louis, MO, USA) which is based on the
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method developed by Lowry et al. (1951) and modified by Peterson 
(1977). Briefly, an alkaline cupric tartrate reagent complexes with 
the peptide bonds and forms a purple -blue colour when a phenol 
reagent is added. Bovine serum albumin was used as a standard. 
Absorbance was read at 750 nm in a Pye-Unicam SP8-400 
s p e c t r o p h o t o m e t e r  ( C a m b r i d g e ,  U K ) .  S pec t ro p h o  to m e  tr ie
determination of cytochrome P450 was carried out according to the 
method of Omuro and Sato (1964). This method is based on the 
ability of cytochrome P450 as a haemoprotein to bind to carbon 
monoxide (CO) and result in a characteristic absorption spectrum at 
450 nm (hence the name) when the haem iron is reduced (sodium 
dithionite  is used as a reducing reagent).  A molar extinction 
coefficient of 91 m M -lcm - l  was used to convert absorbance units 
to nmoles of cytochrome P450.
5.2.1.3 Drug incubation
Incubations were conducted aerobically in a shaking water bath at 
37° C for a period of 1 hour. Incubation mixtures containing 4 mg of 
microsomal protein, 50 jiM of test drug (fenbendazole, oxfendazole, 
albendazole  and tric labendazole were each dissolved in 5 p i  
dimethylsulphoxide),  an NADPH-generating system consist ing of 
ImM NADP+, 0.15 M MgCl2 , isocitrate dehydrogenase (0.2 Units/ml) 
and 15 mM trisodium isocitrate, were made up in a final volume of
1 ml O.IM Tris buffer (pH 7.4) in 10-ml glass test tubes. Piperonyl 
butoxide was dissolved in 5 p i  d imethylsulphoxide (DMSO) and 
used at a final concentration of 100 pM. Tubes without microsomes 
were used as controls for possible nonenzymatic drug conversion. 
Incubations were terminated by putting tubes in boiling water for
2 minutes followed immediately by freezing at -20°C until analysis. 
Incubations were conducted in triplicates.
5.2.2 Hepatocyte  culture
5.2.2.1 Chemical s
Will iams '  Medium E (WME), foetal ca l f  serum, penic i l l in-  
streptomycin, L-glutamine were purchased from Gibco BRL-Life 
Technologies Ltd (Renfrewshire, UK). Collagenase type 1 A, bovine 
pancreas insulin, bovine serum albumin and 1 -aminobenzotriazole 
were purchased from Sigma Chemical Co.(St Louis, MO, USA)
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5-2.2.2 Isolation of  cells
Three  (03) female Sprague-Dawley rats were used. They were 
anaesthetised in an induction chamber using halothane (Fluothane,
ICI Pharmaceuticals, Cheshire, England) and oxygen (BOC Limited.,
Surrey, England). Anaesthesia was induced by turning the vaporiser 
setting to 3% and the oxygen flowmeter to IL/minute. The sleeping 
ra t  was then removed from the chamber and anaesthesia  was 
maintained with halothane at 1.5-2% delivered through a face 
m ask .
The method used for cell isolation was based on the the two-step 
procedure described by Seglen (1975) which consists of an initial 
perfusion with calcium-free  buffer in order to remove blood 
components, followed by perfusion with collagenase buffer which 
enables the dispersion of liver tissue into single cells. The abdomen 
was opened and a loose ligature was placed around the portal vein 
which was then punctured with a 20-gauge cannula  (Ecouen, 
France) and the perfusion immediately started with the calcium- 
free buffer dispensed by a peristaltic pump at a flow rate of 40 
ml/minute .When the liver started blanching (indicating that the 
cannula was in the vein), the ligature was secured and to avoid 
build-up of pressure and permit perfusate efflux, the lower vena 
cava was cut. Buffers used and duration of perfusions are described 
in Appendix D-1.
5.2.2.3 Culture and drug incubation
Cells were washed three times before seeding; once with the 
washing buffer and twice with the medium. Washing consisted of 
resuspending the cells in the buffer or medium (two tubes of 50 ml 
each) by gently inverting the tubes. After centrifugation at 90 g for 
3 minutes, the buffer or medium was discarded and replaced and 
the procedure repeated with new medium. Cells were then counted 
and their viability assessed by trypan blue exclusion which is based 
on the ability of intact (viable) cells to exclude dyes such as trypan 
blue which is taken up by damaged cells and become stained. Cell 
suspensions of 1x106 viable cells per ml of medium were made up. 
Cells were then plated in 6 -mm plastic dishes (Nunc, Roskilde, 
Denmark) at a density of 4 x 1 0 6  viable hepatocytes per dish (i.e, 4 
ml of the suspension). Composition of the media are reported in 
Appendix D-2.
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After 3-4 hours pre-incubation to allow seeded cells to attach, the 
attachment medium (with floating dead cells) was removed and 
rep laced  with se rum -free  medium (A ppend ix  D-2).  Drugs 
(fenbendazole, albendazole or triclabendazole) dissolved in DMSO 
were added. Piperonyl butoxide was added as required.  1- 
aminobenzotriazole was added to triclabendazole incubation dishes 
at a final concentration of 10 mM. Cells were incubated in a 
hu m id i f ied  incuba to r  (Heraeus  In s t ru m en ts  G m bH, Hanau,  
Germany) at 37°C under an atmosphere of 95% 0 2 /5 % CO2 (v/v) 
Incubations were carried out in triplicates. After 24 hours, the 
samples, i.e., medium together with the cells which were detached 
with cell scrapers (Nunc, Roskilde, Denmark) were collected in 10- 
ml plastic tubes and frozen until analysis.
5.2.3 Drug analysis
Drugs and their respective metabolites were analysed according to 
the methods described in Section 4.2.3. Triclabendazole and its 
metabolites were extracted using a solid phase extraction method. 
To 1 ml of sample was added 1ml acetonitrile, the mixture was 
vortexed for 20 seconds and then centrifuged at 1000 g for 15 
minutes. The supernatant  was mixed with an equal volume of 
water  and then passed through a precondit ioned Cl  8 SepPak 
cartridge (see Section 2.2.3.3). Five millilitres of water followed by 
0.4 ml of methanol were passed through the cartridge and the drug 
was eluted with 3 ml of methanol. HPLC conditions were identical to 
those described for FEZ (Section 4.2.3).
Because of the poor aqueous solubility of the benzimidazoles, 
especially of fenbendazole, it was difficult to obtain a solution or 
even a homogeneous suspension in the incubates; this led to 
spurious recoveries of parent drug when samples were transfered 
several times and when an aliquot and not the total sample was 
analysed. This technical problem was reported by other authors 
(Marriner, 1980) and we could not overcome it to achieve an 
accurate est imation of parent compounds in hepatocyte culture 
medium. This was however possible with microsomal preparations 
since samples were not transfered many times, total samples were 
used for drug extraction and each incubation tube was rinsed with 
1 ml acetonitrile which was then used for the sample extraction.
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5.2.4. S ta t i s t i c a l  ana ly s is
Extent of conversion and amount of unchanged drug, with and 
without metabolic inhibition were compared by analysis of variance 
and a P<0.05 was considered significant.
5.3 Results
5.3.1 incubation with hepatic microsomes
Protein and cytochrome P450 contents of the microsomal specimens
used for incubations are reported in Appendix D-3.
Incubation of the substrates without microsomes did only result in 
a slight sulphoxidation (0.4%) for albendazole (Appendix D-4).
In microsomal incubations, all substrates were converted to their 
respective sulphoxide and sulphone metaboli tes. The extent  of 
metabolism was however variable between drugs as can be seen 
from both the disappearance of substrate (Appendix D-5, D-6 , D-7, 
D -8 and Figure 5-1) and the formation of sulphoxide (Appendix D- 
9, D-13 and D-15) and sulphone (Appendix D-10, D-11, D-14 and D-
16) metaboli tes;  while t r ic labendazole  and a lbendazole  were 
extensively metabolised (97% and 82%, respectively) fenbendazole 
was only partially converted to its two S-oxide metabolites (16 % ). 
Oxfendazole incubated for 1 hour was also slowly converted to 
fenbendazole sulphone (13 %).
Effect of inhibition with piperonyl butoxide (PB) on the metabolism 
of FBZ, FBSO, ABZ and TCBZ are shown in Figures 5-2, 5-3, 5-4 and
5-5, respectively (see also Appendix D-9 to D-16). Sulphoxidation 
and sulphonation of fenbendazole were reduced by 65% and 67%, 
respectively, when fenbendazole was incubated with PB. Also, the 
amount  of unchanged fenbendazole  was s ign if ican t ly  higher 
(P<0.01) (Appendix D-5, Figure 5-1) with metabolic inhibition. The 
rate of albendazole sulphoxidation was significantly diminished 
(P<0.05) by PB. Albendazole sulphonation, although very slow and 
variable, was also reduced from 0.14 ± 0.05 to 0.05 ± 0.03 
nmol/mg microsomal protein/hour. Unchanged ABZ remaining in 
the incubation mixture (Figure 5-1) was significantly increased 
(P<0.01) from 8.48 ± 1.91 to 25.25 ± 3.55 nmol/ml when PB was 
added to the reaction mixture. Triclabendazole sulphoxidation did 
not change with inhibition; sulphonation was however reduced by 
61%. Amount of unchanged TCBZ was 1.24 ± 0.96 nmol/ml when 
TCBZ was incubated alone and 6.33 ± 3.85 nmol/ml when
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Figure 5-1. Amount of unchanged drug remaining in the 
microsomal reaction mixture after incubation of BZ (50 |iM) 
with (BZ+PB) and without (control) piperonyl butoxide (n=4). 
** Significantly different from control (P<0.01)
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Figure 5-2. Effect of piperonyl butoxide (PB) (100 }iM) 
on microsomal fenbendazole  metabolism in rat liver 
(n=4).
^Significantly different from control (P<0.05) 
tSignificantly different from control (P<0.001)
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Figure 5-3. Effect of piperonyl butoxide (PB) (100 ]iM) on microsomal 
fenbendazole sulphoxide (FBSO) metabolism in rat liver (n=3).
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Figure 5-4. Effect of piperonyl butoxide (PB) (100 juM) 
on microsomal albendazole metabolism in rat liver 
(n=4).
^Significantly different from control (P<0.05)
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Figure 5-5. Effect of piperonyl butoxide (PB) (100 p.M) on 
triclabendazole (TCBZ) microsomal metabolism in rat liver 
(n=4).
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incubated with PB. Conversion of FBSO into FB S 02  was reduced by 
53% when FBSO was incubated with PB. Minimal reduction of FBSO 
into FBZ occured (Appendix D-12) and this was not affected by 
inhibition of cytochrome P450 with PB.
5.3.2 I n c u b a t i o n  with h e p a to c y te s
Cell viability as assessed by trypan blue exclusion was between 70-
85%, and after the pre-incubation period, viable cells were well
attached to the plastic dish.
With a mean velocity ranging between 232.8-290.3 pmoles of
su lp h o x id e  m e tab o l i te  fo rm ed /1 0 6  v iab le  h e p a to cy tes  /hou r  
(Appendix  D-21 and D-23) ,  t r ic labendazo le  was the most  
extensively S-oxidised substrate. Fenbendazole was more slowly 
sulphoxidised than albendazole and triclabendazole (Appendix D-
17). How ever ,  among the b enz im idazo le  subs tra tes  tested, 
a lbendazo le  dem ons tra ted  the lowest  ra te  of  su lphona t ion  
(Appendix D-20).
Inhibition with 1 -aminobenzotriazole (1-ABT) (Figure 5-8) resulted 
in a highly significant decrease (P<0.001) in both sulphoxidation 
and sulphonation of triclabendazole (Appendix D-21 and D-22).
The effect of piperonyl butoxide is shown in Figures 5-6, 5-7 and 5- 
9 for fenbendazole, albendazole and triclabendazole, respectively. 
Sulphoxidation of FBZ, ABZ and TCBZ was reduced by 69%, 64% and 
50%, respect ively.  Inhibition resulted in undetectable levels of 
albendazole sulphone (Appendix D-20, Figure 5-7). Sulphonation of 
FBZ and TCBZ were also significantly reduced.by piperonyl 
butoxide.
5.4 D iscuss ion
In this study, the S-oxidation of three modern benzimidazoles was 
investigated using two in vitro models. In both models, one 
striking observation was the difference in the speed at which 
substrates were oxidised, and particularly the difference between 
fenbendazole and the two other BZ studied (TCBZ and ABZ). It 
appears clearly from the result of this study that triclabendazole 
and a lbe n d az o le  are far  more rap id ly  m e tab o l i sed  than 
fenbendazole. This finding correlates well with several in vivo 
pharm acokinet ic  studies. Indeed, whereas t r ic labendazole  and 
albendazole undergo first-pass effect in all species studied and are 
absent or detected at trace amounts in the systemic circulation
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Figure 5-6. Effect of piperonyl butoxide (PB)(100 |iM) on 
fenbendazole metabolism in rat hepatocytes (n=3). 
^Significantly different from control (P<0.05) 
***Significantly different from control (P<0.005)
1 2 3
IICL z:D O
150
" " 1 0 0 - ;
■ ABSO
□ ABSOi
0X!cS
1
—X
Xoo —
c3O
£
<
c
CL
ABZ ABZ+PB
Figure 5-7. Effect of piperonyl butoxide (PB) (100 jiM) on 
albendazole metabolism in rat hepatocytes (n=3). 
^Significantly different (P<0.05)
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Figure 5-8. Effect of 1-aminobenzotriazole (1-ABT) (10 mM) on
triclabendazole metabolism in rat hepatocytes (n=3). 
tSignificantly different from control (P<0.001)
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Figure 5-9. Effect of piperonyl butoxide (PB) (100 )lM) 
on triclabendazole metabolism in rat hepatocytes (n=3). 
** Significantly different from control (P<0.01) 
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after administration (Marriner & Bogan, 1980; Gyurik et a l ,  1981; 
M oham m ed-A li  et al., 1986; Hennessy et al., 1987; Bogan et al., 
1988a; Hennessy et a l ,  1989; Also see Chapter 2), fenbendazole, is 
more slowly converted to its sulphoxide metabolite and is detected 
and persists  for several hours postadministrat ion (Marr iner  & 
Bogan, 1981b; Ngomuo et al., 1984; Also Chapters 3 and 4). Two 
factors may influence the rate of sulphoxidation; the hydrophobic
character of the molecules and their steric nature. The first feature
is now seen as a minor factor in the interaction of benzimidazole 
derivatives with cytochrome P450 (Little & Ryan., 1982; Murray et  
al., 1992). The present experiment supports this suggestion since if 
water  so lubi l i ty  was a de te rm inant  factor ,  more ex tens ive  
metabolism would have been expected for fenbendazole than for 
albendazole, the former compound being more hydrophobic than 
the latter. This was not the case in the present experiment. The 
steric nature of benzimidazole derivatives is more likely to be a 
crucial factor involved in the accessibility of the P450-heme to the 
sulphur site (Murray et al., 1992) and the proximity of benzene
rings to this site seems to hinder such interactions (Hennessy,
1993b). The sulphur in the fenbendazole molecule is linked to two 
benzene rings; the phenyl substituent and the benzene ring of the 
benzothiazolyl nucleus; this location could result in steric hindrance. 
Albendazole  has an aliphatic  substi tuent and the su lphur  is
therefore only linked to one benzene ring. The methylthio group of 
triclabendazole is located on position -2 with no benzene group in 
the vicinity of the sulphur thus making it more 'approachable' .  
These structural features may explain why triclabendazole is more
su lphoxid ised  than a lbendazole  and the lat ter  more so than 
fenbendazo le .
In both hepatic microsomes and hepatocyte  cultures, piperonyl 
butoxide was shown to reduce substantially the S-oxidation of the 
drugs studied. Interestingly, the degree of inhibition seemed to be 
inversely related to the initial (without inhibition) velocity, i.e., 
fenbendazole more extensively inhibited than albendazole and the 
lat ter  more so than t r ic labendazole .  In fact  t r ic labendazole  
sulphoxidation was unaffected by piperonyl butoxide in microsomal
preparations.  It could be that the formation of PB reactive 
metaboli tes which are responsible  for the inhibit ion happens 
relatively slowly in comparison to the rapid TCBZ sulphoxidation. 
TCBZ sulphonation, a slower reaction than the sulphoxidation, was
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diminished by PB. The increase in the concentration of unchanged 
TCBZ in microsomal mixtures could have been caused by an 
inhibited hydroxylation (not measured in this study) of the parent 
compound.  In contrast to the finding with hepatic microsomes,  
cultured hepatocytes did show a decrease in TCBZ sulphoxidation 
following incubation with piperonyl butoxide. This could be due to 
several factors which distinguish intact cells from subcellular 
fractions including uptake by and distribution within the cells of 
both drug and inhibitor, NADPH cofactor-supply and the sequential 
arrangement of both cytosolic and microsomal biotransformations 
within the cells. Also the presence of bovine serum albumin in the 
culture medium would be expected to cause protein binding with 
TCBZ and slow down its uptake and metabolism by the cells. It 
appears,  therefore, that  in many respects , pr imary culture  of 
hepatocytes constitute  a more realistic model for the in-vivo 
s i tuat ion.
The main limitation encountered in the study of benzimidazole 
metabolism in vitro was the low expression of sulphonation. This 
meant that a comparison of the impact of inhibition on the two 
oxidative reactions was not possible. Nonetheless, in order to verify 
that the decrease in sulphonation with piperonyl butoxide was not 
a consequence of lower sulphoxide concentrations, inhibition of 
sulphonation was further investigated by incubating oxfendazole at 
high concentrations (50 jiM) with and without  inhibition. This 
resulted in a reduction of sulphonation which did not reach 
statistical significance because of the large interindividual variation. 
However, in all cases the ratio sulphone/sulphoxide was decreased 
by in h ib i t ion  which  sugges t  that  the su lp h o n a t io n  was 
independently affected by inhibition.
Inhibition of TCBZ S-oxidation by 1-aminobenzotriazole, confirms 
the  i n v o l v e m e n t  o f  the  c y t o c h r o m e  P 4 5 0 - d e p e n d a n t  
monooxygenase system in the hepatic biotransformation of this 
anthelmintic . 1-aminobendzotriazole  has been shown to cause a 
70% inhibition of P450 at the concentration used (10 mM) with no 
detectable effect on other metabolizing enzyme systems (Mugford 
et al., 1992). Also 1-aminobenzotriazole has been shown to inhibit 
P450 isozymes responsible  for catalysing e thoxycoumarin  0 -  
deethylation (ECOD) and ethoxyresorufin 0-deethylat ion (EROD), 
activities characteristic of the P450 1A and 2B subfamilies (Ryan et
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al., 1979; Guengerich et al., 1982; Dutton and Parkinson, 1989). It
could be that S-oxidation of TCBZ is catalysed by isozymes
belonging to either or both subfamilies. The P4501A subfamily has 
been shown to interract with albendazole (Souhaili-El Amri et al., 
1988b) and o x fendazo le  (G le izes  et al., 1991a,b), both are 
thiosubsti tuted benzimidazoles. It is therefore possible  that this 
subfamily has an affinity for sulphur-containing benzimidazoles
(Gleizes et al., 1991a), including triclabendazole.
In conclusion, a comparative study of BZ-metabolism in vitro was 
carr ied out and tr ic labendazole  was found to be the most 
ex tens ive ly  metabol ised  molecule  of  the three S-subst i tu ted  
benzimidazoles  studied. The inhibit ion studies with piperonyl 
butoxide give support to the results already reported in vivo ( s e e  
Chapters 3 and 4) by demonstrating the in vitro effect of piperonyl 
butoxide at the main site of BZ biotransformation. The involvement 
of cytochrome P450 as an important catalyzing system for TCBZ S- 
oxidation was confirmed.
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C h a p te r  6
Effect  of  ear ly  t r e a tm e n t  with ra fo x a n id e  on a n t ip y r in e  
c learance  in sheep infected with F a s c io la  h e p a t ica
1 3 0
6.1 In troduct ion
Infection of lambs with the liver fluke Fasc io la  hepatica  has been 
shown to alter significantly the function of some hepatic drug- 
metabolising systems (Galtier et al. 1986b). Fluke infection causes an 
impairment of the oxidative drug metabolism activity as a result of a 
d e c r e a s e  in h e p a t ic  c y to c h r o m e  P 4 5 0 - m e d ia t e d  r e a c t io n s .  
Consequently, the plasma clearance of antipyrine (Figure 6-1), a 
pharmacokinetic  marker of the hepatic oxidative activity, has been 
shown to decrease between 4 and 16 weeks after moderate infection 
with Fasciola hepatica (Tufenkji et a l ,  1988 ).
R afo x an ide ,  3 ,5 -d i io d o -3 ' - c h lo r -4 - (p -c h  lo ro -p h e n o x y ) - sa l i c y la n i l id e ,  
belongs to an important  group of flukicidal  drugs (figure  6 -2 ) 
characterised by their high protein binding and long persistence in the 
plasma (see Chapter 1; section 1.1.1.2). The elimination half-lives of 
rafoxanide and the related salicylanilides closantel and oxyclozanide 
are very long and in sheep, they are in the magnitude of 16.6, 14.4 and
6.4 days, respectively (Mohammed-Ali & Bogan, 1987). In vivo testing 
of salicylanilides against early stages of Fasciola hepatica  has been 
complicated since small immature larvae are difficult to count and most 
efficacy trials have determined the number of readily identifiable adult 
parasites at some stage after treatment. Since salicylanilides have a 
long residence time in the plasma, and immature flukes reach their 
adult stage while sustained concentrations of drug are still present in 
the bloodstream, it has been suggested that the efficacy of these 
compounds against early stages of Fasciola hepatica  may have been 
overestimated and that only mature forms are truly susceptible to this 
group of flukicides (Mohammed-Ali & Bogan, 1987). However, studies 
on the efficacy of closantel against immature flukes (Maes et al. 1988) 
showed similar fluke removal when animals infected with 6 -week old 
Fasciola  hepatica  were killed and liver parasites counted one week 
after treatment (7 weeks post-infection) or 6 weeks after treatment 
(12 weeks after infection). The same authors have suggested that 
immature flukes may not have been killed by the drug but only 
arrested in their development.
The effect of fasciolicide treatment on the restoration of liver metabolic 
capacity has been reported in one study. Sheep treated with a flukicide 
b e n z im id a zo le  , lux ab en dazo le ,  8 w eeks  p o s t - in fe c t io n  had
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Figure 6-1. Chemical structure of antipyrine
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Figure 6-2. Chemical structure of rafoxanide
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normal antipyrine elimination half-life 3 weeks after the anthelmintic 
was given (Burrows et al. 1991).
The aim of the present study was to investigate the stage specificity of 
rafoxanide by measuring antipyrine plasma clearance and relevant  
biochemical parameters (GLDH and yGT) throughout the course of an 
experimental liver fluke infection in lambs.
6.2 Materials and Methods
6.2.1  Animals
Eighteen 10-month old Scottish Blackface sheep weighing 26 .92 ± 0 .7 7  
kg were used in this study. They were parasite-free and kept indoors 
throughout  the enti re  period of inves t iga t ion  with hay, cereal  
concentrate (Stewarts, Larbert, UK) and water provided ad  l ibi tum.
6.2.2  Chemicals
Antipyrine was purchased from Sigma Chemical Co.(St. Louis, MO, USA). 
Rafoxanide pure compound was donated by Merck Sharp & Dohme 
development laboratories (Hertfordshire, UK). Rafoxanide (Flukanide 3% 
W/V, oral drench) for administration to animals was obtained from 
MSD AGVET (Hertforshire, UK). All organic solvents were purchased 
from Rathburn Chemicals Ltd. (Walkerburn, UK)
6.2.3 Drug administration and sample collection
Antipyrine was dissolved in sterile water and was administered as a 
100 mg/ml solution into the left jugular vein at a dose rate of 25 
mg/kg. For each test, blood samples were taken from the contralateral 
vein prior to and 0.083, 0.5, 1, 2, 3, 4, 6 , 8 , 12 and 24 h after the bolus 
inject ion of antipyrine. Rafoxanide was administered orally at the 
recommended dose rate of 7.5 mg/kg. Blood samples for rafoxanide 
pharmacokinetics were taken prior to and 1, 2, 3, 4, 8 , 12, 19, 27, 33, 
39, 47, 53, 63, 70 and 76 days after rafoxanide administration. All 
blood samples were centrifuged, plasma collected and stored at -20 °C 
until analysis by HPLC.
6.2.4 Experimental  design
Antipyrine was administered to all animals one month before infection 
at which time they were allocated to three groups A, B and C, of six 
animals each. Sheep in groups A and B were then each infected with 
200 Fasciola hepatica  metacercariae (MAFF. New Haw, Weybridge, 
Surrey). Group C remained uninfected. Four weeks after infection.
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antipyrine was administered again, and immediately after the 24h- 
blood sample was collected, sheep in group B and C received an oral 
dose of rafoxanide, Antipyrine was subsequently administered to the 
three groups of animals at 6 , 8 , 10, 12 and 14 weeks post-infection. All 
animals were killed 15 weeks post-infection and their livers (Figure 6 -
3) cut into slices for the determination of adult fluke numbers.
6.2.5 Drug analysis
6 .2 .5 .1  A n t ip yr in e
Antipyrine was extracted from alkalinised plasma using a mixture of 
dichloromethane/pentane as described by Danhof  et al. (1979). Briefly, 
to 1 ml of plasma was added 100 pi  of sodium hydroxide (NaOH, 2N); 
after homogenization antipyrine was extracted twice with DCM/pentane 
(50/50).  The organic phase was separated from the p lasma by 
centrifugation at 4000 rpm for 5 minutes; it was then collected and 
evaporated to dryness at 40^C. The HPLC. system comprised a solvent 
delivery pump (Gilson Model 802, Scotlab Instrument sales Ltd, 
Glasgow, UK) connected to an ODS-Hypersil (5p) column (16 cm x 5 mm, 
ID) (Shandon Southern, Cheshire, UK) and a u.v. detector (Model SP 100, 
Burke Electronics Ltd, Glasgow, UK). The mobile phase was a mixture 
methanol-water-0.17M perchloric acid (76:24:0.05, v/v/v) running at a 
flow rate of Iml/min. The u.v. detector was set at a wavelength of 254 
n.m. Recoveries and precision of the method are displayed in Appendix 
E-1. The limit of analytical detection was below 0.05 pg/ml.
6.2.5.2 R afoxanide
Plasma samples were precipitated with acetonitrile and rafoxanide was 
extracted with 4ml of chloroform. After centrifugation, the organic 
phase was evaporated to dryness at 50^C, the residue was then 
reconstituted with methanol and injected on to an ODS-Hypersil (5pl)  
column (16 cm x 5 mm). The mobile phase was a mixture of methanol- 
water- 0.17M perchloric acid (95:5:0.05, v/v/v) running at a flow rate 
of Iml/min. The u.v. detector (Model SP 8450, Burke Electronics Ltd. 
Glasgow, UK) was set at a wavelength of 282 n.m. Drug-free plasma 
fortified with rafoxanide over the concentration range of 0.5-20 p g / m l  
was included with each assay. Recovery of rafoxanide from plasma to 
which the drug had been added was evaluated by reference to peak 
heights resulting from direct injection of rafoxanide standard solutions. 
The mean recovery obtained was 78.69%. and the inter-assay
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coefficients of variation was 5.93% (Appendix E-2). The limit of 
analytical detection achieved was 0.02  p g /m l .
6 .2 .6  B io ch em is tr y
Glutamate dehydrogenase (GLDH) activity, gamma-glutamyl transferase 
(yGT) activity and albumin concentrations were measured in plasma 
before infection and at 4, 6 , 8 , 10, 12, 14 weeks after infection with 
F a s c io l a  h e p a t i c a .  G lu tamate  dehydrogenase  was analysed  as 
reco m m e n d ed  by the German Socie ty  o f  C l in ica l  Chem is t ry  
(Anonymous, 1972) using test kits purchased from Randox Laboratories 
Ltd., Crumlin (UK). Gamma-glutamyl transferase activity was measured 
according to the method described by Szasz (1974) using test kits 
obtained from Boehringer Mannheim (Meylan, France). Plasma albumin 
concentrations were measured ,by a photometric  method (Webster, 
1977) .
6.2.7  P harm acok in et ic  and sta t is t ica l  ana lys is
A multiexponential modelling computer program CSTRIP (Sedman & 
Wagner, 1976) was used for the pharmacokinetic analysis of antipyrine 
plasma concentration time profiles obtained from each individual. Using 
the Akaike information cri ter ion (Yamaoka et al., 1978),  p lasm a 
concentra tions  of antipyrine were best fitted to a b iexponential  
equation which can be expressed as follows;
Cp=Ae’“  ^+ BeP^
Where Cp is the plasma concentration (|Xg/ml) at time t. A and B are 
the intercepts on the Y-axis of the distribution and elimination slopes, 
respectively. Alfa and p are the rate constants (expressed in h-l) o f 
distribution and elimination, respect ively and e is the base of the
natural logarithm. At time zero, the plasma concentration (Cpo) is equal 
to the sum of the intercepts. The elimination half-life ( t l / 2 p )  was
derived from the relationship t l /2 p =  0.693/p The area under the curve 
(AUG), in | ig.h/ml, was calculated as the sum of the ratios of the 
in te rcepts  and the corresponding  f i rs t -order  rate  constants ,  i.e,
A U C  = A / a  -I- B/p. The total body clearance (Clb) expressed in ml/kg.min 
was deduced from the ratio D/AUC, where D is the dose of antipyrine 
administered. The antipyrine clearance index which is defined as the 
ratio of the mean body clearance in the post-infection or pos t­
treatment phase to the mean body clearance in the pre-infection or
pre-treatment phase, was also calculated (Bachmann, 1989). The 
apparent volume of the central compartment (Vc) expressed in ml/kg
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was calculated as D/Cpo. The apparent volume of distribution (Vdarea) 
was calculated from the ratio D/AUC.p. The apparent  volume of 
distribution at steady-state (Vdss) was calculated using transfer rate 
constants k l 2 and k21 from the formula ( k l 2 -t-kl2 /k21 ).Vc, where 1 
and 2 re fe r  to the body compar tm ents .  The pharm acokine t ic  
parameters of rafoxanide were determined from observed values as 
previously described (Section 2.2.4).
All pharm acok ine t ic  data  were analysed  using non-param etr ic  
statistical tests. Comparisons between phases within the same group 
were performed using a Wilcoxon signed-rank test. A Mann-Whitney 
U - tes t  was used for between group com par isons .  B iochem ica l  
parameters were compared by analysis of variance. Values of P < 0 .0 5  
were taken as significant.
6.3 Results
The es tabl ishment  of flukes was high with more than 50% of 
adminis tered  metacercariae  maturing to their  adult  stage in the 
infected group which did not receive rafoxanide (Table 6-1 and 
Appendix E-3 and E-4). The number of adult flukes recovered from the 
livers of infected-rafoxanide treated sheep indicated an efficacy of 85%. 
Mean values for plasma protein, albumin, globulin, GGT and GLDH are 
presented in Table  6-2 ( infected untreated) . Table 6-3 ( infected 
treated) and Table 6-4 (uninfected treated). Individual  values are 
reported in Appendix E-5 to E -1 1 (infected untreated). Appendix E-12 
to E-18 (infected treated) and Appendix E-19 to E-25 (uninfected 
treated). Glutamate  dehydrogenase activity was increased in both
untreated and treated infected sheep between 4 and 12 weeks after 
fluke infection and two peaks were observed for each group (Figure 6 -
4). These occured at 4 and 8 weeks post-infection ( 207 and 219 lU/L
respectively ) for the untreated group and at 4 and 12 weeks (244 and
102 lU/L respectively ) for the rafoxanide-treated group. No changes 
from the normal  range were observed in the unparasit ised group.
Gamma-glutamyl transferase activity increased in all animals (Figure 
6-5), however the greatest rise occurred in the infected untreated 
group which had maximum activity of 232 lU/L, 10 weeks post­
infection. The plasma albumin concentration in all animals prior to
infection was 30.5 ± 2.0 g/1 (mean ± SEM) with no significant alteration 
occuring throughout the study, except in the infected untreated group
(A). In this group, the albumin concentration fell significantly (P^0.05) 
from a pre-infection value of 31.8 ± 2.6 g/1 to 23.7 ± 0.6 g/1 at
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Figure 6-3. Liver lesions caused by F. hepatica in one infected 
untreated sheep.
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Table 6-1. Number of adult Fasciola hepatica (mean ± SEM) 
recovered at necropsy in infected control (group A), infected 
treated (group B) and uninfected treated (group C) sheep.
Number of flukes Efficacy
(mean ± SEM) (%)
Group A 106.67 ± 11.4 -
Group B 15.67 ± 4.46 85.31
Group C - -
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Table 6-2. Plasma parameters (mean ± SEM) in group A (infected
untreated) before and at different times after F. hepat ica  infection.
Tim e
post in fec t ion
Control
4
w e e k s
PI
6
w e ek s
PI
8
w e e k s
PI
10
w e e k s
PI
1 2
w e e k s
P I
14
w e e k s
PI
Total 62.2 70.2 74.3 73.5 76.0 75.3 61.2
p ro te in
( g / 1)
±1.6 ±1.5 ±1.1 ±1.7 ±1.8 ±1.9 ±2.1
A lb u m in 31.8 31.7 31.2 29.7 29.0 27.5 23.7
( g / 1) ±2.6 ±1.2 ±0.9 ±0.8 ±1.0 ±0.9 ±0.6*
Globulin 30.3 38.5 43.2 43.8 48.7 47.8 37.5
( g / 1) ±1.7 ±2.1* ±1.8*** ±2.1*** ±1.1*** ±2.1*** ±2.5*
tGT 32.8 56.7 61.2 98 232 170 88.3
( U / L ) ±3.5 ±3.5*** ±1.9*** ±19** ±13*** ± 2 5 * * * ±9.2***
GLDH 2.2 207 158 219 207 108 68.2
( U / L ) ±0.4 ±44** ±21*** ±34*** ± 1 8 * * ±36.5
* Significantly different from control values (P<0.05) 
** Significantly different from control values (P<0.01) 
*** Significantly different from control values (P<0.001) 
PI (postinfection)
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Table 6-3. Plasma parameters (mean ± SEM) in group B (infected treated)
before and at different times after F. hepatica  infection.
T im e
p o s t in fe c t io n
contro l 4
w e e k s
PI
6
w e e k s
PI
8
w e e k s
PI
1 0
w e e k s
PI
1 2
w e e k s
PI
1 4
w e e k s
P I
Tota l 66.7 75.2 74.3 68.3 69.0 71.5 68.5
p r o t e in
(g /1 )
±3.1 ±2.8 ±2.3 ±1.5 ±2.1 ±2.3 ±2.8
A l b u m i n 31.3 32.7 31.7 30.7 32.7 33.0 29.3
(g /1 ) ±2.2 ±0.9 ±0.4 ±0.5 ±0.5 ±0.6 ±0.8
Globulin 35.3 42.5 42.7 37.7 36.3 38.5 39.2
(g /1 ) ±4.0 ±2.7* ±2.1* ±1.2 ±1.9 ±2.2 ±3.2
iJY 36.2 64.7 55.5 54.8 53.3 85.8 76.2
( U /L ) ±1.2 ±7.8 ±5.1 ±4.0 ±3.1 ±7.2 ±7.4
GLDH 4.0 244 26.0 25.3 42.3 102 5.5
( U /L ) ±1.0 ± 33*** ±7.3* ±5.6** ±8.1** ±28* ±1.7
* Significantly different from control values (P<0.05)
** Significantly different from control values (P<0.01)
*** Significantly different from control values (P<0.001) 
PI (postinfection)
Treatment with rafoxanide was at 4 weeks postinfection.
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Table 6-4. Plasma parameters (mean ± SEM) in group C (uninfected
treated) before and at different times after rafoxanide treatment.
Tim e posttreatment
Control Control 2 4 6 8 1 0
( - S w e e k s ) (TD) w e e k s w e e k s w e e k s w e e k s w e e k s
PT PT PT PT PT
Total 66.7 68.7 69.1 67.8 67.0 69.5 67.7
p r o t e i n ±2.3 ±1.9 ±1.3 ±1.4 ±1.8 ±2.0 ±1.8
(g /1 )
A l b u m i n 33.3 34.2 32.5 31.3 32.5 33.3 30.8
(g /1 ) ± 1.3 ±1.0 ±0.7 ±0.7 ±0.9 ±1.4 ±0.9
Globulin 33.3 34.5 36.7 36.5 34.5 36.2 35.2
(g /1 ) ±2.8 ±1.2 ±0.9 ±1.1 ±1.5 ±1.7 ±1.0
tGT 28.2 33.2 33.0 40.7 44.2 51.2 51.5
(U/1) ±2.3 ±1.6 ±1.7 ±1.8** ±2.5*** ±2.8*** ±3.3***
GLDH 3.2 3.8 6.8 2.0 6.3 12.4 5.8
(U/1) ±1.2 ±0.8 ±2.5 ± 0 . 9 ±1.7 ±3.7 ±1.9
** Significantly different from control values (P<0.01)
*** Significantly different from control values (P<0.001) 
PT (Posttreatment)
TD ( t rea tm ent  day; values de termined immedia te ly  
t r e a t m e n t )
prior  to
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Infected untreated (Group A) (n=6) 
  Infected and treated (Group B) (n=6)
Uninfected treated (Group C) (n=6)
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Figure 6-4. Serum glutamate dehydrogenase (GLDH) 
activity (lU/L) (mean ± SEM) in the three animal groups.
1 4 2
Infected untreated (group A) (n=6)
Infected treated (group B) (n=6) 
Uninfected treated (group C) (n=6)
2 0 0 -
H
a
o
100 -
1 0  1 2  1 40 6 82 4
Time post - in fec t ion  (weeks)
Figure 6-5. Serum gamma-glutamyl transferase (GOT) 
activity (lU/L) (mean ± SEM) in the three animal groups.
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14 weeks post- infection. Plasma globulin concentrations increased 
significantly in infected untreated sheep and in infected treated sheep 
before treatment and two weeks after treatment.
Mean plasma concentrations of rafoxanide are presented in Table 6-11 
(group B) and Table 6-13 (group C). The corresponding pharmacokinetic 
variables are reported in Table 6-12 (group B) and Table 6-14 (group 
C). Individual data are presented in Appendix E-69 to E-72. There were 
no s ignif icant  differences in the pharmacokinet ic  parameters  of 
rafoxanide between infected and uninfected sheep.
Mean p lasma concentra t ions  and pharm acokinet ic  parameters  of 
antipyrine are shown in Table 6-5 and Table 6-6 (group A); Table 6-7 
and Table 6-8 (group B) and Table 6-9 and Table 6-10 (group C). 
Individual values are dispayed in Appendix E-26 to E-39 (group A), 
Appendix E-40 to E-53 (group B) and Appendix E-54 to E-67 (group C). 
The decay of plasma antipyrine was best described by a biexponential 
equation. The semilogarithmic plots of mean plasma concentrations of 
antipyrine versus time obtained before and at two different occasions 
after Fasciola hepatica infection (group A) and, or, rafoxanide treatment 
(group B and C) are depicted in Figures 6-6 , 6-7 and 6 -8 , respectively. 
In pa ras i t ised  untrea ted  sheep an t ipyr ine  body c lea rance  was 
s ignif icantly  decreased and the e l imination half-life s ignificantly 
prolonged between 8 and 14 weeks post-infection. In the same group 
clearance indices were lower than in the uninfected or the infected 
treated group (Figure 6-9; Appendix E-68 ). There was little variation in 
clearance indices in the parasitised untreated sheep from 8 to 14 weeks 
after infection.  In the infected treated animals,  antipyrine body 
clearance was maintained close to the control value until 14 weeks 
post-infection when it was decreased by 23% as reflected by the 
reduced clearance index at that stage of infection. Increases in both 
area under the plasma concentration time curve and biological  
elimination half-life correlated with the decrease in plasma clearance 
(Table 6-6 and Table 6 -8 ). There were no significant changes in the 
volume of distribution in any of the groups. No significant alterations 
in the plasma kinetics of antipyrine were observed in the uninfected 
treated group (Table 6-10).
1 4 4
Table 6-5. Plasma concentrations of antipyrine (mean ± SEM) in
group A (infected untreated) before and at different times after
F. hepatica  infection.
Time postinfection
4 6 8 1 0 1 2 14
T im e Control w e e k s w e e k s w e ek s w e e k s w e e k s w e e k s
(ho u rs ) PI PI PI PI P I PI
0 .0 8 3 43.51 4 7 .24 47 .33 49 .85 4 4 .4 2 4 6 .1 7 , 4 5 .29
± 1.58 ± 1.95 ± 2.02 ± 2.37 ± 1.67 ± 2.64 ± 1.33
0.5 28 .50 30 .38 30 .75 33 .68 3 1 .2 6 31 .18 30 .1 2
± 1.28 ± 0.61 ± 1.52 ± 1.32 ± 1.72 ± 1.19 ± 1.39
1 19.38 22 .99 21 .25 24 .15 2 4 .1 9 25 .23 24.01
± 1.21 ± 1.11 ± 1.31 ± 1.01 ± 1.10 ± 1.23 ± 0.75
2 10.61 14.07 12.65 15.67 15.88 16.57 15.90
± 1.34 ± 0.72 ± 0.96 ± 0.73 ± 1.31 ± 1.42 ± 1.70
3 6 .6 6 9.23 8.26 10.75 11.37 10.83 10.82
± 1.12 ± 0.65 ± 1.05 ± 0.61 ± 1.57 ± 0.65 ± 1.17
4 4 .62 6.09 5.33 7.98 8.36 7.47 8.35
± 0.95 ± 0.59 ± 0.80 ± 0.94 ± 1.42 ± 0.36 ± 1.23
6 1.93 2.91 2.31 3.97 3.79 3.78 3.81
± 0.54 ± 0.31 ± 0.41 ± 0.60 ± 0.54 ± 0.19 ± 0.54
8 1.11 1.49 1.19 2.21 2 .24 2.17 2.65
± 0.30 ± 0.17 ± 0.26 ± 0.44 ± 0.53 ± 0.16 ± 0.71
12 0.27 0.39 0.33 0.71 0.67 0 .69 0 .79
± 0.08 ± 0.05 ± 0.07 ± 0.17 ± 0.18 ± 0.06 ± 0.20
2 4 0 .0 0 0 .0 0 0 .01 0.01 0.05 0 .01 0.03
± 0.00 ± 0.00 ± 0.01 ± 0.01 ± 0.01 ± 0.01 ± 0.02
PI (postinfection)
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Figure 6 -6 . Mean plasma concentrations of antipyrine 
in infected untreated sheep (group A, n=6 ).
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Table 6-6. Pharmacokinetic parameters of antipyrine (mean ± SEM)
in group A (infected untreated) before and at different times after
F, hepatica  infection.
Time postinfection
Control
4
weeks
PÏ
6
weeks
PI
8
weeks
PI
10
weeks
PI
12
weeks
PI
14
weeks
PI
Cpo 48.58 52.57 53.12 54.48 46.12 50.42 49.66
( p g / m l ) ±2 .14 ±2.28 ±2.30 ±3.21 ±2.08 ±3.71 ±1 .72
AUC 70.29 87.21 79.79 102.82 101.82 101.18 102.84
(H g .h /m l ) ±7.97 ±3.78 ±6.30 ±7.46* ±10 .09*t ±4 .80* ±10 .47*
t l / 2p
( h - i ) *
1.90 1.91 1.87 2 .2 1 * 2.44 2 .2 2 * 2.30*
CIb 6.22 4.79 5.34 4.11 4.23 4.13 4.24
( m l / m i n .k g ) ±0.72 ± 0.22 ±0 .50 ±0.26* ± 0 .40*t ± 0 .2 1 * ±0 .35*
Vc 520.1 480.6 475.4 458.9 547.4 512.5 506.4
( m l / k g ) ±24 .8 ± 22.8 ± 22.4 ± 30.7 ±23 .8 ±46.0 ±16.8
Vd(area) 979.6 780.8 874.5 815.2 903.6 798.8 840.0
( m l / k g ) ±104 .4 ±24.0 ±62 .7 ± 23.3 ±71.3 ±40.9 ±36.1
Vdss 763.5 699.1 741.2 690.5 762.5 720.2 758.1
( m l / k g ) ± 20.8 ±16 .8 ±45 .6 ±21.5 ±35.1 ±30.9 ±27 .4
^Significantly different from preinfection (P< 0 .05)
tS ig n i f i c a n t ly  d ifferent  from corresponding  values in group
C(P<0.05).
^Harmonic mean 
PI (postinfection)
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Table 6-7. Plasma concentrations of antipyrine (mean ± SEM) in
group B (infected treated) before and at different times after
F. hepat ica  infection.
Time postinfection
4 6 8 10 1 2 14
T im e Control w e e k s w e e k s w e ek s w e e k s w e e k s w e e k s
(h o u rs ) PI PI P I PI PI P I
0 .0 8 3 42.81 44.11 44 .66 43 .83 43 .65 43 .37 49 .37
± 1.95 ± 2.43 ± 1.73 ± 3.45 ± 6.42 ± 0.73 ± 4.09
0.5 29.21 28 .77 28 .47 29 .6 2 2 8 .9 0 30 .7 8 31 .29
± 1.78 ± 0.91 ± 1.20 ± 1.62 ± 1.89 ± 1.33 ± 1.62
1 22.39 21 .38 21 .4 0 23 .1 4 19.40 2 1 .9 0 25 .47
± 1.79 ± 1.51 ± 1.54 ± 1.22 ± 0.99 ± 1.78 ± 1.73
2 13.49 13.12 12.76 13.35 1 0 .88 12 .60 16.34
± 1.30 ± 1.49 ± 1.56 ± 1.08 ± 1.27 ± 1.44 ± 1.14
3 8.91 8.26 7 .40 9.30 7.03 8.75 11.63
± 0.98 ± 1.27 ± 1.41 ± 1.01 ± 0.84 ± 1.64 ± 1.32
4 6.30 5.78 5.09 6.17 4.90 5 .60 8.76
± 0.89 ± 1.16 ± 1.14 ± 0.82 ± 0.80 ± 1.14 ± 1.06
6 3.08 3.11 2.51 2.89 1.95 2.75 4.77
± 0.53 ± 1.04 ± 0.66 ± 0.62 ± 0.38 ± 0.60 ± 0.69
8 1.70 1.87 1.39 1.42 0.81 1.46 3.11
± 0.36 ± 0.74 ± 0.50 ± 0.31 ± 0.18 ± 0.31 ± 0.61
1 2 0.53 0.57 0.45 0 .42 0.27 0.48 1.07
± 0.13 ± 0.32 ± 0.17 ± 0.16 ± 0.06 ± 0.12 ± 0.26
2 4 0.01 0 .0 2 0 .0 2 0.01 0 .0 0 0.01 0 .04
± 0.01 ± 0.02 ± 0.02 ± 0.01 ± 0.00 ± 0.01 ± 0.01
PI (postinfection)
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Figure 6-7. Mean plasma concentrations of antipyrine 
in infected rafoxanide-treated sheep (group B, n=6 ).
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Table 6-8. Pharmacokinetic parameters of antipyrine (mean ± SEM) in
group B (infected treated) before and at different times after
F. hepatica  infection.
Time postinfection
Control
4
weeks
PI
6
weeks  
' PI
8
weeks
PI
10
weeks
PI
12
weeks
PI
14
weeks
PI
Cpo 47.23 51.40 50.30 47.61 51.58 46.83 54.94
( | i g / m l ) ±2.38 ±3.07 ±3 .27 ±4.04 ±7.21 ±0.80 ±5.42
AUC 86.61 85.07 78.77 85.62 70.74 83.22 112.66
( j i g . h / m l ) ± 8.39 ±12.4 ± 10.20 ±8.29 ±6.98 ±9.62 ±11.07*
tl/2P
( h - 1)*
2.05 1.83 1.93 1.88 1.85 2.13 2.54
CIb 5.09 5.33 5.68 4.99 6.02 5.25 3.90
( m l / m i n .k g ) ±0.60 ± 0.68 ±0 .79 ±0.41 ±0.60 ±0.63 ±0 .38*
Vc 536.0 494.6 507.3 545.4 523.8 534.7 483.4
( m l / k g ) ±26 .4 ±27.8 ±32 .0 ±48.5 ±60 .0 ±9 .2 ±58 .9
Vd(area) 911.2 840.9 962.7 812.9 1002.2 976.7 860.0
( m l / k g ) ±54.1 ±34.9 ±70 .6 ±41.9 ±121 .5 ±86.3 ±72.6
Vdss 780.5 713.6 765.2 720.1 766.5 755.9 760.3
( m l / k g ) ±38 .4 ± 21.2 ±29 .9 ±16.9 ±50.2 ±25 .4 ±45.3
^Significantly different from preinfection (P ^ 0 . 0 5 )  
^Harmonic  mean  
PI (post infection)
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Table 6-9.  Plasma concentrations of antipyrine (mean ±  SEM) in 
group C (uninfected treated) before and at different times after
rafoxanide  treatment.
Time posttreatment
8 1 2 4 6 8 10
Tim e w e e k s d a y w e e k s w e e k s w e e k s w e e k s w e ek s
(ho u rs ) PreT PreT PT PT PT PT PT
0 .0 8 3 4 4 .7 9 46 .08 4 6 .26 53 .16 44.61 4 8 .0 6 52.61
± 3.37 ± 2.83 ± 2.03 ± 3.44 ± 1.68 ± 4.28 ± 2.36
0.5 27 .83 30 .28 2 8 .6 6 29 .37 27 .36 28.81 2 8 .62
± 1.47 ± 1.81 ± 0.87 ± 1.12 ± 2.20 ± 1.93 ± 1.62
1 19.62 2 1 .0 2 2 0 . 2 0 21 .98 18.22 19 .30 2 1 .8 2
± 0.93 ± 1.24 ± 0.88 ± 1.11 ± 1.52 ± 1.41 ± 1.83
2 11 .88 12.56 11 .14 13.10 10.19 10.54 12.65
± 0.88 ± 1.02 ± 1.26 ± 0.72 ± 2.01 ± 1.87 ± 1.92
3 7.66 8 .54 6 .50 8.71 6.28 6 .32 7.73
± 0.82 ± 0.94 ± 1.27 ± 1.06 ± 1.64 ± 1.44 ± 1.92
4 5 .02 5.27 4 .36 6.06 4.25 4.47 5.58
± 0.66 ± 0.79 ± 1.08 ± 1.11 ± 1.47 ± 1.33 ± 1.47
6 2.13 2.42 2 .1 0 2.78 2.17 2 .14 3 .10
± 0.38 ± 0 . 5 4 ± 0.70 ± 0.58 ± 0.94 ± 0.81 ± 1.05
8 1.26 1.26 1.05 1.45 1.04 1.14 1.69
± 0.28 ± 0.40 ± 0.40 ± 0.36 ± 0.46 ± 0.48 ± 0.64
12 0 .36 0.33 0 .30 0.49 0.35 0 .30 0 .50
± 0.10 ± 0.11 ± 0.14 ± 0.21 ± 0.17 ± 0.12 ± 0.20
2 4 0 .0 0 0 .0 0 0 .0 0 0.01 0 .0 2 0 .0 0 0.03
± 0.00 ± 0.00 ± 0.00 ± 0.01 ± 0.01 ± 0.00 ± 0.02
PT (posttreatment)
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Figure 6 -8 , Mean plasma concentrations of antipyrine 
in uninfected treated sheep (group C, n=6 ).
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Table 6-10. Pharmacokinetic parameters of antipyrine (mean±SEM) 
in group C (uninfected treated) before and at different times after
rafoxanide treatment.
Time postinfection
8
w eeks
PreT
1
day
PreT
2
weeks
PT
4
weeks
PT
6
weeks
PT
8
weeks
PT
10
weeks
PT
Cpo 50.60 50.81 51.15 61.48 48.60 54.27 61.08
( p g / m l ) ±4.13 ±3.31 ±2.88 ±4.63 ±2.51 ±5.19 ±3.53
AUC 74.88 79.61 71.98 85.86 68.80 71.52 84.04
(p ,g .h /m l) ± 6.31 ±7 .9 ±8.59 ±8.20 ±12.11 ±10.93 ±13.24
t l /23
( h - l ) *
1.82 1.77 1.72 1.87 1.82 1.77 1.94
CIb 5.73 5.41 5.97 5.01 6.74 6.29 5.50
(m l /m in .k g ) ±0.50 ±0.48 ±0.50 ±0.38 ±0.90 ±0.80 ±0.76
Vc 507.6 502.3 497.4 419.8 521.5 486.3 429.1
( m l / k g ) ±33.5 ±31.9 ±31.0 ±35.0 ±27.7 ±54.6 ±31.9
Vd(area) 902.6 825.5 890.2 812.6 1044.5 963.9 920.4
( m l / k g ) ±33 .5 ±38.3 ±37 .8 ±12 .4 ±52.2 ±71.4 ±49 .9
Vdss 790.5 719.5 729.8 760.3 773.6 733.7 743.0
( m l / k g ) ±31 .8 ±32.1 ±21.5 ±28.2 ±10 .4 ±47.4 ±22 .9
^Harmonic mean 
PreT (pretreatment)  
P T (p o s t t r ea tm e n t )
153
0 .3  1
u
am3
I  Infected untreated (group A)
E3 Infected treated (group B)
□  Uninfected treated (group C)
4  6 8 1 0 1 2 1 4
T i m e  p o s t - i n f e c t i o n  ( w e e k s )
Figure  5-8. C learance  Index (Cl) o f  an tipyrine  at different 
o f  infection and/or treatm ent in group A , B and C.
* Body c learance  (CIb) s ign if ican tly  d iffe ren t  
from  the control (P c0 .05 )
s tages
Cl = mean CIb (post- in fect ion  and, or, post-treatm ent)/m ean CIb (control)
1 5 4
Table 6-11. Plasma concentrations of rafoxanide (}ig/ml) in 
infected and uninfected sheep.
Mean ± SEM (n=6)
Time (days) Group B Group C
(In fec ted ) (un in fec ted )
0 0.00  ± 0.00 0.00  ± 0.00
1 17.67 ± 1.37 18.84 ± 1.35
2 *19.31 ± 0.97 20.65 ± 1.45
3 19.48 ± 0.96 20.64 ± 1.32
4 18.55 ± 0.94 18.73 ± 1.03
8 14.64 ± 0.69 14.36 ± 0.91
1 2 11.80 ± 0.50 11.50 ± 0.85
19 7.44 ± 0.21 7.24 ± 0.74
27 4.17 ± 0.73 4.66 ± 0.60
33 2.95 ± 0.36 3.11 ± 0.60
39 2.01 ± 0.23 1.83 ± 0.46
47 1.09 ± 0.14 1.08 ± 0.31
5 2 0.78 ± 0.14 0.87 ± 0.27
63 0.44 ± 0.09 0.51 ± 0.16
7 0 0.29 ± 0.06 0.38 ± 0.12
7 6 0.18 ± 0.04 0.28 ± 0.09
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Figure 6-10.  Plasma concentrations of  rafoxanide (mean ±
SEM) in infected (group B, n=6) and uninfected (group C, n=6)
sheep.
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Table 6-12. Pharmacokinetic parameters of rafoxanide in infected
and uninfected sheep.
Mean ± SEM (n=6)
Group B 
( infected)
Group C 
(un in fec ted )
AUC obs(M«g.d/ml) 362.76 ± 9.27 367.8 ± 29.4
AUMCobs(lig.d2/ml) 5607 ± 330 5773 ± 856
MRT (d) 15.45 ± 0.81 15.29 ± 1.22
Cmax (|ig/ml) 19.95 ± 0.91 21.77 ± 1.39
tmax (d) 2.67 ± 0.33 2.00 ± 0.37
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6.4 Discussion
6.4.1 Suitabil i ty of  the animal  model
Sheep are the host species in which Fasciola hepatica infection imposes 
the greatest economic loss and it is in this species that salicylanilides 
are most widely used. The use of antipyrine as a pharmacokinetic 
marker for liver damage caused by Fasciola hepatica in sheep has been 
previously  reported (Tufenkji  et aL, 1988, Burrows et al., 1991). 
Antipyrine possesses pharmacokinetic  characteristics which make it 
suitable for assessing liver function during the course of various types 
of hepatic dysfunction (Poulsen and Loft, 1988; St Peter and Awni,
1991) .  A n t ip y r in e  is (1) e l im in a te d  p r in c ip a l ly  th ro u gh  
biotransformation reactions which take place almost entirely in the 
liver, metabolic processes involved are catalysed by the hepatic
cytochrome P450-enzyme system (which has been shown to be 
impaired by liver fluke infection); (2) Its volume of distribution 
equals body water and protein binding is negligible (less than 10%),
variations in plasma protein concentrations are therefore unlikely to 
affect its pharmacokinetic disposition; (3) it is characterised by a low 
extraction ratio; liver blood flow rate has therefore little bearing on the 
elimination of the drug. With such pharmacokinetic  features, and 
provided that animals are kept in a stable environment, changes in the 
clearance of this probe drug reflect liver damage inflicted by the fluke 
burden. Also the evolution of the disease following flukicidal therapy 
could be assessed, provided that direct or indirect interaction between 
the therapeutic agent and the probe drug do not occur.
In the present study, the clearance of antipyrine was significantly 
decreased in the infected untreated sheep (group A) at 8 , 10, 12 and
14 weeks after infection, indicative of liver damage attributable to the
parasites, thus demonstrating the applicability of the model. Also,
conduct ing  the tests under  s imilar  env ironm enta l  condit ions,  
minimises intraindividual variation in antipyrine disposition (Vessel & 
Penno, 1983). In the present  study, small intraindividual variation 
were observed (less than 6% for the plasma clearance and the 
elimination half-life) after two antipyrine tests undertaken 8 weeks 
apart on the uninfected sheep (group C) before they were dosed with 
rafoxanide (Table 6-10). This group also served as a control for any
interaction between antipyrine and rafoxanide.
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6 .4 .2  An t ip yr i ne  p h a rm a c o k i n e t i c s
The mean plasma clearance and elimination half-life of antipyrine in 
pre-infection animals is consistent with that reported by Tufenkji et  
al. (1988). Although it has been shown that 4 weeks after infection 
with F a sc io la  hepa t ica ,  the cytochrome P450 activi ties and the 
antipyrine clearance start to decrease (Galtier et al., 1983, G al tier et  
a/. ,  1986b, Tufenkji et a i ,  1988), in the present study it was not until 8 
weeks post-infection that the first significant decrease in antipyrine 
body clearance occurred. This could be related to breed differences of 
the hosts in their susceptibi l i ty  to the parasi te.  Alternatively ,  
differences in the pathogenicity of the strains of parasite used could be 
the reason, since impairment of host metabolic capacity has been 
imputed to toxic excretions by the fluke (Galtier et al., 1983, Galtier et  
a l . ,  1985b, Galtier et al., 1986b). Flukicidal  treatment  with the 
salicylanilide drug rafoxanide at 4 weeks post-infection prevented the 
decrease in the rate of elimination of antipyrine for up to 12 weeks 
post-infection. This was due to the action of rafoxanide on the parasite 
rather  than to its intrinsic effect on antipyrine metabolism, since 
rafoxanide did not induce any significant change in the plasma kinetics 
of antipyrine at any post-treatment stage when given to uninfected 
sheep. A significant decrease in antipyrine clearance was observed 14 
weeks post-infection in group B. This could be due to parasites which 
survived the treatment depressing the oxidative metabolism of the 
liver when they matured to the adult stage. Another explanation may
be that rafoxanide exerted a transient inhibitive action on parasites 
development. The inhibited parasites may have resumed development 
8 to 10 weeks after treatment, as the plasma concentration of 
rafoxanide declined.
6.4.3 Biochemical  changes
In the infected treated animals, the biochemical findings indicate an 
early effect of rafoxanide reflected by the fall in GLDH activity 2 
weeks after treatment. Surprisingly, however, 6 weeks later  GLDH 
activity rose to values equivalent to those in the parasitised untreated 
sheep. Gamma-glutamyl dehydrogenase is indicative of liver necrosis 
induced by migrating immature flukes (Sykes et al., 1980a, Cornelius, 
1989), therefore the increased activity of the enzyme manifested later
in the course of infection in treated animals supports the hypothesis of 
a d rug - induced  re ta rded  deve lopm ent .  Studies  based on the
measurement of fluke size at different stages after treatment with
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closantel (Maes et al., 1988, Maes et al., 1990), the sulphonamide 
clorsulon (Malone et a / . ,1984), or even with the more recent flukicide 
triclabendazole (Buscher et al., 1987) indicate a stunting effect of the 
drugs on the parasite. Maes et al (1988) postulated that arrested forms 
eventually resume their development and reach maturity after a delay 
of at least 10 weeks. The same phenomenon could explain the putative 
high efficacy (98%) of rafoxanide reported by Armour & Corba (1970) 
against 4 week-old Fasciola hepatica  when assessed by counting adult 
flukes at 10 weeks post-infection rather than at more advanced stages 
of infection. The peak of yGT activity occurred two weeks after that of 
GLDH (10 weeks post-infection in the untreated animals) and is in 
agreement with previous observations which established that the yG T
increase was mainly caused by adult flukes reaching the bile ducts 
(Sykes et a i ,  1980a, Galtier et al., 1986b). The increase in yGT in 
uninfected sheep was within the normal range and could be explained 
by an inductive effect of rafoxanide. It has previously been reported 
that increased yGT is induced by xenobiotics such as the steroid drug 
prednisolone (Kramer, 1989). Increased globulinaemia in infected 
sheep is consistent with previous findings (Sykes et al., 1980b).
6 .4 .4  Rafoxan ide  pha rm ac ok i ne t i c s
Kinetic  parameters of rafoxanide were similar in infected and
uninfected sheep. Studying the disposition of radiolabelled rafoxanide 
in healthy and Fasciola h ep a t ica -m i tc i t é  rats, Galtier and collègues. 
(1985a) made a similar observation. This could be related to the fact 
that salicylanilides are not extensively metabolised (McKellar  &
Kinabo, 1991) and therefore their elimination is not compromised by 
changes in liver metabolism which may be caused by subclinical 
F a sc io la  hepatica  infection. Another factor that could modify the 
disposit ion of extensively plasma protein bound drug would be 
hypoalbuminaemia associated with haematophagic Fasciola hepatica . 
In the present study no changes were observed in plasma protein 
except in the untreated group (A) where a hypoalbuminaemia was
observed 14 weeks after infection. However, this was not clinically 
significant .
Hepatic drug-metabolism during the course of fascioliasis has been 
s tudied using bromosulfophthalein (BSP) as another probe drug, 
whose clearance has been shown to decrease with fluke infection 
(Tufenkji et al., 1987). In sheep experimentally infected with F asc io la  
h e p a t i c a  the elimination half-life and the volume of distribution of
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pentobarbital were increased causing a prolonged narcosis (Tufenkji et  
a l . ,  1991). The macrolide  compound,  e ry throm ycin ,  which is 
extensively metabolised in the liver by N-demethylation also has its 
elimination impaired during acute and subacute fascioliasis in sheep 
whereas no changes were observed with oxytetracycline,  a less 
extensively biotransformed antibiotic (Burrows et al., 1991). The 
plasma kinetics of albendazole metabolites were also altered by 
subclinical fluke infection in lambs (Galtier et al., 1991) In vitro 
studies on microsomal UDP-glucuronyl  transferase  act ivity and 
microsomal cytochrome P450 activity indicate that the metabolism of 
the fasciolicide drugs nitroxynil and oxyclozanide could be impaired 
during fascioliasis (Facino et a i ,  1984, Facino et aL, 1985).
In conclusion, this study gives a further insight in the understanding 
of salicylanilide action against immature stages of Fasciola hepatica. 
Although rafoxanide acts at an early stage of the parasite as evidenced 
by the unchanged clearance of antipyrine and the decline of GLDH 
activity during the pre-patent period of the infection, changes in these 
parameters occurring later in the course of infection indicate that 
rafoxanide may not kill immature flukes but temporarily inhibit their 
d ev e lo p m e n t .
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C h a p te r  7
G e n e r a l  D iscuss ion
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The first study reported in this thesis was set out to generate 
pharmacokinetic data on three chemically related benzimidazole 
compounds ,  in goats. It was found,  that albendazole  and 
albendazole sulphoxide, given at the same dose rate of 7.5 mg/kg, 
were bioequivalent. The albendazole-prodrug netobimin given at 
7.5 mg/kg, which is 37% lower than the equimolar dose, resulted 
in a 45 % lower AUC for the sulphoxide metabolite than that 
ob ta ined  after  ABZ adm in is t ra t ion .  A ssum ing  f i r s t -o rde r  
c o n v e r s io n ,  it could  th e re fo re  be e s t im a te d  that  the 
gastrointestinal  microflora of the goat is 87% efficient  at 
converting the prodrug into albendazole.
Knowledge of anthelmintic disposition in goats is important given 
the contribution of this animal species in the development of 
anthelmintic resistance (Jackson, 1993). Reported studies have 
shown that a number of anthelmintic drugs are less bioavailable 
in goats than they are in sheep (Weir & Bogan, 1985; Bogan et a l ,  
1987; Sangster et a l ,  1991; Sundlof & Whitlock, 1992; Hennessy 
et a l ,  1993a,b). Concurrent deworming of sheep and goats is 
generally based on a dosage regime established in the former 
species. Nematodes harboured by goats are consequently exposed 
to sublethal levels of anthelmintic, become resistant  and are 
passed on to sheep.
For these reasons, goats used in the studies described in this 
thesis were given higher doses of albendazole and fenbendazole 
than those recommended for sheep. For the latter drug, it is even 
the manufacturer 's recommendation to use the same dose as 
recommended for sheep. When fenbendazole was given to goats 
at 7.5 mg/kg. The AUC (FBZ) was 4.76 p.g.h/ml, whereas in sheep 
a lower dose (5 mg/kg) resulted in an AUC (FBZ) of 7.54 jig.h/ml. 
Taking sheep as the reference species, the relative bioavailability 
corrected for dose (Shargel & Yu, 1993b) achieved in goats was 
only 42%. Fenbendazole systemic availability was also found to 
be lower in goats than in cattle (Short et a l ,  1987a,b).
Interspecies differences in biovailability were less pronounced 
with albendazole  in our studies. However a recent  report  
suggested a lower AUC of ABSO in goats than in sheep (Hennessy 
et a l ,  1993c). This was explained by a higher liver sequestration, 
rather than metabolism, of the sulphoxide metabolite in goats.
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the elimination rate being the same in both species. It would be 
of interest to compare the hepatic metabolism of albendazole in  
vitro  and also to determine liver tissue concentrations of ABSO in 
both species.
One of the main objectives of this thesis was to explore the link 
between pharmacokinet ic  behaviour and clinical eff icacy of 
anthelmintic drugs. Because of the extensive hepatic metabolism 
which benzimidazole molecules undergo and also because their 
mode of action is based on the intensity as well as the duration of 
parasite exposure, BZ's represented an ideal anthelmintic group 
for  p h a rm a co k in e t ic /p ha rm aco dy n am ic  m an ipu la t ion  th rough  
inhib i t ion  of  hepatic  drug-metabol ism. In the" pre l im inary  
s tud ies ,  a d ram atic  increase  in the b io av a i la b i l i ty  of 
benz im idazo le  act ive  m etabol i tes  was observed  when the 
m etabo l ic  inh ib i to r  p iperony l  bu tox ide  was adm in is te red  
intramuscularly one hour prior to anthelmintic  administration. 
However, piperonyl butoxide failed to increase significantly the 
plasma ABSO levels in goats, despite a substantial increase in the 
level of the same metabolite in sheep. This may have been 
caused by the lower availability of the inhibitor observed in the 
former species. If this is the case, piperonyl butoxide given 
orally, could have a more pronounced inhibitory effect as it is 
more bioavailable by this route. Alternatively, goats could be less 
responsive to inhibition of albendazole metabolism by piperonyl 
butoxide in which case, in vitro comparative studies would prove 
valuable in elucidating the difference. In a similar context, 
Lanusse and Prichard (1992a,b) reported that when netobimin 
was a d m in i s t e re d  c o n c u r re n t ly  with  the  F M O - in ih b i to r  
methimazole, a much higher response in terms of sulphoxidase 
inhibition, was achieved in sheep than in cattle. This observation 
was later substantiated by a comparat ive  study using liver 
microsomal preparations from sheep and cattle (Lanusse et a i ,  
1993c).
An attempt was made to study the absolute bioavailability of 
piperonyl butoxide given at 0.5 g/kg, however, unfortunately, the 
intravenous administration proved fatal in one animal and the 
study was aborted. A lower dose and a more appropriate
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formulation would probably enable a proper investigation of the 
bioavailability of this drug. Also piperonyl butoxide is reported to 
be readily absorbed through the skin. This route could also be 
investigated in different animal species and compared to other 
routes of administration in terms of BZ potentiation. Another 
topic which deserves exploration is the metabolic pathway of 
p iperonyl  butoxide and the characterization of the reactive
metaboli tes which cause the metabolic inhibition. It is also
important  to determine the toxicity of this drug when given 
orally to ruminants. However, in the rat, orally administered 
piperonyl butoxide is reported to have a very low toxicity (Haley, 
1978) .
The dose titration study in sheep showed that significantly higher 
levels of FBZ and FBSO could be achieved with a dose rate of
piperonyl butoxide 16 times lower than the dose administered in
the preliminary study. This study also showed that piperonyl 
butoxide is absorbed and has an inhibitory effect when given
orally.  This was an important  prerequisi te  for any further
c o n s id e ra t io n  c o nce rn in g  the p o ten t ia l  benef i t s  of  the 
combinat ion as all BZ, with the exception of netobimin,  are
limited to oral formulations.
The efficacy trial with the combination fenbendazole-piperonyl  
butoxide  confi rmed previous reports  that susta ined higher 
plasma levels of active metabolites resulted in enhanced efficacy 
against  BZ-resistant nematodes (Prichard et al., 1978; Hennessy 
et al., 1985). The BZ-resistant strains of O. circumcincta  and H . 
co n to r tu s  proved highly susceptible to the combination. The ratio 
PB /FBZ used in this trial was 12.6/1; this was because the
efficacy trial, for deadline reasons, had to overlap with the 
analytical phase of the dose titration study and a choice of a dose 
for piperonyl butoxide had to be made. It can be seen from the 
end result of the dose titration study that a dose of 31 mg/kg 
could have been used. Future eff icacy assessments in sheep 
should therefore be tried at a ratio amounting to 6.2/1.
There was no apparent effect of PB given alone, on nematode 
burden with both strains studied and the potentiating effect is 
likely to be limited to changes induced in the pharmacokinetic
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pattern of the BZ in the host. Notwithstanding this, it would be 
interesting to look at the effect of the combination against 
nematodes in vitro and to determine wether piperonyl butoxide 
affects the t ranscut icu lar  delivery of benzimidazole  drugs. 
Studies in insects have shown that piperonyl butoxide delays the 
penetration of pyrethrins through cuticles (O’Brien, 1967). Effect 
of piperonyl butoxide on the absorbtion rate of BZ by the animal 
host also requires investigation.
Benzimidazoles seem to undergo more extensive metabolism in 
the equine species than they do in ruminants  or in man 
(Marriner & Bogan, 1985; Bogan et al., 1987). A fast sulphonation 
of FBZ resulted in no detectable levels of the sulphoxide 
metabolite in horse's plasma after administration of  fenbendazole 
(Marriner & Bogan, 1985). Studies on the effect of metabolic 
inhibition with piperonyl butoxide in this species would provide 
further information on how the benzimidazoles are handled by 
the equine liver.
A r e l a t i v e l y  new and u n e x p lo r e d  a s p e c t  o f  the  
p h a r m a c o k i n e t i c / p h a r m a c o d y n a m i c  p r o p e r t i e s  o f  the  
b e n z im id a z o le  d rugs  is the i r  ch ira l  na tu re  and the 
enantioselective biotransformation which they undergo (Delatour 
et al., 1994). Cytochrome P450 Inhibition is likely to change the 
proportion (+)/(-) which could have an impact on anthelmintic 
activity since it is generally believed that individual enantiomers 
of a chiral compound exibit  d if ferent  b io logical  actions.  
Characterization of the biological action (eudismic ratio) and 
toxicity of enantiomers is clearily needed. This would provide a 
direction to follow in terms of metabolic manipulation of the 
benzimidazoles in different target species.
The use of metabolic inhibition for therapeutic benefit has been 
reported in man and it has been shown, for example that the cost 
of cyc lospor in  therapy can be dram atica l ly  lowered  by 
administering the drug with ketoconazole. The interaction was 
due to the inhibition by ketoconazole of P450IIIA, which is 
implicated in the metabolism of cyclosporin (First et al., 1989). 
Also, in relation to helminth therapy, a study on the therapeutic 
effect of mebendazole  against larval echinococcosis  in man 
sugges ted  that  h igher  and more e f fec t ive  m ebend azo le
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concentrations could be achieved by inhibition of the drug 
metabolizing capacity of the liver rather than by increasing the 
dose of mebendazole (Witassek & Bircher, 1983). In dogs, 
McKellar  et al. (1990, 1993a) have shown that gastrointestinal 
absorption of fenbendazole follows a zero-order  process and 
increasing the dose does not enhance the bioavailability of this 
drug; metabolic inhibition may also prove useful in this species.
The in vitro S-oxidation of th iosubs t i tu ted  benz im idazoles  
revealed dramatic differences in the rates at which these drugs 
were metabolised. In both microsomal preparations and cultured 
hepa tocy tes ,  t r ic labendazole  was found to be extensively  
converted into its sulphoxide and sulphone metabolites, more so 
than albendazole or fenbendazole. Although it is general ly 
believed that TCBZ metabolites achieve much higher plasma 
levels than ABZ or FBZ metabolites because of their extensive 
binding to plasma proteins, it is possible that a more efficient S- 
oxidation of the parent TCBZ may contribute to the high plasma 
AUC for TCBSO and TCBS02. It would be interesting to look at the 
S-oxidation of the three benzimidazoles and their respective 
su lphox ide  metaboli tes  when incuba ted  with and without  
albumin in the microsomal reaction mixture and monitor the 
impact  of protein binding on the microsomal metabolism of the 
d rugs .
In terspecies  differences in the pharm acok ine t ic  pattern  of 
triclabendazole metabolites have been reported (Bogan et a i ,  
1988a; Oukessou et al., 1991; Sanyal, 1994) in vitro studies with 
different species would provide useful data to corroborate the 
differences observed in vivo.
The in vitro inhibition of ABZ and FBZ with piperonyl butoxide 
conf i rm ed  the changes  observed  in the p ha rm acok ine t ic  
behaviour of the two benzimidazoles when coadministered with 
the inhibitor. The nature of this inhibition was not studied. 
However, since the substrate concentrations used were similar to 
the Michaelis  constant  Km (53.6 p M )  reported for ABZ 
su lphoxidat ion  (Farget ton et al., 1986), it was assumed that 
saturation of the system was not achieved and therefore both 
possibilities of competitive and noncompetitive inhibition exist.
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It was found that the S-oxidation of TCBZ was affected by 
piperonyl butoxide and it would be interesting to investigate this 
effect in vivo. 1-aminobenzotriazole also had a dramatic effect on 
the metabolism of TCBZ confirming the catalytic activity of the 
c y t o c h r o m e  P 4 5 0 - e n z y m e  s y s te m  in the  o x d a t i v e  
biotransformation of this anthelmintic . Further work is now 
needed in order to identify  the P450 isozymes involved.
Combining immunoinhibit ion and molecular  biology techniques 
would facilitate such characterization. Also the involvement of 
the flavin-monoxygenase system ought to be considered and 
investigated using heat-treated microsomes and purified FMO
from hog liver microsomes.
It has been shown that in vitro, unchanged TCBZ inhibited the 
motility of immature and adult F. hepatica  and that this action 
was slow and necessitated the accumulation of TCBZ within the 
parasite (Bennet t  and Kohler, 1987). The use of metabolic
inhibitors, such as piperonyl butoxide and 1-aminobenzotriazole 
may help understand further  this effect  by inhibi t ing the
conversion of the parent drug into the sulphoxide metabolite.
Hydroxylated metabolites of the benzimidazoles investigated in 
this thesis, were not measured because of the very low or 
undetectable levels they achieve in the systemic circulation and 
it was not within the scope of this project to measure them in bile 
or in urine where they tend to be the main metabolites. However, 
given that hydroxylation is likely to be a cytochrome P450 
catalyzed reaction (Gibson & Skett, 1994), it would be interesting 
to examine the effect of inhibitors on this reaction. Moreover, 
hydroxyfenbendazole  (OH.FBZ) has been shown to bind to 
parasite tubulin (Lacey et al., 1987) and authors have attributed 
part of the efficacy of fenbendazole and oxfendazole against 
intest inal  parasi tes , to this metaboli te.  It would be worth 
investigating the effect of OH.FBZ administered per  jg o n 
abomasal parasites.
The study described in the last chapter was set out to elucidate 
whether the action of salicylanilides against juvenile  flukes was 
due to their peak level or to the long lasting residual levels which
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are contemporaneous with the adult stage of the fluke. It was 
concluded that peak plasma levels achieved by rafoxanide had an 
action against 4-week-old F. hepatica\ however, liver function 
tests, namely antipyrine clearance and GLDH activity, suggest 
that this action is partially a result of a 'stunting' rather than a 
lethal effect. As drug levels in the blood circulation decline, it is 
suggested that f lukes which have been retarded in their 
development would, eventually achieve maturity and start laying 
eggs (Maes et a l ,  1988).
The antipyrine clearance test proved to be a useful tool in this 
study since it permitted the assessment of liver damage caused 
by fluke infection and also, together with GLDH activity 
measurements, it enabled us to follow the evolution and outcome 
of flukicidal treatment with rafoxanide.
Although, in the present study fluke infection did not have any 
effect on the pharmacokinetic behaviour of rafoxanide, a number 
of studies have shown that drugs which, unlike rafoxanide, are 
extensively metabolised in the liver, may have their elimination 
impaired by fascioliasis. However, all studies so far published on 
hepatic  drug metabolism during fluke infection have been 
limited to the effect of single moderate infections and therefore 
are not reflective of pasture infections where sheep are exposed 
to a continuous intake of metacercariae which leads to the 
cumulat ive establ ishment of trematodes of mixed age in the 
liver. The effect of these natural infections on the metabolic 
response of parasitised animals to xenobiotics would be of 
interest. Also, it is worth investigating how liver fluke impairs 
hepatic drug-metabolising capacity. An initial step would involve 
in vitro drug metabolism studies using excretory-secretory (E-S) 
products from F. hepatica.
Unlike liver fluke infection, infection with H. contortus  has been 
shown to increase significantly the body clearance of antipyrine 
(Kawalek and Fetterer, 1990). It was suggested that H. contortus 
may have an inductive effect on cytochrome P450 mediated 
metabol ism via a general ised increase in hepatic  protein 
synthesis associated with the physiologic response to compensate 
the loss of plasma proteins and other blood components caused 
by the infection. A closer examination of the effect of nematodes
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on drug metabolism would be useful given that many 
anthelmintic  drugs are extensively biotransformed and their 
clearance may therefore be altered by nematode infections.
In conclusion, the work carried out throughout this project has 
mainly led to the development of a drug combination which 
assoc ia tes  a benzimidazo le  with a po ten t ia t ing  metabolic  
inhibitor. Many aspects of  this combinat ion are still to be 
scrutinised. An important one is the safety to both the animal 
t reated and, in relation to food-producing animals,  to the 
consumer. This research program has also involved a comparison 
of the in vitro metabol ism of  S-subst i tu ted  benzimidazoles .  
Finally, a better understanding of the flukicidal action of 
salicylanilides has been achieved.
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Appendix A
Pharmacokinet ics  of albendazole ,  a lbendazole  sulphoxide
and netobimin in goats
Appendix A-1. Recovery and coeff ic ien ts  of va r ia t ion  for 
albendazole metabolites following ether extraction from plasma
Added concentration 
(M-g/ml)
Recovery
(%)
B e tw e e n -a s s a y  
coefficient of variation 
(%)
albendazole
0.05 101.29 (n=6) 4 .97
0 .1 0 90.95 (n=6) 2 .79
0.25 93.25 (n=6) 5 .43
0 .5 0 96.13 (n=6) 4 .68
1.0 98.24 (n=6) 3 .76
M ean 95.97 (n=30) 4 .33
albendazole su phoxide
0 .10 68.69 (n=8) 8.47
0.25 73.55 (n=8) 10.19
0.5 76.68 (n=8) 6 .82
1 83.25 (n=8) 6 .05
2 83.02 (n=8) 6 .78
M ean 77.04 (n=40) 7 .6 6
albendazole su Iphone
0 .10 84.66 (n=8) 4 .5 2
0 .25 82.12 (n=8) 3 .82
0 .50 88.85 (n=8) 6.51
1.0 90.57 (n=7) 4 .2 6
M ean 86.55 (n=31) 4 .78
Coefficient of variation = (SD/mean recovery) X 100
2 0 3
Appendix A-2. Recovery and coefficients of variation for netobimin
Added concentration 
(M-g/ml)
Recovery
(%)
B e tw e e n -a s s a y  
coefficient of variation 
(%)
netobimin
0 .25 84.43 (n=6) 10.92
0 .5 0 97.67 (n=7) 13.40
1 95.33 (n=8) 9 .04
2 92.96 (n=5) 16.22
Mean 92.60 (n=26) 12.40
a lbendazo le
0 .05 92.46 (n=6) 15.04
0 .10 99.53 (n=6) 5.68
0 .25 92.65 (n=6) 9 .29
0 .50 93.15 (n=7) 7 .92
1 102.56 (n=7) 5 .16
M ean 96.07 (n=32) 8 .62
albendazole sul phoxide
0 .10 82.18 (n=6) 8.17
0 .25 85.43 (n=6) 6.23
0 .50 77.53 (n=6) 5 .10
1 73.81 (n=6) 7 .86
2 79.34 (n=6) 7 .37
M ean 79.66 (n=30) 6.95
albendazole snip tone
0 .1 0 77.20 (n=6) 7 .99
0 .25 91.48 (n=6) 6 .6 2
0 .50 87.39 (n=6) 6 .13
1 83.10 (n=6) 7 .05
M ean 84.79 (n=24) 6 .95
Coefficient of variation = (SD/mean recovery) X 100
2 0 4
Appendix A-3.  Plasma concentrations of albendazole sulphoxide
(|ig/ml) in goats following oral administration of albendazole at 7.5
mg/kg bodyweight.
Animal number
Time (h) G1 G3 G7 GIO G l l G12 G13
0 0 .00 0 .00 0 .0 0 0 .00 0 .00 0 .00 0 .00
0 .25 0 .00 0.00 0 .0 0 0 .00 0.05 0 .00 0 .0 0
0.5 0 .09 0.07 0 .00 0.11 0 .14 0 .09 0 .00
1 0 .23 0.17 0 .18 0 .25 0 .2 4 0 .22 0.08
2 0 .62 0.39 0 .42 0 .60 0.58 0.53 0 .27
4 1.08 0.71 0.95 1.32 0 .97  ' 0 .99 0 .59
8 2.15 1.74 2.01 2.47 2.07 2 .40 1.24
1 2 2 .09 2 .32 2 .74 2.58 2 .24 2 .90 1.73
2 4 1.36 1.48 1.45 1.47 1.46 2.51 1.03
3 2 0 .54 0.38 0 .59 0.51 0 .69 1.81 0.15
4 8 0 .00 0 .00 0 .0 0 0 .00 0 .00 0 .10 0 .00
7 2 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00
9 6 0 .00 0 .00 0 .00 0 .00 0 .00 0 .0 0 0 .00
A p p e n d ix  A-4.  P h a rm ac o k in e t ic  p a ra m e te r s  o f  a lb e n d az o le  
sulphoxide  (ABSO) in goats following oral administra t ion of 
albendazole at a dose rate of 7.5 mg/kg bodyweight
Animal number
G1 G3 G7 GIO G l l  G12 G13
AUCobs (|ig.h/ml)
AUMCobs(flg.h2/ml)  
MRT (h)
Cmax (jig/ml) 
tmax (h)
49.78  47 .76  55 .16  56 .4 4  33 .1 4  53.11 85 .50  
818.2 78 9 . 4  914 .7  893 .9  518 .5  910.1  1758.5  
16.44 16.53 16.58 15 .84  15.65 17 .14  20 .57  
2.15 2 .32  2 .74  2 .58 1.73 2 .24  2 .30  
8 .00  12.00 12.00  12.00  12 .00  12 .00 12.00
2 0 5
Appendix A-5. Plasma concentrations of  albendazole sulphone
(}ig/ml) in goats following oral administration of albendazole at
7.5 mg/kg bodyweight.
Animal number
Time (h) G1 G3 G7 GIO G l l G12 G13
0 0 .00 0 .00 0 .0 0 0 .00 0 .00 0 .00 0 .0 0
0 .25 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00 0 .0 0
0.5 0 .00 0 .00 0 .00 0 .02 0 .00 0 .00 0 .00
1 0 .00 0 .00 0 .02 0.02 0 .00 0 .00 0 .00
2 0.03 0.03 0.05 0 .04 0.03 0 .04 0 .0 0
4 0 .04 0.07 0 .12 0.11 0.07 0.08T 0.05
8 0.21 0.27 0 .34 0.33 0.17 0.26 0 .20
1 2 0 .34 0.51 0 .65 0.55 0 .36 0.69 0 .4 0
2 4 0.68 1.12 1.22 0.97 0.91 0.98 0 .88
3 2 0 .77 1.19 1.35 1.02 0 .64 1.14 1.20
4 8 0 .02 0 .00 0 .00 0 .02 0 .00 0 .00 0 .79
7 2 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00
9 6 0 .00 0 .0 0 0 .00 0 .00 0 .00 0 .00 0 .00
Appendix A-6. Pharmacokinetic  parameters of albendazole sulphone 
(ABS02) in goats following oral administration of albendazole at a dose 
rate of 7.5 mg/kg bodyweight.
Animal number
G1 G3 G7 GIO G l l  G12 G13
AUCobs (M.g.h/ml) 
AUMCobs(^g-h2/ml)  
MRT (h)
Cmax (|ig/ml) 
tmax (h)
2 0 .1 7  3 0 .9 0  35.41 28 .51  2 0 .6 0  3 0 .3 6  43.01
5 1 8 .0  7 84 .3  886.1 7 0 9 .7  505.1  7 4 8 .7  1470 .0  
2 5 .6 9  2 5 .3 9  2 5 .0 2  2 4 .8 9  2 4 .5 2  2 4 .6 6  34 .18  
0 .77  1.19 1.35 1.02 0.91 1 .14  1.20
3 2 .0 0  3 2 .0 0  3 2 .0 0  3 2 .0 0  2 4 .0 0  3 2 .0 0  32 .00
A p p e n d ix  A- 7 .  Plasma concentrat ions  o f  a lb en d azo le
sulphoxide (pg/ml)  in goats following oral administration of
albendazole sulphoxide at 7.5 mg/kg bodyweight.
2 0 6
Anima number
Time (h) G1 G3 G7 GIO G l l G12 G13
0 0 .00 0 .00 0 .00 0 .00 0 .00 0 .0 0 0 .00
0 .25 0 .05 0 .04 0 .00 0.03 0.05 0 .06 0 .04
0.5 0 .15 0.11 0 .14 0 .19 0.19 0 .19 0 .14
1 0 .36 0.25 0 .42 0.55 0.61 0 .49 0.47
2 0 .92 0 .50 1.00 1.20 1.25 1.07 1.09
4 1.78 0 .92 1.81 2 .18 2.81 1.77 1.98
8 2.01 1.67 2.47 2 .94 2.89 2 .69 3.45
1 2 2.31 1.96 2.68 2.43 3.04 2 .88 3.58
2 4 1.87 0.68 1.49 1.01 1.56 1.87 2 .34
3 2 0 .89 0 .00 0 .62 0 .28 0.25 0.81 1.63
4 8 0 .0 0 0 .00 0 .00 0 .0 0 0.00 0 .0 0 0 .14
7 2 0 .0 0 0 .00 0 .00 0 .00 0 .00 0 .0 0 0 .00
9 6 0 .00 0 .00 0 .00 0 .00 0.00 0 .0 0 0 .00
A p p e n d ix  A-8.  P h a rm ac o k in e t ic  p a ram ete rs  for  a lb e n d az o le  
sulphoxide (ABSO) following administration albendazole sulphoxide to 
goats at a dose rate of 7.5 mg/kg bodyweight.
Animal number
G1 G3 G7 GIO G l l  G12 G13
AUCobs (fig.h/ml) 
AUMCobs(ftg.h^/ml)  
MRT (h)
Cmax (pg/ml) 
tmax (h)
62 .9 6  3 2 .9 0  60 .95  5 3 .4 9  65 .33  6 9 .5 9  96 .19  
1 101 .0  417 .5  957 .0  7 07 .5  892 .7  1147 .3  1803.4  
17 .49  12 .69  15.70 13.23 13.66 16 .49  18.75 
2.31 1.96 2.68 2 .94  3 .04  2 .88  3.58 
12 .00  12 .00  12.00 8 .00  12.00 12 .00  12.00
2 0 7
Appendix A-9. Plasma concentrations of  albendazole sulphone
( A B S 0 2 )  (pg/ml)  in goats fo llowing oral administration of
albendazole sulphoxide at 7.5 mg/kg bodyweight.
Animal number
Time (h) G1 G3 G7 GIO G l l G12 G13
0 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00
0.25 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00
0.5 0 .00 0 .00 0 .00 0 .00 0 .00 0 .0 0 0 .00
1 0 .00 0 .00 0 .00 0.03 0.05 0 .0 0 0.03
2 0 .05 0.05 0.07 0.07 0 .10 0 .07 0.07
4 0.11 0 .12 0 .20 0 .20 0 .30 0.15 0.18
8 0.27 0.31 0 .49 0 .50 0.47 0 .38 0 .44
1 2 0.47 0 .59 0 .76 0.66 0 .70 0 .59 0.57
2 4 1.00 1.29 1.25 0 .94 1.18 1.05 0 .87
32 1.14 0 .24 1.31 0 .92 0.89 1.06 1.00
48 0 .00 0 .00 0 .00 0 .02 0 .00 0.03 0.63
7 2 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00
96 0 .00 0 .00 0 .00 0 .00 0 .00 0 .0 0 0 .00
A ppend ix  A-10.  P h a rm ac o k in e t ic  pa ram ete rs  of  a lbendazo le  
sulphone ( A B S 0 2 )  in goats fol lowing oral adminis t ra t ion  of 
albendazole sulphoxide at a dose rate of 7.5 mg/kg bodyweight.
Animal number
G1 G3 G7 GIO G l l  G12 G13
AUCobs (|ig.h/ml) 
AUMCobs (|lg.h2/ml) 
MRT (h)
Cmax (pg/ml) 
tmax (h)
28.93 2 2 .1 8  36 .9 7  28 .83  31 .03  3 0 .62  40 .2 4
733.0  4 6 9 .9  894 .3  679 .9  7 1 0 .7  75 8 .7  1267.3  
25.34 2 1 .1 9  2 4 .1 9  23 .59  2 2 .9 0  24 .7 8  31 .49  
1.14 1.29 1.31 0 .94  1.18 1.06 1.00
32.00 2 4 .0 0  3 2 .0 0  2 4 .00  2 4 .0 0  3 2 .0 0  32 .00
2 0 8
Appendix A-11.  Plasma concentrations of  albendazole sulphoxide
(ABSO) (jig/ml) in goats following oral administration of netobimin
at 7.5 mg/kg bodyweight.
Animal number
Time (h) G1 G3 G7 GIO G l l G12 G13
0 0 .00 0 .0 0 0 .0 0 0 .00 0 .0 0 0 .00 0 .0 0
0 .25 0 .00 0 .0 0 0 .00 0 .00 0 .00 0 .00 0 .00
0.5 0 .00 0 .00 0 .0 0 0 .00 0 .03 0 .00 0 .00
1 0 .18 0.11 0 .06 0 .06 0 .1 2 0 .19 0.21
2 0 .46 0 .47 0 .3 4 0.18 0.53 0 .59 0 .67
4 1.05 0.63 0 .72 0.61 1.09 0.98 1.17
8 1.55 0.95 0 .88 1.04 1.65 1.21 1.68
1 2 1.73 1.00 0 .96 1.13 1.76 1.09 1.43
2 4 0 .76 0 .27 0.51 1.19 0 .90 0 .76 0 .98
3 2 0.23 0 .00 0.11 0.49 0 .18 0.23 0 .56
4 8 0 .00 0 .0 0 0 .00 0 .00 0 .00 0 .00 0 .00
7 2 0 .00 0 .0 0 0 .0 0 0 .00 0 .00 0 .00 0 .00
9 6 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00 0 .00
A p p en d ix  A - 1 2. P h a rm ac o k in e t ic  pa ram e te r s  of  a lbendazo le  
sulphoxide (ABSO) in goats following oral administration of netobimin 
at a dose rate of 7.5 mg/kg bodyweight
Animal number
G1 G3 G7 GIO G l l  G12 G13
AUCobs (M-g.h/ml) 
AUMCobs(M^g.h2/ml) 
MRT (h)
Cmax (|ig/ml) 
tmax (h)
34 .37  17.18 2 0 .3 4  3 3 .1 4  36.01 2 7 .8 6  39 .35  
500 .5  200 .3  294 .7  6 23 .5  512 .7  4 2 7 .4  657.5  
14.56 1 1.66 14.49 18.81 14.49 15 .34  16.71 
1.73 1 .00 0 .96  1.19 1.76 1.21 1.68 
12 .00  12 .00  12 .00  2 4 .0 0  12 .00  8 .00  8 .00
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Appendix A-13. Plasma concentrations of albendazole sulphone 
(ABS02) (|i,g/ml) in goats following oral administration of netobimin 
at 7.5 mg/kg bodyweight.
Animal number
Time (h) G1 G3 G7 GIO G l l G12 G13
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.5 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 0.00 0.04 0.00 0.04 0.05 0.00 0.00
4 0.06 0.09 0.09 0.09 0.11 0.07 0.07
8 0.18 0.20 0.20 0.16 0.22 0.20 0.16
12 0.32 0.35 0.40 0.33 0.33 0.27 0.41
24 0.53 0.71 0.73 0.53 0.64 0.61 0.51
32 0.56 0.00 0.63 0.43 0.60 0.57 0.64
48 0.00 0.00 0.00 0.00 0.00 0.00 0.00
72 0 . 0 0 / 0.00 0.00 0.00 0.00 0.00 0.00
96 O.OJd 0.00 0.00 0.00 0.00 0.00 0.00
jendix A-14. Pharmacokinetic parameters of albendazole sulphone (ABS02) 
“oats following oral administration of netobimin at a dose rate of 7.5 mg/kg
Ifweight
Animal number
G1 G3 G7 GIO G l l G12 G13
AUCobs (M-g.h/ml) 15.48 11.03 19.09 14.07 17.53 16.11 16.91
AUMCobs(^ig.h2/ml) 379.4 211.6 462.5 330.3 424.2 398.4 413.5
MRT (h) 24.51 19.18 24.23 23.48 24.20 24.73 24.45
Cmax (M-g/ml) 0.56 0.71 0.73 0.53 0.64 0.61 0.64
tmax (h) 32.00 24.00 24.00 24.00 24.00 24.00 32.00
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Appendix B
Effect of piperonyl butoxide on the pharmacokinetics of 
albendazole and fenbendazole in sheep and goats
Appendix B-1. Recovery and coefficients of variation for piperonyl 
butoxide and albendazole metabolites following extraction by
Added concentration 
( j ig /m l )
Recovery
(%)
Betw een-assay 
coefficient of variation
(%)
piperonyl butoxide
0.25 102.88 (n=6) 7.97
0.50 93.59 (n=7) 3.94
1 100.41 (n=7) 6.16
2 99.80 (n=8) 5.41
5 101.97 (n=7) 9.95
Mean 92.60 (n=35) 6.69
albendazole
0.10 99.09 (n=6) 4.27
0.50 95.46 (n=6) 3.72
1 93.23 (n=6) 9.06
Mean 95.93 (n=18) 5.68
albendazole sul phoxide
0.10 85.13 (n=8) 10.62
0.50 83.78 (n=8) 4.77
1 89.82 (n=6) 6.44
2 93.11 (n=7) 2.31
Mean 87.96 (n=29) 6.04
albendazole sulphone
0.10 82.56 (n=7) 6.90
0.50 86.49 (n=7) 5.71
1 91.40 (n=6) 9.49
Mean 84.79 (n=20) 7.38
Coefficient of variation = (SD/mean recovery) X 100
21 1
Appendix  B-2. Recovery  and coeff ic ien ts  of var ia t ion  for 
fenbendazole metabolites following extraction by precipitation
Added concentration 
( l i g / m l )
Recovery
(%)
B e tw e e n - a s s a y  
coefficient of variation 
(%)
fen b en dazo le
0 .1 0 84.11 (n=4) 9 .25
0 .25 83.31 (n=5) . 8 .59
0 .5 0 78.27 (n=5) 11 .74
M ean 81.90 (n=14) 9 .86
fenbendazole  su phoxide
0 .1 0 86.87 (n=5) 10.21
0 .25 85.03 (n=6) 11.35
0 .5 0 92.60 (n=5) 9 .06
1 90.98 (n=6) 8 .1 0
M ean 88.87 (n=22) 9 .68
fenbendazole sulphone
0 .1 0 83.06 (n=6) 11.58
0 .5 0 85.98 (n=5) 11.19
1 88.42 (n=5) 9 .65
M ean 85.82 (n=16) 10.81
Coefficient of variation = (SD/mean recovery) X 100
2 1 2
Appendix B-3. Plasma concentrations of  fenbendazole (FBZ) ( |ig/ml) in
goats following administration of fenbendazole (7.5 mg/kg) alone.
Animal number
Time (h) G1 G3 G7 GIO s w SB
0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.25 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.5 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
1 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 0 .0 2 0 .00 0 .03 0 .0 2 0.03 0 .0 0
4 0 .1 2 0 .04 0.13 0.05 0.13 0 .04
8 0.18 0.11 0.25 0 .1 0 0 .2 2 0.25
1 2 0.18 0.15 0 .24 0 .09 0 .18 0 .24
2 4 0.15 0 .10 0.11 0.07 0 .14 0 .2 2
3 2 0.07 0 .10 0.07 0.05 0 .0 2 0.13
4 8 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0.03
7 2 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
9 6 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
Appendix B-4. Pharmacokinetic parameters of fenbendazole (FBZ) in goats 
following administration of fenbendazole (7.5 mg/kg) alone.
Animal number
G1 G3 G7 GIO SB SW
AUCobs ( |ig.h/ml) 4 .89 3 .96 5 .30 2 .60 7 .40 4.40
AUMCobs ()ig.h2/ml) 87 .42 80 .8 0 85 .97 4 8 .5 0 1 63 .04 67.25
MRT (h) 17.88 2 0 .4 0 16 .24 18.65 22 .03 15.30
Cmax (|ig/ml) 0 .18 0.15 0.25 0 .1 0 0.25 0 .22
tmax (h) 10 1 2 8 8 8 8
2 1 3
Appendix B-5. Plasma concentrations of fenbendazole (FBZ) (}ig/ml) in
goats fo l low ing  administration of  fenbendazole  (7.5 mg/kg) and
piperonyl butoxide (0.5 g/kg).
Animal number
Time (h) G1 G3 G7 GIO SW SB
0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.25 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.5 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
1 0 .0 2 0 .0 0 0.01 0 .0 0 0 .0 2 0 .0 0
2 0.13 0.01 0.08 0 .0 0 0 .0 2 0 .0 4
4 0 .34 0.11 0 .16 0 .05 0.05 0.13
8 0 .50 0.38 0.27 0 .3 4 0 .26 0 .18
12 0 .57 0 .30 0 .2 5 0 .45 0.38 0.25
2 4 0 .39 0 .50 0.19 0 .45 0.67 0 .2 0
3 2 0 .34 0.45 0.15 0 .42 0 .34 0 .18
48 0 ,16 0 .10 0 .02 0 .30 0 .2 0 0 .04
7 2 0 .0 0 0 .00 0 .0 0 0 .06 0.03 0 .0 0
96 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0.01 0 .0 0
Appendix B-6. Pharmacokinetic parameters of fenbendazole (FBZ) in 
goats following administrat ion of fenbendazole  (7.5 mg/kg) and 
piperonyl butoxide (0.5 gr/kg).
Animal number
G1 G3 G7 GIO SB SW
AUCobs (M'g-h/ml) 18.97 16.67 7 .79 2 2 .0 9 8.13 19.90
AUMCobs (|lg.h2/ml) 4 5 2 .9 7 431.11 157.21 7 1 5 .6 4 1 86 .96 5 92 .2 0
MRT (h) 23 .8 8 25 .87 2 0 .1 9 3 2 .4 0 2 3 .0 0 29.77
Cmax (|ig/ml) 0 .57 0 .50 0.28 0.45 0.25 0.67
tmax (h) 12 2 4 8 1 8 1 2 2 4
2 1 4
Appendix B-7. Plasma concentrations of fenbendazole sulphoxide (FBSO) 
(|ig/ml) in goats following administration of fenbendazole (7.5 mg/kg) 
alone.
Animal number
Time (h) G1 G3 G7 GIO s w SB
0 0.00 0.00 • 0.00 0.00 0.00 0.00
1 0 .0 0 0.00 0.00 0.00 0.00 0.00
2 0.00 0.00 0.00 0.00 0.00 0.00
4 0.03 0.00 0.02 0.02 0.03 0 .0 0
8 0.16 0.09 0.18 0.10 0.17 0.14
1 2 0.27 0.14 0.27 0.13 0.23 0.27
24 0.31 0.20 0.23 0.13 0.29 0.34
32 0 .19 0.14 0.13 0.12 0 .28 0.29
48 0 .0 0 0.02 0.00 0 .03 0.05 0.07
72 0 .0 0 0.00 0.00 0.00 0.00 0 .0 0
96 0.00 0.00 0 .0 0 0.00 0.00 0.00
Appendix B-8. Pharmacokinetic parameters of fenbendazole sulphoxide 
(FBSO) in goats following administration of fenbendazole (7.5 mg/kg) 
alone.
Animal number
G1 G3 G7 GIO SB SW
AUCobs (Kg.h/ml) 8.27 5.56 6 .80 4 .84 11 .00 9.87
AUMCobs (!lg.h2/ml) 178 .76 137.28 1 3 7 .0 4 1 2 2 .0 0 2 9 0 .5 6 2 53 .0 0
MRT (h) 2 1 .6 2 24 .69 2 0 .1 5 25.21 26.41 25.63
Cmax (ng/ml) 0.31 0 .20 0 .23 0.13 0 .34 0.29
tmax (h) 2 4 2 4 2 4 1 8 2 4 2 4
2 1 5
Appendix B-9. Plasma concentrations of  fenbendazole sulphoxide (FBSO)
(p.g/ml) in goats following administration of fenbendazole (7.5 mg/kg)
and piperonyl butoxide (0.5 g/kg).
Animal number
Time (h) G1 G3 G7 GIO SW SB
0 0 .00 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.25 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.5 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
1 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
4 0 .0 2 0 .02 0.07 0 .0 2 0.01 0 .04
8 0 .42 0.21 0 .2 2 0.15 0.11 0 .16
1 2 0 .70 0.69 0.33 0 .40 0.27 0.25
2 4 0 .88 0.45 0 .42 0 .6 6 0.69 0 .39
3 2 0.65 0.83 0.38 0 .6 6 0 .69 0 .36
4 8 0 .34 0 .24 0.05 0.48 0.58 0 .16
7 2 0 .0 0 0 .0 0 0 .0 0 0.11 0 .09 0 .0 0
9 6 0 .0 0 0 .00 0 .0 0 0 .0 0 0.01 0 .0 0
A ppend ix  B-10.  P h a rm ac o k in e t ic  pa ram ete rs  of  fenbend azo le  
sulphoxide (FBSO) in goats following administration of fenbendazole 
(7.5 mg/kg) and piperonyl butoxide (0.5 g/kg).
Animal number
G1 G3 G7 GIO SB SW
AUCobs (|Lig.h/ml) 3 0 .7 4 25 .68 13.49 3 0 .6 2 14.18 31 .69
AUM Cobs (|lg.h2/ml) 868 .08 7 3 0 .3 2 3 3 4 .2 8 1106 .2 4 1 5 .0 4 1184.0
MRT (h) 2 8 .2 4 28 .4 4 24 .7 8 3 6 .13 2 9 .2 7 37.36
Cmax (pig/ml) 0 .88 0.83 0 .42 0 .66 0 .39 0 .69
tmax (h) 2 4 32 2 4 28 2 4 28
2 1 6
Appendix B-11. Plasma concentrations of fenbendazole sulphone (FBS02)
()ig/ml) in goats following oral administration of  fenbendazole (7.5
mg/kg) alone.
Animal number
Time (h) G1 G3 G7 GIO SW SB
0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.25 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.5 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
1 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
4 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
8 0 .0 2 0.01 0 .0 2 0.01 0.01 0.01
1 2 0 .04 0 .02 0 .05 0.01 0 .0 2 0 .04
2 4 0 .09 0.07 0 .09 0 .04 0.05 0.08
3 2 0.09 0.08 0 .07 0 .04 0 .06 0 .1 2
48 0.03 0.06 0.03 0.03 0 .04 0 .09
7 2 0 .0 0 0.01 0 .0 0 0 .0 0 0.01 0.01
96 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
Appendix B-12. Pharmacokinetic parameters of F B S 0 2  in goats following 
administration of fenbendazole(7.5 mg/kg) alone.
Animal number
G1 G3 G7 GIO SB SW
AUCobs (iig.h/ml) 3 .04 3.27 2 .80 1.74 2.56 4 .70
AUMCobs ( | ig.h2/ml) 92.01 1 20 .8 0 81 .2 2 6 3 .3 2 93.61 174 .06
MRT (h) 30 .24 3 6 .9 4 28 .98 36 .45 36 .57 37.03
Cmax (jig/ml) 0 .09 0 .08 0.09 0 .04 0 .06 0 .12
tmax (h) 28 3 2 2 4 28 3 2 3 2
2 1 7
Appendix B-13. Plasma concentrations of  fenbendazole sulphone
(FBS02)  ( |ig/ml) in goats following administration of fenbendazole
(7.5 mg/kg) and piperonyl butoxide (0.5 g/kg).
Animal number
Time (h) G1 G3 G7 GIO SW SB
0 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.25 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.5 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
1 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 0 .02 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
4 0.05 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
8 0 .09 ' 0 .04 0 .04 0.01 0 .0 0 0.05
12 0 .12 0 .14 0 .04 0.01 0 .0 0 0.05
2 4 0 .16 0.06 0 .06 0 .04 0.05 0 .09
3 2 0.13 0 .1 2 0.08 0 .07 0 .06 0 .1 0
48 0.13 0.15 0.08 0.11 0 .1 0 0 .09
7 2 0 .06 0 .02 0 .02 0 .1 0 0 .07 0.03
96 0.01 0 .0 0 0 .0 0 0.01 0 .0 2 0.01
Appendix B-14. Pharmacokinetic parameters of F B S 0 2  in goats 
following administrat ion of fenbendazole  (7.5 mg/kg) and 
piperonyl butoxide (0.5 g/kg).
Animal number
G1 G3 G7 GIO SB SW
AUCobs (^ig.h/ml) 8 .86 6 .80 4 .06 6.13 5 .36 4.98
AUMCobs (| ig.h2/ml) 347.81 2 5 2 .0 9 155 .80 3 3 2 .8 7 2 1 9 .1 9 266 .41
MRT (h) 39 .28 37 .0 9 3 8 .36 54.31 40 .8 7 53 .47
Cmax (|ig/ml) 0 .16 0 .14 0 .08 0.11 0 .1 0 0 .10
tmax (h) 2 4 1 2 4 0 4 8 3 2 48
2 1 8
Appendix B-15. Plasma concentrations of albendazole sulphoxide (ABSO)
(jig/ml) in goats following oral administration of  albendazole (7.5
mg/kg) alone.
Animal number
Time (h) G1 G3 G7 GIO SW SB
0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0 .25 0 .0 0 0 .04 0.03 0 .0 0 0 .0 2 0 .0 0
0.5 0 .13 0 .1 0 0 .07 0.13 0 .07 0.05
1 0.45 0 .2 0 0 .15 0 .62 0 .15 0.15
2 1.27 0 .30 0 .40 1.52 0 .3 4 0.49
4 2 .60 0 .9 5 ' 0 .83 1.95 0 .75 1.14
8 2.51 2.67 1.21 1.47 1.07 1.52
1 2 1.55 3 .00 1.30 1.16 1.61 1.27
2 4 0 .0 0 0.61 0 .05 0 .0 2 1 .20 0.31
3 2 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .16 0 .0 0
48 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 2 0 .0 0
7 2 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
96 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
Appendix B-16. Pharmacokinetic parameters of albendazole sulphoxide 
(ABSO) in goats following administration of albendazole (7.5 mg/kg) 
alone.
Animal number
G1 G3 G7 GIO SW SB
A U C o b s  (|ig.h/ml) 32 .53 44 .2 8 18.98 2 4 .0 0 34 .3 8 23.63
A U M C o b s  ( | ig.h2/ml) 26 4 .49 532 .31 186.81 191.65 5 6 7 .5 9 260 .23
MRT (h) 8.13 12 .02 9 .84 7.98 16.51 11.01
Cmax (|ig/ml) 2 .60 3 .00 1.30 1.95 1.61 1.52
tmax (h) 4 1 2 1 2 4 1 2 8
2 1 9
Appendix B-17.  Plasma concentrations of albendazole sulphoxide
(ABSO) (|ig/ml) in goats following administration of albendazole (7.5
mg/kg) and piperonyl butoxide (0.5 g/kg).
Animal number
Time (h) 01 G3 G7 GIO SW SB
0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.25 0 .0 0 0 .00 0 .0 2 0.05 0 .0 0 0 .0 0
0.5 0 .07 0.06 0.11 0.25 0.05 0 .0 4
1 0 .2 2 0.15 0 .4 0 0 .56 0.13 0 .1 2
2 0 .68 0.87 0 .94 1.37 0.25 0 .32
4 1.53 2 .00 2.85 1.96 "0.51 0.63
8 1.56 1.76 2.08 1.75 0 .92 1.19
1 2 1.28 1.09 1 .00 1.19 1.56 1.83
2 4 0 .37 0.21 0 .0 0 0.27 2 .68 0 .59
3 2 0 .0 0 0 .00 0 .0 0 0.01 2 .04 0 .0 0
48 0 .0 0 0 .00 0 .0 0 0 .0 0 0.55 0 .0 0
7 2 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .04 0 .0 0
96 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
Appendix  B-18.  Pha rm acok ine t ic  pa ram eters  of a lbendazo le  
sulphoxide (ABSO) in goats following administration of albendazole 
(7.5 mg/kg) and piperonyl butoxide (0.5 g/kg).
Animal number
G1 G3 G7 GIO SW SB
AUCobs (|ig.h/ml) 25.98 2 5 .3 0 26.63  2 7 .8 0 27 .7 8 81 .4 2
AUMCobs (|ig.h2/ml) 282 .18 2 3 8 .0 9 199 .90  2 6 6 .9 8 3 6 3 .9 8 2 2 0 9 .9
MRT (h) 10.86 9.41 7.51 9 .60 13.10 2 7 .1 4
Cmax (|ig /m l) 1.56 1.76 2.85  1.96 1.83 2 .68
tmax (h) 8 8 4 4 1 2 2 4
2 2 0
Appendix B-19. Plasma concentrations of albendazole sulphone (ABS02) 
( |ig/ml) in goats following administration of albendazole (7.5 mg/kg) 
alone .
Animal number
Time (h) G1 G3 G7 GIO SW SB
0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.25 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.5 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
1 0 .0 2 0 .0 2 0 .0 0 0.03 0 .0 0 0 .0 0
2 0.08 0 .04 0 .0 0 0.11 0.01 0 .0 2
4 0.25 0 .1 2 0 .1 2 0 .28 0 .06  ' 0 .07
8 0 .49 0.41 0 .32 0 .54 0.13 0 .17
1 2 0.73 0.83 0 .56 0.65 0 .26 0.41
2 4 0 .0 0 1.44 0.31 0 .29 0.71 0 .58
3 2 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .26 0 .49
4 8 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0.01
7 2 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
96 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
Appendix B-20. Pharmacokinetic  parameters of albendazole sulphone 
(ABS02) in goats following administration of albendazole (7.5 mg/kg) 
alone.
Animal number
G1 G3 G7 GIO SW SB
AUCobs (fig.h/ml) 8 .69 2 3 .1 2 9 .22  11.29 13 .02 16.08
AUMCobs (Pg.h2/ml) 8 9 .0 2 4 39 .9 8 1 39 .8 4  152 .99 300 .11 3 82 .66
MRT (h) 10.25 19.03 15.17  13.55 2 3 .0 6 16.08
Cmax (ng/ml) 0 .73 1.44 0 .56  0 .65 0.71 0.58
tmax (h) 1 2 2 4 12 12 2 4 2 4
2 21
Appendix B-21. Plasma concentrations of  albendazole sulphone (A B S 0 2 )
(| ig/ml)  in goats following administration of  albendazole (7.5 mg/kg)
and piperonyl butoxide (0.5 g/kg).
Animal number
Time (h) G1 G3 G7 GIO SW SB
0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0 .25 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.5 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
1 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 0 .07 0 .00 0 .08 0 .08 0 .0 0 0 .0 0
4 0 .19 0 .29 0 .35 0 .24 0 .0 0 0 .14
8 0 .40 0 .68 0 .74 0.55 0 .09 0 .47
1 2 0.71 0.85 0.87 0.73 0 .2 0 0 .97
2 4 1.19 1.00 0 .0 0 0.97 0.75 1.78
3 2 0.25 0.13 0 .0 0 0 .32 1.13 0 .1 0
4 8 0 .0 0 0 .0 0 0 .0 0 0 .0 0 1.33 0 .0 0
7 2 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
9 6 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
Appendix B-22. Pharmacokinetic  parameters of albendazole sulphone 
(A B S 02)  in goats following administration of albendazole (7.5 mg/kg) 
and piperonyl butoxide (0.5 g/kg).
Animal number
G1 G3 G7 GIO SW SB
A U C o b s  (M-g.h/ml) 
A U M C o b s  (lig.h^/ml) 
MRT (h)
Cmax (fig/ml)  
tmax (h)
2 2 .8 6  21 .95  11 .09  2 2 .4 2  4 9 .6 2  29 .06  
4 6 5 .0 5  3 9 6 .7 6  11 1.64 4 4 6 .4 8  1912 .8  5 7 5 .4 4  
20 .35  18.08 10.07 19.91 38 .5 5  19.80 
1.19 1.00 0 .87  0 .97  1.33 1.78 
2 4 .00  2 4 .0 0  12 .00  2 4 .0 0  4 8 .0 0  24 .00
2 2 2
Appendix  B-23 .  Plasma concentrations of  a lbendazole
sulphoxide (ABSO) (jig/ml) in sheep following administration
of albendazole (7.5 mg/kg) alone.
Animal number
Time (h) 1 2 3 4 5
0 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
0 .25 0 .07 0 .10 0 .1 0 0 .0 0 0 .1 4
0.5 0 .26 0 .30 0 .39 0.07 0 .49
1 0 .56 0.53 0 .99 0 .18 1.06
2 1.70 1.39 1.61 0.43 1.86
4 2.71 2.60 1.82 0.83 1.78
8 1.90 1.74 1.29 1.04 1.36
1 2 1.19 1.18 1.05 0 .94 0 .89
2 4 0.23 0.38 0 .1 0 0.41 0 .16
3 2 0 .0 0 0.03 0 .0 2 0 .04 0 .0 0
4 8 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
7 2 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
9 6 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
Appendix B-24. Pharmacokinetic parameters of albendazole sulphoxide 
(ABSO) in sheep following administration of albendazole alone at 7.5 
mg/kg bodyweight.
Animal number
1 2 3 4 5
AUCobs (M-g.h/ml) 3 0 .6 4 30.98 2 3 .5 9 19.56 2 3 .3 0
AUMCobs (M-g-h^/ml) 2 6 8 .3 3 3 07 .5 0 2 0 1 .2 5 2 4 8 .6 8 195 .19
MRT (h) 8.76 9.93 8.53 12.72 8.38
Cmax (M-g/ml) 2.71 2.60 1.82 1.04 1.86
tmax (h) 4 4 4 8 2
2 2 3
Appendix  B-25 .  Plasma concentrations  of  a lbendazole
sulphoxide (}ig/ml) in sheep fo l lowing  administration of
albendazole (7.5 mg/kg) and piperonyl butoxide (0.5 g/kg).
Animal number
Time (h) 1 2 3 4 5
0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0 .25 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0.5 0 .1 0 0.08 0.17 0.05 0 .0 0
1 0.28 0.23 0 .46 0.21 0 .09
2 ' 0 .8 6 0 .54 0 .94 0.41 0 .2 0
4 1.38 1.04 1.85 0 .87 0 .37
8 1.78 1.47 2.41 3 .52 2 .98
1 2 1.65 1.68 1.80 2 .60 3 .29
2 4 0.95 1.05 0 .42 1.09 1.21
3 2 0.35 0 .48 0 .05 0 .40 0 .47
4 8 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
7 2 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
9 6 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
Appendix B-26. Pharmacokinetic  parameters of albendazole sulphoxide 
(ABSO) in sheep following administration of albendazole (7.5 mg/kg) and 
piperonyl butoxide (0.5 g/kg).
Animal number
1 2 3 4 5
AUCobs (fig.h/ml) 39 .70 39.71 36.21 53 .98 57 .4 6
AUMCobs ( |ig.h2/ml) 5 97 .13 6 58 .93 3 9 5 .3 2 7 8 9 .2 8 887 .19
MRT (h) 15 .04 16.59 10.92 14.62 15.44
Cmax (iLig/ml) 1.78 1.68 2.41 2 .60 3.29
tmax (h) 8 1 2 8 1 2 1 2
Appendix B-27. Plasma concentrations of albendazole sulphone
( A B S 0 2 )  (jLLg/ml) in sheep following oral administration of
albendazole (7.5 mg/kg) alone.
2 2 4
Animal number
Time (h) 1 2 3 4 5
0 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
0 .25 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
0.5 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
1 0 .0 0 0 .02 0 .03 0 .0 0 0.03
2 0 .07 0.05 0 .09 0 .0 0 0.11
4 ' 0 . 2 0 0.16 0 .19 0.05 0 .2 2
8 0.35 0.29 0 .28 0.16 0 .34
1 2 0 .39 0.35 0 .35 0 .22 0 .38
2 4 0 .36 0 .44 0.31 0.25 0 .29
3 2 0.01 0 .12 0 .01 0.23 0 .0 0
4 8 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
7 2 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
96 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
Appendix B-28. Pharmacokinetic parameters of albendazole sulphone 
(ABS02) in sheep following administration of albendazole (7.5 mg/kg) 
alone.
Animal number
1 2 3 4 5
AUCobs (M-g.h/ml) 8.95 10.37 7 .87 5 .74 8.15
AUMCobs (Hg.h2/ml) 141.49 196.65 123 .37 88.31 119 .95
MRT (h) 15.82 18.96 15.68 15.40 14.72
Cmax (M-g/ml) 0 .39 0 .44 0 .35 0 .25 0.38
tmax (h) 12 .00 2 4 .0 0 1 2 .0 0 12 .00 12 .00
A ppendix  B -29 .  Plasma concentrat ions  o f  a lbendazo le
sulphone (A B S 0 2 )  (}ig/ml) in sheep following administration
of albendazole (7.5 mg/kg) and piperonyl butoxide (0.5 g/kg).
2 2 5
Number number
Time (h) 1 2 3 4 5
0 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
0 .25 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
0.5 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
1 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
2 0 .1 0 0 .00 0 .07 0 .0 2 0 .0 0
4 0.35 0.05 ' 0.21 0.08 0 .0 0
8 0 .39 0.23 0 .57 0 .29 0 .35
1 2 0 .68 0 .30 0 .80 0 .60 0 .69
2 4 0 .68 0.59 0.81 0.83 0 .96
3 2 0.08 0 .69 0 .49 0 .84 0 .17
48 0 .0 0 0.33 0.05 0 .19 0 .0 0
7 2 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
96 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0
Appendix B-30. Pharmacokinetic parameters of albendazole sulphone 
(ABS02)  following administration of albendazole (7.5 mg/kg) and 
piperonyl butoxide (0.5 g/kg).
Animal number
1 2 3 4 5
AUCobs ( | ig .h /ml) 15.96 24 .25 2 4 .4 0 28.41 18.56
AUMCobs (p-g.h^/ml) 2 76 .1 8 7 6 0 .1 2 52 8 .3 3 7 7 2 .0 6 3 7 3 .1 2
MRT (h) 17.30 31 .3 5 2 1 .6 6 2 7 .1 8 2 0 .1 0
Cmax (|ig/ml) 0 .68 0 .69 0.81 0 .8 4 0.96
tmax (h) 1 8 3 2 2 4 3 2 2 4
2 2 6
Appendix B-31. Plasma concentrations of piperonyl butoxide ( | ig/ml) in
goats following intramuscular injection of piperonyl butoxide at 0.5
g/kg bodyweight.
Animal number
Time (h) G1 G3 G7 GIO SW SB
0 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0 .1 6 7 0 .17 ND 0.19 ND 0.37 0 .29
0.5 0 .23 ND 0 .29 ND 0 .64 0 .37
1 0 .30 0.17 0 .37 0 .0 0 0 .67 0 .6 4
2 0 .38 0.68 0 .46 0 .46 0 .88 0 .6 8
3 0 .5 0 0.61 0 .4 9  ' 0 .62 1.01 0 .8 4
5 0.81 0 .86 0 .59 0 .82 1.14 0 .98
9 1 .02 1.06 0 .49 1.32 1.54 1.21
1 3 1.46 1.23 0 .59 1.66 1.65 1.33
2 5 1.03 0.89 0 .58 1.25 1.82 0.81
33 0 .77 0.76 0 .47 0 .94 1.73 0 .8 6
4 9 0 .72 0.53 0 .5 2 0.81 1.52 0 .8 6
7 3 0.63 0.58 0 .36 0 .8 6 0 .97 0 .7 9
97 0 .55 0.65 0.61 0 .8 6 0 .76 0 .36
Appendix B-32. Pharmacokinetic  parameters for piperonyl butoxide 
administered intramuscularly to goats at a dose rate of 0.5 g/kg.
Animal number
G1 G3 G7 GIO SB SW
A U C o b s  (M-g.h/ml) 75.11 68 .75 4 7 .7 9 9 3 .4 2 7 9 .7 4 127 .80
A U M C o b s  (M-g-h^/ml) 3 19 4 .2 3001 .1 2 27 2 .8 4 2 2 5 .5 3 3 7 6 .9 5 4 6 1 .6
MRT (h) 42 .5 2 43 .65 47 .55 45 .2 3 4 2 .3 5 42 .75
Cmax (M-g/ml) 1.46 1.23 0.59 1.66 1.33 1.82
tmax (h) 13 13 1 3 1 3 1 3 25
2 2 7
Appendix B 33. Plasma concentrations of  piperonyl butoxide
(} ig /ml)  in sheep fo l low in g  intramuscular in jection of
piperonyl butoxide at 0.5 g/kg bodyweight.
Animal number
Time (h) 1 2 3 4 5
0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0 .1 6 7 0.37 0.31 0 .4 0 0 .40 0 .78
0.5 0.51 0 .50 0 .57 0 .72 1.05
1 0 .62 0 .50 1.01 1.28 1.94
2 0.83 0.87 1.18 1.97 2 .87
3 1.43 1.21 1.53 2 .30 3 .59  '
5 1.36 1.86 1.53 2.35 3 .62
9 1.83 2.48 1.80 3 .09 1.75
1 3 2 .19 3.89 1.80 2.08 3.41
25 1.89 3.31 1.58 2 .12 3.55
33 1.18 2 .14 0 .72 1.38 2 .18
4 9 0 .64 1.18 0 .56 0.71 0 .9 9
73 0 .82 1.25 0 .50 0 .68 0.93
97 0.85 1.97 ■ 0 .47 0 .68 0 .68
Appendix  B 34. Pharmacokinetic  parameters for piperonyl butoxide 
administered intramuscularly to sheep at a dose rate of 0.5 g/kg
Animal number
1 2 3 4 5
AUCobs (|lg.h/ml) 108 .40 18 5 .90 84.05 119 .12 167.31
AUMCobs (^g.h2/ml) 4 3 1 5 .0 7 8 3 9 .7 2 9 3 5 .4 4 1 2 3 .6 5 632 .8
MRT (h) 39 .8 0 4 2 .1 7 3 4 .9 2 3 4 .6 2 33 .67
Cmax (|ig/ml) 2 .19 3 .89 1.80 3.08 3.62
tmax (h) 1 3 1 3 1 1 9 5
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Appendix C
Dose titration and efficacy studies with the combination  
fen bend a zo le -p ip ero n y l  butoxide  in sheep
Appendix  C-1. Recovery and coefficients  of variation for 
fenbendazole metabolites following chloroform extraction from 
p la s m a
Added concentration 
( p g / m l )
Recovery
(%)
B e tw e e n -a s s a y  
coefficient of variation 
(%)
fenbendazole
0.05 96.66 (n=6) 10.80
0 .1 0 93.45 (n=6) 8.19
0.25 93.63 (n=6) 11.09
0 .50 84.26 (n=6) 1.95
1 84.43 (n=6) 8 .12
M ean 90.49 (n=30) 8.03
fenbendazole sulphoxide
0.05 85.35 (n=7) 7 .70
0 .1 0 92.78 (n=7) 4 .10
0.25 92.84 (n=7) 4 .90
0 .50 89.24 (n=7) 5 .20
1 86.24 (n=7) 4 .29
M ean 89.29 (n=35) 5 .24
fenbendazole sulphone
0.05 87.03 (n=7) 7 .36
0 .1 0 91.69 (n=7) 7 .86
0.25 87.29 (n=7) 7 .00
0 .50  • 93.59 (n=7) 5.18
1 86.58 (n=7) 3 .34
M ean 89.24 (n=30) 6.15
Coefficient of variation = (SD/mean recovery) X 100
2 2 9
Appendix C-2. Plasma concentrations of  fenbendazole (FBZ) (pg/ml)
following administration of  fenbendazole (5mg/kg) alone.
Animal number
Time (h) 7 6 7 7 78 97 98 99
0 .0 0 0 .00 0 .0 0 0 .0 0 0 .00 0 .0 0 0 .00
0 .25 0 .0 0 0 .0 0 0 .0 0 0 .00 0 .0 0 0 .00
0 .5 0 0 .0 0 0 .0 0 0 .0 0 0 .00 0 .0 0 0 .00
1 0.01 0 .0 0 0 .0 0 0 .00 0.03 0.03
2 0.07 0 .19 0 .04 0 .04 0.13 0.03
4 0.15 0 .29 0 .14 0 .1 0 0 .27 0.11
8 0.21 0.13 0.31 0 .14 0 .26 0.17
12 0 .2 0 0 .08 0.31 0 .1 0 0.25 0.17
2 4 0 .2 0 0 .09 0 .2 2 0.18 0 .16 0.13
3 2 0.13 0 .06 0.15 0.07 0.13 0 .12
4 8 0 .06 0 .0 2 0.07 0.09 0 .05 0.09
7 2 0.01 0 .0 0 0 .0 2 0 .02 0.01 0.03
9 6 0 .0 0 0 .0 0 0 .0 0 0 .00 0 .0 0 0 .00
Appendix C-3. Pharmacokinetic parameters of fenbendazole (FBZ) 
(| ig/ml) following administration of fenbendazole (5mg/kg) alone.
Animal number
7 6  • 77 7 8 97 98 99
AUCobs (iig.h/ml) 8 .00 4 .34 10 .08 6.64 8.47 7 . 7 0 -
AUMCobs (pg.h^/ml) 2 0 0 .7 0 79 .73 2 5 3 .6 0 2 0 6 .4 0 18 9 .60 2 3 8 .7 0
MRT (h) 25 .0 8 18.39 2 5 .1 6 31 .0 9 2 2 .3 9 31.01
Cmax (pg/ml) 0 .21 0 .29 0.31 0 .18 0 .27 0.17
tmax (h) 8 4 10 2 4 4 10
2 3 0
Appendix C-4. Plasma concentrations of  fenbendazole (FBZ) (pg/ml)
following administration of fenbendazole (5 mg/kg) in combination
with piperonyl butoxide (15 mg/kg).
Animal number
Time (h) 7 6 77 7 8 97 9 8 99
0 .0 0 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0 .25 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0 .5 0 0 .0 0 0 .0 2 0 .0 0 0 .0 0 0 .0 0 0 .0 0
1 0 .0 0 0.09 0 .0 0 0 .0 0 0 .01 0 .0 0
2 0.01 0.19 0 .0 2 0 .0 2 0 .03 0.05
4 0 .06 0.16 0 .1 0 0 .09 0 .11 0.13
8 0 .1 4 0.15 0 .2 0 0 .16 0.21 0 .19
1 2 0 .16 0.13 0 .2 0 0 .19 0 .18 0.15
2 4 0 .18 0.17 0.21 0 .16 0 .16 0.13
3 2 0 .2 0 0.09 0 .18 0 .1 2 0.11 0.11
4 8 0 .16 0.06 0 .1 0 0.07 0 .06 0 .09
7 2 0 .0 2 0.01 0 .04 0 .0 2 0.01 0 .02
9 6 0 .0 0 0 .00 0 .0 2 0 .0 0 0 .0 0 0 .0 0
Appendix C-5. Pharmacokinetic parameters of fenbendazole (FBZ) 
following administration of fenbendazole (5 mg/kg) in combination 
with piperonyl butoxide (15 mg/kg).
Animal number
7 6 7 7 7 8  97 98 9 9
AUCobs (jig.h/ml) 9 .92 6 .70 10.19  7 .38 7 .02 7.33
AUMCobs ( | ig.h2/ml) 3 2 8 .8 0 17 0 .10 3 3 4 .5 0  2 1 0 .7 0 18 0 .90 2 1 6 .6 0
MRT (h) 33 .1 6 2 5 .3 9 32 .83  2 8 .5 6 25 .7 7 29 .5 7
Cmax (pg/ml) 0 .2 0 0 .19 0.21 0 .19 0.21 0 .19
tmax (h) 3 2 2 2 4  12 8 8
23 1
Appendix C-6. Plasma concentrations of fenbendazole (FBZ) ( |ig/ml)
following administration of fenbendazole (5 mg/kg) in combination
with piperonyl butoxide (31 mg/kg).
Animal number
Time (h) 7 6 7 7 78 9 7 98 9 9
0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0 .25 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .00
0 .5 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0.01
1 0.01 0.01 0 .0 2 0 .0 0 0 .05 0 .0 2
2 0.03 0.05 0 .09 0 .0 2 0 .19 0.06
4 0.11 0.11 0.27 0 .1 0 0 .40 0.18
8 - 0 .23 0.15 0.48 0 .18 0.46 0.21
1 2 0 .27 0 .1 2 0.39 0 .26 0 .39 0.23
2 4 0 .25 0 .16 0 .32 0 .27 0 .32 0.27
3 2 0 .16 0.13 0 .2 2 0.23 0.21 0.25
4 8 0 .1 2 0.07 0 .13 0.43 0.11 0.07
7 2 0 .0 2 0.03 0.03 0 .0 4 0.01 0.03
9 6 0 .0 0 0.01 0.01 0 .0 0 0 .0 0 0.01
Appendix C-7. Pharmacokinetic parameters of fenbendazole (FBZ) (pg/ml) 
following administration of fenbendazole (5 mg/kg) in combination with 
piperonyl butoxide (31 mg/kg).
Animal number
7 6 7 7 7 8  97 98 9 9
AUCobs (pg.h/ml) 10 .76 7 .37 15.28 18 .15 14.64 11.27
AUMCobs (| ig.h2/ml) 3 0 5 .9 0 2 3 6 .7 0 4 0 5 .8 0  6 6 7 .0 2 3 3 8 .0 0 3 2 2 .5 0
MRT (h) 2 8 .4 2 3 2 .1 0 2 6 .5 6  36 .7 5 23 .08 2 8 .6 2
Cmax (jig/ml) 0 .27 0 .16 0 .48  0 .43 0.46 0 .27
tmax (h) 1 2 2 4 8 4 8 8 2 4
2 3 2
Appendix C-8. Plasma concentrations of  fenbendazole  (}ig/ml)
following administration of fenbendazole (5 mg/kg) in combination
with piperonyl butoxide (63 mg/kg).
Animal number
Time (h) 7 6 77 7 8 97 98 99
0 .0 0 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .00
0 .25 0 .0 0 0.01 0 .0 0 0 .0 0 0 .0 0 0 .00
0 .5 0 0 .0 0 0.06 0.01 0.01 0 .0 0 0 .02
1 0.01 0.19 0 .0 2 0.03 0.01 0 .02
2 0 .05 0 .39 0 .0 4 0 .1 0 0.03 0.09
4 0.21 0.41 0.25 0.23 0.13 0.25
8 0.21 0.33 0.38 0.35 0 .27 0.33
1 2 0 .18 0.13 0 .36 0 .26 0.37 0.28
2 4 0 .22 0 .04 0.37 0 .34 0 .40 0.29
3 2 0.17 0 .02 0 .32 0 .19 0.31 0.16
4 8 0.13 0.01 0 .18 0.07 0.18 0.09
7 2 0.07 0.03 0 .1 0 0.01 0 .04 0 .02
9 6 0 .0 0 0 .00 0.05 0 .0 0 0 .0 0 0 .00
A ppendix  C-9. P ha rm acok ine t ic  pa ram eters  o f  fenbendazo le  
(jig/ml) following administration of fenbendazole (5 mg/kg) in 
combination with piperonyl butoxide (63 mg/kg).
Animal number
7 6 7 7 78 97 98 99
AUCobs (pg.h/ml) 11.51 5 .90 19.37 11.67 16.76 11.57
AUMCobs (pg.h^/ml) 3 9 0 .5 2 1 08 .00 6 6 4 .7 0 2 7 8 .3 0 5 0 2 .8 0 2 9 2 .7 0
MRT (h) 3 3 .9 2 18 .30 3 4 .3 2 23 .85 2 9 .9 9 25.31
Cmax (jig/ml) 0 .2 2 0.41 0 .38 0.35 0 .40 0.33
tmax (h) 2 4 4 8 8 2 4 8
2 3 3
Appendix C-10.  Plasma concentrations of  fenbendazole  (FBZ)
(lig/mi) fo l lowing administration of  fenbendazole (5 mg/kg) in
combination with piperonyl butoxide (125 mg/kg).
Animal number
Time (h) 7 6 77 78 9 7 98 99
0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .00
0 .25 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 2 0 .0 0
0 .5 0 0 .0 0 0.05 0.01 0 .0 0 0.03 0 .0 0
1 0.01 0.21 0 .04 0 .0 2 0 .07 0.05
2 0 .05 0.31 0.08 0 .08 0.31 0.11
4 0 .16 0.45 0.31 0 .26 0 .64 0 .22
8 0 .28 0 .65 0 .49 0 .42 0 .68 0.31
1 2 0 .29 0 .94 0 .58  ■ 0 .37 0 .70 0 .40
2 4 0 .32 0.53 0.61 0 .4 2 0.63 0.63
3 2 0 .26 0.33 0 .43 0 .3 4 0 .56 0 .44
48 0.23 0.13 0.18 0 .25 0 .2 0 0 .29
7 2 0.08 0.03 0.01 0 .13 0.05 0.05
9 6 0 .0 2 0 .0 2 0.01 0 .0 4 0.01 0 .0 0
Appendix C -1 1. Pharmacokinetic parameters of fenbendazole (FBZ) 
following administration of fenbendazole (5 mg/kg) in combination 
with piperonyl butoxide (125 mg/kg).
-
Animal number
7 6 7 7  7 8  97 98 9 9
AUCobs (pg.h/ml) 17.08 2 4 .93  2 2 .9 0  2 2 .4 4 29.11 23 .88
AUMCobs (pg.h^/ml) 5 9 7 .6 0 5 7 1 .1 0  5 8 8 .4 7  7 9 4 .4 0 7 5 3 .8 0 7 3 6 .3 0
MRT (h) 34 .98 22.91  2 5 .6 9  35 .41 25 .8 9 30 .83
Cmax (pg/ml) 0 .32 0 .94  0 .42  0 .4 2 0 .70 0.63
tmax (h) 2 4 1 2 2 4  2 4 12 2 4
2 3 4
Appendix C-12. Plasma concentrations of  fenbendazole (}ig/ml)
following administration of fenbendazole (5 mg/kg) in combination
with piperonyl butoxide (250 mg/kg).
Animal number
Time (h) 7 6 77 7 8 97 9 8 99
0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .00
0.25 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .00
0 .5 0 0.01 0 .0 2 0.01 0.01 0.01 0.01
1 0 .0 2 0.11 0 .04 0 .0 2 0 .0 2 0.03
2 0 .06 0 .29 0 .20 0 .09 0 .06 0 .1 0
4 0 .2 0 0 .42 0 .34 0.25 0.18 0.35
8 0.37 0 .40 0.49 0 .34 0.28 0 .42
12 0.38 0 .68 0 .52 0 .36 0 .37 0.58
2 4 0.46 0 .76 0 .72 0.49 0.61 0.76
3 2 0 .49 0 .67 0.58 0 .54 0 .60 0 .82
48 0.48 0.38 0.58 0.51 0 .63 0 .64
7 2 0.21 0 .06 0.17 0 .19 0 .26 0 .12
9 6 0 .07 0.01 0.06 0.06 0.05 0 .04
Appendix  C-13. Pharm acokine t ic  pa ram eters  of fenbendazole  
following administration of fenbendazole (5 mg/kg) in combination 
with piperonyl butoxide (250 mg/kg).
Animal number
7 6 77 78 97 98 99
AUCobs (pg.h/ml) 31 .1 9 33 .63 38 .03 3 2 .0 0 37 .47 41 .15
AUMCobs ( | ig.h2/ml) 1253 .8 1003 .7 1385 .5 1260 .7 1535 .3 1438.8
MRT (h) 4 0 .2 0 29 .85 36 .43 39 .3 9 4 0 .9 8 34 .97
Cmax (|ig/ml) 0 .49 0.76 0 .72 0 .54 0.63 0 .82
tmax (h) 3 2 2 4 2 4 3 2 48 3 2
2 3 5
Table  C-14. Plasma concentrations of fenbendazole  sulphoxide 
(FBSO) ( |ig/ml) following administration of fenbendazole (5mg/kg) 
alone.
Animal number
Time (h) 7 6 77 7 8 9 7 98 9 9
0 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
0 .25 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .00
0 .5 0 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .00
1 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .00
2 0.01 0 .04 0.01 0 .0 0 0 .02 0 .00
4 0.07 0.15 0.05 0 .0 2 0 .1 2 0 .0 2
8 0.18 0.18 0.21 0 .1 2 0.27 0.11
1 2 0 .29 0.16 0 .30 0 .14 0.33 0.18
2 4 0.35 0 .12 0 .32 0.23 0 .30 0 .20
3 2 0 .36 0.09 0.28 0 .17 0.23 0.16
4 8 0 .19 0.03 0.13 0 .09 0.11 0 .12
7 2 0.03 0 .00 0 .04 0 .0 2 0 .0 2 0 .00
9 6 0 .0 0 0 .00 0.01 0 .0 0 0 .0 0 0 .00
T a b le  C - 1 5. P h a rm a c o k in e t ic  p a ra m ete r s  
su lp h o x id e  (FB SO ) ( | ig /m l)  fo l low ing
fenbendazole (5mg/kg) alone.
o f  f en b e n d az o le  
a d m in is t r a t io n  of
Animal number
7 6 7 7  7 8 9 7 98 99
AUCobs (pg.h/ml) 15.61 5 .39  13 .64 8.28 12.55 8.26
AUMCobs (pg.h^/ml) 4 9 1 .0 0 1 15 .2 0  425 .91 2 5 8 .9 6 3 4 2 .3 0 2 4 5 .7 0
MRT (h) 31 .46 2 1 .3 7  31.21 3 1 .2 8 2 7 .2 7 2 9 .7 4
Cmax (pg/ml) 0 .36 0 .18  0 .32 0.23 0.33 0 .20
tmax (h) 3 2 8 2 4 2 4 1 2 2 4
2 3 6
Appendix C-16. Plasma concentrations of  fenbendazole sulphoxide
(FBSO) (|J.g/ml) following administration of  fenbendazole (5 mg/kg)
in combination with piperonyl butoxide (15 mg/kg).
Animal number
Time (h) 7 6 7 7 78 9 7 98 99
0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 .0 0 0 ,0 0 0 .00
0 .25 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .00
0 .5 0 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .00
1 0 .0 0 0.01 0 .0 0 0 .0 0 0 .0 0 0 .00
2 0 .0 0 0.05 0 .0 0 0 .0 0 0 .0 0 0.01
4 0 .02 0.13 0.01 0 .0 2 0.03 0.05
8 0 .1 0 0.19 0 .1 0 0.11 0 .14 0.18
1 2 0.15 0.28 0.17 0 .19 0 .2 2 0 .22
2 4 0.26 0.33 0.23 0 .26 0 .2 2 0.21
3 2 0 .32 0 .24 0 .22 0 .24 0 .2 0 0.21
4 8 0 .2 0 0 .14 0.13 0 .13 0.08 0.15
7 2 0.03 0 .02 0 .04 0 .03 0 .0 2 0.05
96 0 .0 0 0 .00 0.01 0 .0 0 0 .0 0 0 .00
Appendix  C-17.  Pharm acokine t ic  param eters  of fenbendazole  
sulphoxide (FBSO) following administration of fenbendazole (5 
mg/kg) in combination with piperonyl butoxide (15 mg/kg).
Animal number
7 6 7 7 78  9 7 98 9 9
AUCobs (ng.h/ml) 12 .82 12.93 10.41 10 .82 9.09 11.47
AUMCobs ( | ig.h2/ml) 4 4 7 .0 0 3 7 5 .0 0 3 6 4 .8 0  3 5 3 .2 0 2 6 6 .9 0 3 8 9 .0 0
MRT (h) 34 .86 2 9 .0 0 3 5 .0 4  3 2 .6 4 2 9 .36 33 .9 2
Cmax (p.g/ml) 0 .32 0 .33 0.23 0 .26 0 .2 2 0 .22
tmax (h) 3 2 2 4 2 4  2 4 1 8 12
2 3 7
Appendix C-18. Plasma concentrations of  fenbendazole sulphoxide
(FBSO) ( |ig/ml) following administration of  fenbendazole (5 mg/kg)
in combination with piperonyl butoxide (31 mg/kg).
Animal number
Time (h) 7 6 77 7 8 9 7 98 99
0 .0 0 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .00 0 .0 0
0 .25 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .00
0 .50 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .00 0 .00
1 0 .0 0 0 .00 0 .0 0 0 .0 0 0 .0 0 0 .0 0
2 0.01 0.01 0.01 0 .0 0 0 .02 0.01
4 0 .05 0.05 0 .07 0 .0 2 0.13 0 .04
8 0 .19 0.13 0 .32 0 .13 0.33 0.17
1 2 0 .3 4 0.17 0 .40 0.21 0.43 0.27
2 4 0 .48 0 .20 0.51 0 .3 8 0.51 0.28
3 2 0 .48 0 .2 0 0 .40 0 .39 0.43 0 .32
4 8 0 .2 4 0.11 0.21 0 .4 9 0 .17 0.18
7 2 0 .05 0 .04 0 .08 0 .05 ‘ 0.11 0 .04
9 6 0.01 0.01 0.01 0 .0 0 0.01 0 .0 0
A p pend ix  C-19. Pha rm aco k ine t ic  p a ra m ete r s  of  f enbendazo le  
sulphoxide (FBSO) following administration of fenbendazole (5 mg/kg) 
in combination with piperonyl butoxide (31 mg/kg).
Animal number
7 6 7 7 7 8  97 98 99
AUCobs (|lg.h/ml) 20 .33 9.73 2 0 .8 5  2 1 .7 4 2 1 .6 0 14.18
AUM Cobs (M-g.h2/ml) 6 67 .1 9 3 3 2 .2 0 6 7 6 .9 0  8 2 2 .3 0 7 0 5 .8 0 4 6 3 .9 0
MRT (h) 32 .83 34 .15 3 2 .4 7  37 .8 3 32 .68 3 2 .7 2
Cmax (|ig/ml) 0 .48 0 .2 0 0.51 0 .49 0.51 0 .32
tmax (h) 28 2 8 2 4 4 8 2 4 3 2
2 3 8
Appendix C-20. Plasma concentrations of  fenbendazole sulphoxide
(FBSO) ( |ig/ml) following administration of  fenbendazole (5 mg/kg)
in combination with piperonyl butoxide (63 mg/kg).
Animal number
Time (h) 7 6 7 7 7 8 9 7 98 99
0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .25 0 . 0 0 0.01 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .5 0 0 . 0 0 0.03 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
1 0 . 0 0 0.13 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
2 0.01 0 .30 0.01 0 . 0 2 0 . 0 0 0 . 0 0
4 0 .11 0 .47 0.05 0 . 1 0 0 .04 0 .09
8 0 .21 0 .44 0.23 0 .25 0 . 2 0 0.28
12 0 .29 0 .19 0 .32 0 .44 0.38 0.39
2 4 0 .39 0 .08 0.45 0 .64 0 . 6 8 0 .50
3 2 0 .40 0 . 0 2 0.51 0 .57 0.65 0.37
4 8 0 .24 0 . 0 0 0.31 0 .25 0.33 0.18
7 2 0 .07 0 . 0 0 0 .14 0.03 0.08 0 . 0 2
9 6 0 .01 0 . 0 0 0.05 0. 01 0.01 0 . 0 0
Appendix  C-21. Pharm acok ine t ic  param eters  of fenbendazo le  
su lp h o x id e  (F B S O )  (p,g/ml) fo l lo w in g  a d m in i s t r a t io n  of  
fenbendazole (5 mg/kg) in combination with piperonyl butoxide (63 
m g /k g ) .
Animal number
7 6 7 7 7 8  97 98 9 9
AUCobs ( | ig.h/ml) 18.81 6.29 24 .4 3  23 .93 2 7 .2 0 18.03
AUMCobs (p.g.h2/ml) 6 4 6 .0 0 6 5 .8 4 9 3 9 .7 0  7 2 7 .3 0 9 2 2 .7 0 5 1 6 .9 0
MRT (h) 34 .35 10.47 38 .4 7  3 0 .3 9 3 3 .9 2 28 .6 7
Cmax (jig/ml) 0 .40 0.47 0.51 0 .64 0 . 6 8 0 .50
tmax (h) 3 2 4 3 2  2 4 2 4 2 4
2 3 9
A p p e n d ix  C -2 2 .  P lasm a co n cen tra t io n s  o f  f e n b e n d a z o le
sulphoxide(FBSO) (fig/ml) following administration of  fenbendazole
(5 mg/kg) in combination with piperonyl butoxide (125 mg/kg).
Animal number
Time (h) 7 6 77 7 8 9 7 98 99
0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .25 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0.01 0 . 0 0
0 .5 0 0 . 0 0 0.05 0 . 0 0 0 . 0 0 0.01 0 . 0 0
1 0 . 0 0 0.21 0 . 0 0 0 . 0 0 0.01 0.01
2 0 . 01 0.31 0.01 0.01 0 .04 0.01
4 0 .06 0.45 0.09 0 .06 0.23 0.06
8 0.25 0.65 0 .30 0.23 0.57 0.18
1 2 0 .39 0 .94 0.49 0 .38 0.81 0 .34
2 4 0 .57 0.53 0.78 0 .50 0.98 0.77
3 2 0 .5 4 0.33 0 .74 0 .47 0.99 0 .72
4 8 0 .42 0.13 0.38 0 .39 0.47 0.41
7 2 0 .17 0.03 0 . 0 2 0 .19 0.18 0 .09
9 6 0 .04 0 . 0 2 0.03 0 .04 0 . 0 2 0.01
Appendix C-23. Pharmacokinetic  parameters of fenbendazole sulphoxide 
(FBSO) following administration of fenbendazole (5 mg/kg) in combination 
with piperonyl butoxide (125 mg/kg).
Animal number
7 6 7 7 78 9 7 98 99
AUCobs (|Xg.h/ml) 29 .45 3 6 .6 9 30.53 2 7 .6 4 45 .1 6 3 0 .4 6
AUMCobs (jig.h^/ml) 1133.4 9 3 6 .9 9 63 .0 0 1 093 .9 1499 .5 1061.1
MRT (h) 38 .48 2 5 .35 31 .55 3 9 .5 8 3 3 .2 0 34 .83
Cmax ()ig/ml) 0.57 1.15 0.78 0 .50 0.99 0 .77
tmax (h) 2 4 2 4 2 4 2 4 3 2 2 4
2 4 0
Appendix C-24. Plasma concentrations of  fenbendazole  sulphoxide
(FBSO) ( |ig/ml) following administration of fenbendazole (5 mg/kg) in
combination with piperonyl butoxide (250 mg/kg).
Animal number
Time (h) 7 6 77 7 8 97 98 99
0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .25 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .5 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 .01 0 . 0 0
1 0 . 0 0 0.01 0 . 0 0 0 . 0 0 0 . 0 2 0.01
2 0.01 0.05 0.01 0.01 0 .06 0.01
4 0.07 0.21 0.03 0 .07 0 .18 0.09
8 0 .28 0.48 0 .14 0.21 0 .28 0.31
1 2 0 .44 0.75 0 .32 0.31 * 0 .37 0.60
2 4 0 .67 0 .94 0 .69 0 .57 0.61 0.97
3 2 0 .75 0 .96 0 .65 0.63 0 .60 1.08
4 8 0.61 0 .58 0.55 0 .57 0.63 0.73
7 2 0.33 0 .14 0.23 0.33 0 .26 0.17
9 6 0.11 0 . 0 2 0.07 0.07 0 .05 0 . 0 2
Appendix C-25. Pharmacokinet ic  parameters of fenbendazole  
su lp h ox id e  (FBSO) ( | ig /m l)  fo l low ing  a d m in is t ra t io n  of 
fenbendazole (5 mg/kg) in combination with piperonyl butoxide 
(250 mg/kg).
Animal number
7 6 7 7 7 8 9 7 9 8 9 9
AUCobs (iig.h/ml) 42 .01 44 .7 5 35 .29 36 .97 3 7 .4 7 47.91
AUMCobs (|Lig.h2/ml) 1 783 .4 1 506 .0 1456 .9 1614 .2 1535 .3 1733 .8
MRT (h) 4 2 .4 6 33 .65 4 1 .2 9 4 3 .67 4 0 .9 8 3 6 .19
Cmax ()ig/ml) 0 .75 0 .96 0 .69 0.63 0.63 1.08
tmax (h) 3 2 3 2 2 4 3 2 4 8 3 2
2 4 1
Appendix C-26. Plasma concentrations of  fenbendazole sulphone
( F B S 0 2 )  ( | ig /m l)  fo l lowing  administration of  fenbendazole
(5mg/kg)  alone.
Animal number
Time (h) 7 6 77 7 8 9 7 98 99
0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .25 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .5 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
1 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
2 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
4 0 . 0 0 0.01 0 . 0 0 0 . 0 0 0.01 0 . 0 0
8 0 .01 0.03 0 . 0 2 0 . 0 2 0.03 0.01
1 2 0.03 0 .04 0.05 0.03 0 .06 0.03
2 4 0 .07 0.05 0 . 1 0 0 . 1 0 0.11 0.08
3 2 0 . 1 2 0.06 0 . 1 2 0.07 0 . 1 0 0.07
48 0 .14 0.05 0 . 1 0 0.09 0 .09 0 . 1 0
7 2 0 .08 0.03 0 .07 0.05 0 .04 0.07
96 0 .0 4 0 . 0 0 0 .04 0.03 0 . 0 2 0 .04
Appendix C-27. Pharmacokinet ic  parameters of  fenbendazole  
su lp h on e  ( F B S 0 2 )  (jag/ml) fo l lo w in g  a d m in i s t r a t io n  of 
fenbendazole (5mg/kg) alone.
Animal number
-7  6 7 7 7 8 9 7 9 8 9 9  -
AUCobs (jig.h/ml) 7 .62 3.41 7 .08  5 .5 2 5 .93 6.08
AUMCobs (}xg.h2/ml) 3 8 4 .8 0 139 .80 3 3 8 .5 6  2 6 1 .8 0 2 5 0 .2 0 3 1 2 .3 2
MRT (h) 5 0 .5 0 4 1 .0 0 4 7 .8 2  4 7 .4 2 4 2 .1 9 51 .37
Cmax (|ig/ml) 0 .14 0 .06 0 . 1 2  0 . 1 0 0 . 11 0 . 1 0
tmax (h) 4 8 3 2 3 2 2 4 2 4 4 8
2 4 2
Appendix C-28. Plasma concentrations of  fenbendazole  sulphone
(FBS02)  (p.g/ml) following administration of fenbendazole (5 mg/kg) in
combination with piperonyl butoxide (15 mg/kg).
Animal number
Time (h) 7 6 7 7 78 9 7 98 99
0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .25 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .5 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
1 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
2 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
4 0 . 0 0 0.01 0 . 0 0 0 . 0 0 0.01 0.01
8 0.01 0 . 0 2 0.01 0.01 0 . 0 2 0.03
12 0.03 0 .05 0.03 0 . 01 0.05 0.06
2 4 0.07 0 .09 0 .06 0.03 0 .09 0.11
3 2 0.11 0.08 0 .08 0 .0 4 0 . 1 0 0.13
48 0 .16 0 . 1 0 0.08 0 .08 0 .07 0.13
7 2 0 .08 0 .04 0.05 0 . 1 0 0 .04 0.08
96 0 .0 4 0 .04 0 .04 0 .05 0.03 0 . 0 2
Appendix C-29. Pharmacokinetic parameters of fenbendazole sulphone 
(FBS02) (|ig/ml) following administration of fenbendazole (5 mg/kg) in 
combination with piperonyl butoxide (15 mg/kg).
-—  —
Animal number
7 6 7 7  7 8  9 7 9 8 9 9
AUCobs (p,g.h/ml) 7 .90 5.81 5 .12  5 .50 5.33 8.05
AUMCobs (jig.h^/ml) 4 0 0 .2 0 2 6 9 .1 0  2 5 7 .6 0  3 3 1 .0 0 2 3 6 .4 0 3 6 9 .2 0
MRT (h) 50 .65 46.31  50.31 60 .1 9 4 4 .3 6 45 .8 7
Cmax (|ig/ml) 0 .16 0 . 1 0  0 .08  0 . 1 0 0 . 1 0 0.13
tmax (h) 48 4 8  4 0  7 2 3 2 4 0
2 4 3
Appendix  C-30. Plasma concentrations of  fenbendazole  sulphone
( F B S 0 2 )  ( |ig/ml) following administration of  fenbendazole (5 mg/kg)
in combination with piperonyl butoxide (31 mg/kg).
Animal number
Time (h) 7 6 77 7 8 9 7 98 99
0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 .0 0
0 .25 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .5 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
1 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
2 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
4 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0.01 0.01
8 0 . 0 2 0.01 0 . 0 2 0.01 0.03 0.03
12 0.05 0.03 0.03 0 . 0 2 0.05 0.06
2 4 0.13 0.06 0 .08 0 .06 0 . 1 2 0.11
3 2 0.17 0.08 0 . 1 0 0 .09 0.13 0.14
4 8 0 .16 0.08 0 .09 0 .09 0 . 1 0 0.19
7 2 0.09 0 .06 0 .08 0 .06 0.06 0.11
96 0 .06 0.05 0 .05 0.03 0 .04 0.06
Appendix C-31. Pharmacokinetic parameters of fenbendazole sulphone 
(FBS02)  ( |ig/ml) following administration of fenbendazole (5 mg/kg) 
in combination with piperonyl butoxide (31 mg/kg).
—
Animal number
7 6 ' 7 7 7 8 97 98 99
AUCobs (p.g.h/ml) 9 .90 5 .48 6 .6 4  5 .48 7.23 10.57
AUMCobs (jo.g.h2/ml) 4 8 0 .2 0 2 8 6 .4 0 3 4 3 .4 0  2 7 5 .8 0 3 3 0 .4 0 5 2 8 .6 0
MRT (h) 4 8 .5 0 52 .26 51.71  5 0 .3 4 4 5 .6 9 50.01
Cmax (|ig/ml) 0 .17 0.08 0 .1 0  0 .09 0.13 0 .19
tmax (h) 3 2 4 0 3 2  4 0 3 2 4 8
2 4 4
Appendix C-32.  Plasma concentrations of  fenbendazole  sulphone
(FB S 02)  ( |ig/ml) following administration of  fenbendazole (5 mg/kg) in
combination with piperonyl butoxide (63 mg/kg).
, Animal number
Time (h) 7 6 77 7 8 9 7 98 99
0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .25 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .50 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
1 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
2 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
4 0 . 0 0 0.01 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
8 0 . 0 2 0.03 0.01 0 .01 0.01 0.03
1 2 0.03 0 .04 0.01 0.03 0 . 0 2 0 .04
2 4 0 .08 0.08 0 .04 0 .07 0 .07 0 . 1 2
3 2 0 . 1 0 0.07 0 .09 0 . 1 2 0 . 1 2 0.13
4 8 0 .14 0.05 0.11 0 .14 0 .18 0.13
7 2 0 . 11 0.03 0 . 1 0 0 .08 0 .14 0 .09
96 0 .06 0 . 0 2 0.07 0 .04 0 .06 0 .04
Appendix C-33. Pharmacokinetic parameters of fenbendazole sulphone 
(FBS02) ( |ig/ml) following administration of fenbendazole (5 mg/kg) in 
combination with piperonyl butoxide (63 mg/kg).
Animal number
76 7 7 7 8  9 7 98 9 9
AUCobs (}ig.h/ml) 8.48 4 .07 7 .0 4  7 .6 2 10 .0 2 8 .44
AUMCobs (p,g.h2/ml) 4 5 4 .7 0 1 73 .9 0 4 0 4 .5 0  3 8 4 .8 0 5 4 9 .0 0 4 0 9 .9 0
MRT (h) 5 3 .62 4 2 .7 2 57 .45  5 0 .5 0 5 4 .7 9 4 8 .5 7
Cmax (jig/ml). 0 .14 0 .08 0.11 0 .1 4 0.18 0.13
tmax (h) 48 2 4 4 8  4 8 4 8 4 0
2 4 5
Appendix C-34. Plasma concentrations of  fenbendazole  sulphone
( F B S 0 2 )  (}ig/ml) following administration of  fenbendazole (5 mg/kg)
in combination with piperonyl butoxide (125 mg/kg).
Animal number
Time (h) 7 6 77 7 8 97 98 99
0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .25 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .5 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
1 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
2 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
4 0 . 0 0 0.01 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
8 0.01 0 . 0 2 0.01 0.01 0 . 0 2 0.01
1 2 0 . 0 2 0 .0 5 ' 0 . 0 2 0 . 0 2 0 .04 0 . 0 2
2 4 0.07 0.16 0.05 0.05 0.11 0.08
3 2 0 . 1 0 0.18 0 .08 0.08 0 .19 0 . 1 2
4 8 0.15 0.15 0.13 0 .16 0 .24 0.18
7 2 0 .14 0.08 0.08 0.16 0.15 0.15
96 0 .09 0.05 0 .09 0.08 0.08 0.07
A p p e n d ix  C-35.  Ph a rm acok in e t ic  pa ram ete rs  of  fenbend azo le  
sulphone (FBS02) (fig/ml) following administration of fenbendazole (5 
mg/kg) in combination with piperonyl butoxide (125 mg/kg).
Animal number
7 6 7 7 7 8 9 7 98 9 9
AUCobs ( |ig.h/ml) 9 .54 9.75 7 .2 6  9 .66 13.14 10.48
AUMCobs (iig.h2/ml) 5 4 7 .0 0 4 5 2 .9 0 4 1 1 .7 0  5 6 7 .2 0 6 8 5 .6 0 5 8 0 .2 0
MRT (h) 5 7 .3 4 4 6 .26 56.71  5 8 .7 2 52 .1 8 55 .3 6
Cmax (|ig/ml) 0 .15 0.18 0 .13  0 .16 0 .24 0 .18
tmax (h) 48 3 2 4 8  6 0 4 8 4 8
2 4 6
Appendix  C-36.  Plasma concentrations of  fenbendazole  sulphone
(F B S 0 2 )  (jig/ml) following administration of  fenbendazole (5 mg/kg)
in combination with piperonyl butoxide (250 mg/kg).
Animal number
Time (h) 7 6 77 7 8 97 98 99
0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0.25 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
0 .5 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
1 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
2 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
4 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0 0 . 0 0
8 0 .01 0.03 0 .01 0.01 0.01 0.01
1 2 0 . 0 2 0.06 O.'Ol 0.01 0 .01 0.03
2 4 0 .06 0.18 0.05 0 .05 0 .06 0 . 1 0
3 2 0 . 1 0 0.18 0 .07 0 .09 0 . 1 0 0.15
4 8 0 .26 0.21 0 .09 0.13 0 .14 0.23
7 2 0 .16 0 . 2 0 0 . 11 0 .19 0 .18 0 .24
9 6 0 . 1 2 0.13 0 .09 0 . 1 2 0 . 1 2 0.13
Appendix C-37. Pharmacokinetic parameters of fenbendazole sulphone 
(FBS02)  (| ig/ml) following administration of fenbendazole (5 mg/kg) 
in combination with piperonyl butoxide (250 mg/kg).
Animal number
7 6 7 7 7 8 9 7 9 8 9 9
AUCobs (|Lig.h/ml) 12.48 15.12 6.98  10 .30 10.48 15.00
AUMCobs (p.g.h2/ml) 7 1 9 .4 0 8 1 6 .0 0 4 2 0 .3 0  6 3 9 .2 0 6 3 7 .8 0 8 7 0 .1 0
MRT (h) 5 7 .6 4 53 .97 6 0 .2 2  6 2 .0 6 60 .85 58.01
Cmax (|ig/ml) 0 .26 0.21 0.11 0 .1 9 0 .18 0 .24
tmax (h) 48 ■ 48 7 2  7 2 7 2 7 2
2 4 7
Appendix C-38. Individual values for adult worm and faecal egg counts 
obtained during the efficacy trial.
Animal
n u m b e r
Faecal egg 
coun ts  
(epg)*
Haemonchiis  
con tor tus  
(adult worms)t
Ostertagia  
circumcincta  
(adult worms)
X6860 9 0 0 4 5 0 3 3 5 0
X1007 3 0 0 3 0 0 1 7 5 0
Group A X1070 2 5 0 2 9 0 2 8 5 0
X1069 3 5 0 2 9 0 3 2 0 0
X I 126 4 0 0 4 1 0 3 6 1 0
X I 114 7 5 0 3 3 0 3 1 5 0
X1093 1 0 0 40 2 6 0 0
X I 141 0 20 ' 5 4 0 0
Group B X I 129 2 0 0 80 1 7 5 0
XIOOO 150 60 2 1 0 0
X 987 0 1 0 0 3 0 0 0
X1039 150 50 2 4 0 0
X1032 600 2 9 0 3 7 0 0
X I 113 250 2 6 0 4 2 5 0
Group C X1018 700 2 5 0 3 0 0 0
X1014 100 5 2 0 3 8 0 0
X I 133 1 0 0 0 4 4 0 4 1 5 0
]( 999 250 1 60 3 8 0 0
X1065 0 0 0
X1098 0 0 0
Group D X I 175 0 1 0 200
XIOIO 5 0 0 400
X1024 0 10 600
X1035 0 2 0 1 5 0 0
* Seven days posttreatment, 
t  No larval stages were found 
the sheep.
in the abomasal digests of any of
2 4 8
Appgndix V 
Metabolism (S-oxidation) of  benz imidazole  
anthelm int ics :  in vitro studies
Appendix D-1 Buffer composition 
Calcium-free buffer:
NaCl 8.30 g/1
KQ 0.50 g/1
Hepes  2.40 g/1
Adjust pH to 7.4 by adding 5.5 ml of IM NaOH.(l  litre of buffer). 
Collagenase buffer:
NaCl 3.90 g/1
KQ 0.50 g/1
Hepes  24.0 g/1
CaCl2 . 2H2O 0.70 g/1
Collagenase 0.50 g/1
Adjust pH to 7.6 by adding 66 ml of IM NaOH (1 litre of buffer).
N.B. Collagenase to be added just before perfusion.
Washing buffer:
NaCl 8.30 g/1
KQ 0.50 g/1
Hepes  2.40 g/1
CaCl2. 2H2O 0.18 g/1
Adjust pH to 7.4 by adding 5.5 ml of IM NaOH (1 litre of buffer) 
Perfusion time:
Calcium-free buffer 12 minutes
Collagenase buffer 20 minutes
Appendix D-2 Culture media 
Attachment  medium 
To 100 ml EWM add;
1 ml L-glutamine (i.e, 2mM)
1 ml (10000 lU -10000 pg)  Penicil lin-streptomycin
5 ml Foetal calf serum
1 p M  insulin 
Replacement medium 
To 100 ml EWM add;
1 ml L-glutamine (2mM)
1 ml of (10000 lU -10000 pg)  Penicillin- streptomycin
1.33 ml of 7.5% (W/V) Bovine serum albumin
2 4 9
Appendix D-3 Microsomal protein and cytochrome P450 in 
rat liver (n=4)
1 2 3 4 Mean ± SEM
Microsomal protein 
(mg/g of liver) 21 .09  14 .52  15.30 14 .70  16.40 ± 1.57
Cytochrome P450 
( n m o l / m g  
microsomal protein)
0 .45 0 .5 2  0 .47  0 .67  0.53 ± 0.05
Appendix D-4 Amount of drug and metabolites recovered 
(nmoles/ml) after one hour incubation without microsomes.
Sulphide Sulphoxide Su lphone
FBZ (n=3) 51 .7 2 0 . 0 0 0 . 0 0
FBSO (n=3) 0 . 0 0 4 7 .5 4 0 . 0 0
ABZ (n=3) 49 .13 0.21 0 . 0 0
TCBZ (n=3) 48.71 0 . 0 0 0 . 0 0
2 5 0
Appendix D-5. Amount of  fenbendazole (FBZ) remaining in the
microsomal reaction mixture after one hour incubation.
FBZ (nmoles/ml) (n=4)
I n h ib i to r 1 2 3 4 Mean ± SEM
a d d e d
None 40 .9 2 39.11 4 2 .2 2 4 1 .7 5 41.00 ± 0.68
PB 50 .37 4 5 .5 9 56 .08 5 3 .6 4 51.42 ± 2.27**
**Significantly different from the control value (P<0.01)
Appendix  D -6 Amount  of fenbendazole  sulphoxide (FBSO) 
remaining in the microsomal reaction mixture after one hour 
incubat ion .
FBSO (nmoles/ml) (n=3)
I n h ib i to r
a d d e d
1 2 3 Mean ± 
SEM
None 44 .4 8 4 7 .0 2 39 .2 8 43.59 ± 
2 .28
PB 4 9 .5 6 4 8 .8 0 51 .33 49.90 ± 
0 .75
Appendix D-7 Amount of albendazole (ABZ) remaining in the 
microsomal reaction mixture after one hour incubation.
ABZ (nmoles/ml) (n=4)
In h ib i to r
a d d e d
1 2  3 4 Mean ± SEM
None
PB
12.33 10 .67  7 .20  3.73 
2 0 .3 9  18 .47  3 3 .7 4  28 .3 8
8.48 ± 1.91 
25.25 ± 3.55**
**Significantly
Appendix D -8 i 
microsomal reac
different from the control value (P<0
\mount  of triclabendazole (TCBZ) rei 
:tion mixture after one hour incubati
.01)
naining in the 
ion.
TCBZ (nmoles/ml) (n=:4)
In h ib i to r 1 2 3 4 Mean ±
a d d e d SEM
None 0 . 0 0 4.11 0.28 0 .56 1.24 ± 0.96
PB 0.89 17.04 6.84 0 .56 6.33 ± 3.85
2 5 1
Appendix D-9. Effect of  piperonyl butoxide (PB) on microsomal
sulphoxidation of  fenbendazole in rat liver.
FBSO formed 
(nmoles/mg protein/hour) (n=4)
I n h ib i to r
a d d e d
1 2  3 4 Mean ± SEM
None
PB
1.99 1.06 1.01 1.70 
0 .76  0 .3 2  0 .33 0 .63
1.44 ± 0.24 
0.51 ± 0.11*
'Significantly different from the control value (P<0.05)
Appendix D-10. Effect of piperonyl butoxide (PB) on microsomal 
sulphonation of fenbendazole in rat liver.
FBSO] formed 
(nmoles/mg protein/hour) (n=4)
In h ib i to r
a d d e d
1 2  3 4 Mean ± SEM
None
PB
0 .65  0 .63 0 .5 4  0.51 
0.21 0 .24  0 .15  0 .17
0.58 ± 0.03 
0.19 ± 0 .02t
t  Signficantly different from the control value (P<0.001)
2 5 2
Appendix D -1 1. Effect of piperonyl butoxide (PB) on microsomal
sulphonation of fenbendazole sulphoxide (FBSO) in rat liver.
FB S02 formed 
(nmol/mg protein/hour) (n=3)
I n h ib i to r 1 2 3 Mean ±
a d d e d SEM
None ' 2 .16 0.35  2 .38 1.63 ± 0.64
PB 1.15 0.27  0 .87 0.76 ± 0.26
Appendix D-12. Effect of piperonyl butoxide (PB) on microsomal 
reduction of fenbendazole sulphoxide (FBSO) in rat liver.
FBZ formed 
(nmol/mg protein/hour) (n=3)
I n h ib i to r
a d d e d
1 2 3 Mean ± 
SEM
None 0 .08 0 .06 0 .07 0.07 ± 0.01
PB 0.08 0 . 1 0 0 .07 0.08 ± 0.01
2 5 3
Appendix D-13. Effect of piperonyl butoxide (PB) on microsomal
sulphoxidation of  albendazole in rat liver.
ABSO formed 
(nmoles/mg protein/hour) (n=4)
In h ib i to r
a d d e d
1 2  3 4 Mean ± SEM
None
PB
10.17 7 .30  10.63 10 .74  
7 .52  4 .88  5 .55  7 .0 2
9.71 ± 0.81 
6.24 ± 0.62*
^Significantly different from the control value (P<O.I
Appendix D-14 Effect of piperonyl butoxide (PB) o 
sulphonation of albendazole in rat liver.
35)
n microsomal
ABSO] formed 
(nmoles/mg protein/hour) (n=4)
I n h ib i to r
a d d e d
1 2  3 4 Mean ± SEM
None
PB
0.13 0 .05  0 .08  0 .29  
0 . 1 0  0 . 0 0  0 . 0 0  0 . 1 0
0.14 ± 0.05 
0.05 ± 0.03
2 5 4
Appendix D-15. Effect of  piperonyl butoxide (PB) on microsomal
sulphoxidation of triclabendazole in rat liver.
TCBSO formed 
(nmoles/mg protein/hour) (n=4)
I n h ib i to r
a d d e d
1 2 3 4 Mean ± 
SEM
None 7.87 9 .72  1 1.08 . 9 .90 9.64 ± 0.66
PB 9.55 6.46  9 .82 10.92 9.19 ± 0.96
Appendix  D-16. Effect  of p iperonyl  butoxide  (PB) on 
microsomal sulphonation of triclabendazole in rat liver.
TCBSO] formed 
(nmoles/mg protein/hour) (n=4)
I n h ib i to r
a d d e d
1 2 3 4 Mean ± 
SEM
None 0 . 6 8 0 .70  1.13 2.03 1.14 ± 0.32
PB 0.56 0 .11  0.21 0.93 0.45 ± 0.19
2 5 5
Appendix D-17. Effect of piperonyl butoxide (PB) on sulphoxidation of
FBSO formed 
(p m o les / lO ^  viable cel ls/hour) 
(n=3)
In h ib i to r
a d d e d
1 2 3 Mean ± SEM
None
PB
12.60  18 .50  17 .50  
5.61 4 .95  4 .62
16.20 ± 1.82 
5.06 ± 0.29***
♦ ♦♦Significantly different from the control value (P<0.005)
Appendix D-18. Effect of piperonyl butoxide (PB) on sulphonation of
FBSO2 formed 
(p m ole s / lO ^  viable cells/hour) 
(n=3)
I n h ib i to r
a d d e d
1 2 3 Mean ± SEM
None
PB
0 .94  2 .2 0  1.57 
0.31 0 .0 0  0.31
1.75 ± 0.36 
0.21 ± 0 . 10*
'Significantly different from the control value (P<0.05)
2 5 6
D -19 .  Effect  of  piperonyl butoxide (PB) on sulphoxidation of
ABSO formed 
( p m o l e s / 1 0  ^ viable cel ls/hour) 
(n=3)
I n h ib i to r
a d d e d
1 2 3 Mean ± SEM
None
PB
85 .5 4  107 .39  13 2 .94  
31.1 1 56 .6 6  2 9 .9 9
108.62 ± 13.70 
39.25 ± 8.71*
* Significantly different from the control value (P<0.05).
D-20. Effect of piperonyl butoxide (PB) on sulphonation of albendazole
A B S 0 2  formed 
(p m ole s / lO ^  viable cel ls/hour) 
(n=3)
In h ib i to r
a d d e d
1 2 3 Mean ± SEM
None
PB
0 .70  0 .70  0 .7 0  
0 . 0 0  0 . 0 0  0 . 0 0
0.70 ± 0.00 
0.00  ± 0 .0 0 *
Significantly different from the control value (P<0.05)
2 5 7
Appendix  D-21. Effect of 1-aminobenzotriazole  (1-ABT) on
TCBSO formed 
(p m ole s / lO ^  viable cel ls/hour) 
(n=3)
I n h ib i to r
a d d e d
1 2 3 Mean ± SEM
None
1-ABT
2 9 5 .1 0  3 0 1 .3 0  2 7 4 .4 0
7 2 .1 0  51 .0 2  63 .77
290.30 ± 8.13 
62.30 ± 6.13t
Significantly different from the control value (P<0.001)
Appendix  D-22. Effect  of 1-aminobenzotriazole  (1-ABT) on
TCBSO2 formed 
( p m o l e s / 10  ^ viable cel ls/hour) 
(n=3)
I n h ib i to r
a d d e d
1 2 3 Mean ± SEM
None
1-ABT
4 6 .5 7  44 .41  4 7 .87
9 .57  7 .18  7 .98
46.28 ± 1.01 
8.24 ± 0.70t
tSignificantly different from the control value (P<0.001)
2 5 8
A pp en d ix  D-23. E ffec t  of  p iperony l  bu tox ide  (PB) on
TCBSO formed 
(p m o le s / lO ^  viable cel ls/hour) 
(n=3)
In h ib i to r
a d d e d
1 2 3 Mean ± SEM
None
PB
2 4 1 .2 0  2 0 4 .6  2 5 2 .6 0  
14 8 .60  97 .87  109 .50
232.80 ± 14.48 
118.66 ± 15.34**
Significantly different from the control value (P<0.01)
Appendix D-24. Effect of piperonyl butoxide (PB) on sulphonation
TCBSO2 formed 
( p m o le s / 106  viable 
(n=3)
cells/hour)
In h ib i to r
a d d e d
1 2 3 Mean ± SEM
None 8 5 .9 0 94.41 9 6 .0 0 92.10 ± 3.14
PB 5 3 .7 2 38 .56 36 .43 42.90 ± 5.44***
***Significantly different from the control value (P<0.005)
2 5 9
Appendix E
Effect of early treatment with rafoxanide on antipyrine  
clearance in sheep infected with Fasciola hepatica
Appendix E-1. Recovery and coefficients of variation for antipyrine 
extracted from plasma.
Added concentration 
( K g / m l )
Recovery
(%)
B e tw e e n -a s s a y  
coefficient of variation 
(%)
0.5 80.53 (n=4) 6 .07
2 81.56 (n=4) 1.37
5 77.59 (n=4) 5 .59
1 0 90.77 (n=4) 2 .94
2 0 89.47 (n=4) 5 .35
4 0 92.73 (n=4) 6 .50
M ean 85.44 (n=24) 4 .6 4
Coefficient of variation = (SD/mean recovery) X 100
Appendix E-2. Recovery and coefficients of variation for rafoxanide 
extracted from plasma.
Added concentration 
( | i g / m l )
Recovery
(%)
B e tw e e n -a s s a y  
coefficient of variation 
(%)
0.5 77.10 (n=5) 3.41
1 79.14 (n=5) 8 .39
5 78.19 (n=5) 7.43
10 78.68 (n=5) 5.73
2 0 80.34 (n=5) 3 .98
M ean 78.69 (n=25) 5.93
Coefficient of variation = (SD/mean recovery) X 100
2 6 0
Appendix E-3. Number and size of flukes recovered at necropsy 
in group A (infected untreated)
Animal number
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 00 0
n u m b e r  
of fluke
107 109 107 156 88 73
size of 
f lu k e
>12 mm >12 mm >12 mm >12 mm >12 mm >12 mm
Appendix E-4. Number and size of flukes recovered at necropsy 
in group B (infected treated)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
n u m b e r  
of fluke
4 15 2 0 9 35 1 1
size of 
f lu k e
>12 mm >12 mm >12 mm >12 mm >12 mm >12 mm
2 6 1
Appendix E-5. Plasma parameters in group A (before F. hepatica
in fection)
Animal number
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
Total protein (g/1) 66 5 8 63 66 57 63
Albumin (g/1) 35 3 2 3 4 35 1 9 3 6
Globulin (g/1) 3 1 2 6 29 3 1 38 27
tGT(U/L) 35 2 0 26 38 4 4 3 4
GLDH (U/L) 1.0 2.3 1.8 ND ND 3.5
Appendix E-6. Plasma
F.
parameters in group 
hepatica infection)
A (4 weeks after
Animal number •
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
Total protein (g/1) 68 6 6 7 4 75 7 1 67
Albumin (g/1) 3 2 33 3 2 33 26 3 4
Globulin (g/1) 3 6 33 4 2 4 2 45 33
tGT(U/L) 65 4 6 67 6 0 53 4 9
GLDH (U/L) 3 5 6 2 7 6 53 2 4 9 168 137
Appendix E-7. Plasma
F
parameters in group A (6 
hepatica infection)
weeks after
Animal number
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
Total protein (g/1) 7 2 7 1 77 7 6 77 73
Albumin (g/1) 3 2 3 2 28 33 2 9 33
Globulin (g/1) 4 0 3 9 49 43 48 4 0
tGT(U/L) 5 9 5 4 6 0 61 67 66
GLDH (U/L) 149 1 00 133 2 0 9 2 3 2 124
2 6 2
Appendix E-8. Plasma parameters in group A (8 weeks after F
h e p a t i c a  infection)
Animal number
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
Total protein 7 0 6 7 7 6 7 4 7 8 7 6
(g/1)
Albumin (g/1) 3 0 3 0 2 8 3 1 2 7 3 2
Globulin (g/1) 4 0 3 7 4 8 4 3 5 1 4 4
tGT(U/L) 7 3 7 8 83 7 9 8 4 1 8 8
GLDH (U/L) 184 2 2 4 176 1 9 4 2 3 7 2 9 8
Appendix E-9. Plasma parameters in group A (10 weeks after F.
hepatica infection)
Animal number
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
Total protein 7 9 6 9 7 4 7 8 8 1 7 5
(g/1)
Albumin (g/1) 3 2 2 8 2 5 3 0 2 9 3 0
Globulin (g/1) 4 7 5 1 4 9 4 8 5 2 4 5
tGT (U/L) 2 2 9 2 2 7 2 8 4 2 4 5 188 221
GLDH (U/L) 3 05 157 2 2 4 2 3 4 2 5 4 6 9
2 6 3
Appendix E-10. Plasma parameters in group A (12 weeks after
F. hepatica  infection)
Animal number
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
Total protein 7 5 68 7 9 7 6 8 1 73
(g/1)
Albumin (g/1) 2 7 2 6 2 4 2 9 2 9 3 0
Globulin (g/1) 4 8 4 2 5 5 4 7 5 2 4 3
tGT(U/L) 2 6 0 9 0 185 2 0 8 1 6 2 114
GLDH (U/L) 154 3 1 132 113 137 85
Appendix E-11 . Plasma parameters in group A (14 weeks after
F. hepatica infection)
Animal number
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 00 0
Total protein 5 8 5 5 68 6 4 65 5 7
(g/1)
Albumin (g/1) 2 4 2 4 2 2 2 5 2 2 25
Globulin (g/1) 3 4 3 1 4 6 3 9 4 3 3 2
tGT(U/L) 103 5 6 119 9 8 7 9 7 5
GLDH (U/L) 14 1 2 2 4 5 4 2 2 5 7 2
2 6 4
Appendix E-12. Plasma parameters in group B (before F. hepat ica
infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Total protein 5 6 7 2 69 7 7 6 4 6 2
(g/1)
Albumin (g/1) 3 0 2 1 3 4 3 4 3 5 3 4
Globulin (g/1) 2 6 5 1 35 4 3 2 9 2 8
tGT (U/L) 3 8 3 4 3 2 4 0 3 6 3 7
GLDH (U/L) 4 .50 ND 7.10 0 .4 0 3 .40 4 .70
Appendix E-13. Plasma parameters in group B (4 weeks after
F. hepatica infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Total protein 65 7 5 77 8 0 8 4 7 0
(g/1)
Albumin (g/1) 3 0 33 3 2 3 6 3 1 3 4
Globulin (g/1) 35 4 2 4 5 4 4 53 3 6
tGT (U/L) 7 5 4 5 8 4 5 3 86 4 5
GLDH (U/L) 321 118 3 3 9 2 0 2 2 2 2 2 6 5
Appendix E-14 Plasma parameters in group B (6 weeks after F .
hepatica  infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Total protein 6 7 7 8 7 4 7 6 82 6 9
(g/1)
Albumin (g/1) 3 0 3 2 3 1 33 3 2 3 2
Globulin (g/1) 3 7 4 6 43 4 3 5 0 3 7
tGT (U/L) 6 9 3 9 55 5 0 7 1 4 9
GLDH (U/L) 5 9 1 3 2 9 9 2 8 1 8
2 6 5
Appendix E-15. Plasma parameters in group B (8 weeks after
F. hepatica  infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Total protein 6 4 6 9 7 0 7 3 7 0 6 4
(g/1)
Albumin (g/1) 3 0 3 1 3 0 33 3 0 3 0
Globulin (g/1) 3 4 3 8 4 0 4 0 4 0 3 4
tGT (U/L) 6 9 4 4 6 3 5 4 5 4 4 5
GLDH (U/L) 3 1 1 6 4 8 9 2 8 2 0
Appendix E-16. Plasma parameters in group B (10 weeks after
F. hepatica infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Total protein 63 7 2 7 4 7 2 7 1 6 2
(g/1)
Albumin (g/1) 3 2 3 2 3 3 3 5 3 2 3 2
Globulin (g/1) 3 1 4 0 41 3 7 3 9 3 0
tGT (U/L) 63 4 9 6 0 5 3 53 4 2
GLDH (U/L) 6 5 19 6 4 2 2 4 0 4 4
2 6 6
Appendix E-17. Plasma parameters in group B (12 weeks after
F. hepatica  infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Total protein 6 4 7 1 7 6 7 4 7 8 66
(g/1)
Albumin (g/1) 3 2 3 2 3 2 3 6 33 33
Globulin (g/1) 3 2 3 9 4 4 3 8 4 5 33
tGT (U/L) 9 5 6 6 109 7 1 1 0 0 7 4
GLDH (U/L) 8 1 3 4 2 1 4 3 7 1 3 9 108
Appendix E-18. Plasma parameters in group B (14 weeks after
F. hepatica infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Total protein 5 9 68 7 5 7 2 7 5 6 2
(g/1)
Albumin (g/1) 3 0 2 9 2 6 3 2 2 9 3 0
Globulin (g/1) 2 9 3 9 4 9 4 0 4 6 3 2
yGT (U/L) 104 7 0 5 1 7 4 8 8 7 0
GLDH (U/L) 8 .40 1.40 6 .40 1.10 12 .00 3.50
2 6 7
Appendix E-19. Plasma parameters in group C (8 weeks before
rafoxanide t r e a t m e n t ) __________
Animal number
7 8 7 791 793 7 9 4 7 9 5 7 9 6
Total protein 6 6 67 59 7 6 69 63
(g/1)
Albumin (g/1) 3 1 3 4 3 0 3 1 3 6 3 8
Globulin (g/1) 3 5 33 2 9 4 5 33 2 5
tGT (U/L) 3 2 3 4 21 3 2 2 8 2 2
GLDH (U/L) 2 .10 0 .90 2.40 ND 2.20 8 .60
Appendix E-20 Plasma parameters in group C (immediately
before rafoxanide treatment)
Animal number
7 8 7 7 9 1 7 9 3 7 9 4 7 9 5 7 9 6
Total protein 65 7 0 63 7 6 7 0 6 8
(g/1)
Albumin (g/1) 3 1 3 5 3 1 3 6 36 3 6
Globulin (g/1) 3 4 3 5 3 2 4 0 3 4 3 2
TGT (U/L) 3 2 3 5 27 3 7 3 1 3 7
GLDH (U/L) 3 .60 1.80 4 .10 2 .1 0 3.70 7 .60
Appendix E-21. Plasma parameters in group C (2 weeks after
rafoxanide treatment)
Animal number
7 8 7 791 7 9 3 7 9 4 7 9 5 7 9 6
Total protein 6 6 7 2 66 7 4 68 6 9
(g/1)
Albumin (g/1) 3 0 3 5 3 1 3 3 33 3 3
Globulin (g/1) 3 6 3 7 35 41 35 3 6
tGT (U/L) 3 0 3 2 2 9 4 0 3 1 3 6
GLDH (U/L) 4 .90 2 .60 2 .80 5 .4 0 19.20 6 .10
2 6 8
Appendix E-22. Plasma parameters in group C (4 weeks after
rafoxanide treatment)____________________
Animal number
7 8 7 7 91 7 9 3 7 9 4 7 9 5 7 9 6
Total protein 6 4 7 0 6 4 7 2 6 7 7 0
(g/1)
Albumin (g/1) 3 0 3 4 2 9 3 1 3 2 3 2
Globulin (g/1) 3 4 3 6 3 5 41 3 5 38
tGT (U/L) 3 8 3 9 41 4 9 3 6 41
GLDH (U/L) 4 .00 0 .20 2 .00 0 .70 5 .00 0 .00
Appendix E-23. Plasma parameters in group C (6 weeks after
rafoxanide treatment)
Animal number
7 8 7 791 7 9 3 7 9 4 7 9 5 7 9 6
Total protein 6 2 6 7 6 4 7 5 6 7 67
(g /U
Albumin (g/1) 3 1 3 4 3 2 3 5 3 4 2 9
Globulin (g/1) 3 1 33 3 2 4 0 33 3 8
tGT (U/L) 4 2 4 3 4 0 5 6 4 0 4 4
GLDH (U/L) 3 .80 4 .10 13.40 8 .00 6 .70 1.50
2 6 9
Appendix E-24. Plasma parameters in group C (8 weeks after
rafoxanide treatment)____________________
Animal number
7 8 7 7 91 7 9 3 7 9 4 7 9 5 7 9 6
Total protein 63 7 0 6 6 7 7 6 9 7 2
(g/1)
Albumin (g/1) 3 0 3 6 3 2 3 7 3 6 2 9
Globulin (g/1) 33 3 4 3 4 4 0 33 4 3
tGT (U/L) 43 5 0 4 8 6 2 4 8 5 6
GLDH (U/L) ND 3.90 19 .50 14 .60 2 2 .1 0 1.90
Appendix E-25. Plasma parameters in group C (10 weeks after
rafoxanide treatment)
Animal number
7 8 7 791 7 9 3 7 9 4 7 9 5 7 9 6
Total protein 6 2 6 7 65 73 6 6 7 3
(g/1)
Albumin (g/1) 28 3 2 3 1 3 3 33 2 8
Globulin (g/1) 3 4 3 5 3 4 4 0 33 3 5
tGT (U/L) 4 8 4 6 4 7 6 7 4 7 5 4
GLDH (U/L) 3 .20 ND 9.00 4.3 11.90 0 .60
2 7 0
Appendix E-26. Plasma concentrations of antipyrine in group A
(before F. hepatica  infection)
Animal number
Time
(hours )
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
0 .083 44.33 42.05 45 .6 6 44 .0 2 4 8 .2 0 36 .77
0.5 31.37 30.85 29 .18 24 .07 30 .45 25.11
1 20 .74 20.79 21 .3 4 14.92 2 2 .1 0 16.39
2 12.52 10.52 11.69 7 .14 15.20 6.58
3 8.35 7.21 6.46 3.53 10.70 3.73
4 6.06 4 .84 4 .42 2.03 8 .14 2 .22
6 2.76 1.40 2.07 0.63 4 .02 0 .68
8 1.48 1.12 1.09 0 .30 2 .29 0 .36
1 2 0 .32 0.23 0.27 0 .06 0 .59 0.13
2 4 0.00 0.00 0 .00 0 .0 0 0 .00 0 .00
Appendix E-27. Pharmacokinetic parameters of antipyrine in 
group A (before F. hepatica infection)
Animal number
7 85 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
Cpo (jig/ml) 50.23 4 5 .8 0 50 .4 2 5 0 .1 5 5 5 .1 0 39 .7 5
AUC (pg.h/ml) 81.77 7 1 .6 0 73 .37 4 7 .8 6 9 8 .4 4 4 8 .6 9
t l / 2 p  (h-l) 1.91 1.82 1.78 1.76 2.15 2 .04
Clb (ml/min.kg) 5.05 5.65 5\55 8 .42 4 .25 8.37
Vc (ml/kg) 497 .70 5 4 5 .9 0 4 9 5 .8 0 4 9 8 .5 0 4 5 3 .7 0 6 2 9 .0 0
V d ( a r e a ) ( m l /k g ) 836 .20 8 8 8 .8 0 865 .3 0 1019 .7 7 9 0 .4 0 14 7 7 .0
Vdss (ml/kg) 735 .40 7 2 7 .0 0 7 4 5 .2 0 7 8 7 .7 0 7 2 8 .8 0 8 5 7 .0 0
2 7 1
Appendix E-28. Plasma concentrations of antipyrine in group A
(4 weeks after F. hepatica  infection)
Animal number
T im e
(h o u rs )
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 100
0 .0 8 3 48 .45 5 2 .2 2 4 5 .8 2 5 0 .8 4 38 .6 9 47 .3 9
0.5 32 .19 33..73 30.11 30 .28 28 .13 31 .17
1 20 .36 2 8 .2 6 22.01 22.91 22 .3 6 22 .03
2 11.00 15.61 13.31 14.05 15.74 14.68
3 6.57 10.20 9.21 8.45 11.20 9 .72
4 3.85 6 .20 6.81 5 .27 8.13 6 .27
6 1.71 2 .83 3 .54 2 .55 3 .85 2 .98
8 0 .69 1.69 1.56 1.42 1.75 1.80
1 2 0 .20 0 .45 0 .57 0 .3 0 0 .47 0 .36
2 4 0 .00 0 .00 0 .00 0 .0 0 0 .0 0 0 .00
Appendix E-29. Pharmacokinetic parameters of antipyrine in 
group A (4 weeks after F. hepatica infection)
Animal number
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
Cpo (ng/ml) 53 .65 5 8 .0 0 50.51 5 7 .9 0 42 .93 5 2 .4 0
AUC (|ig.h/ml) 7 0 .69 97 .1 2 8 9 .0 4 83 .95 92 .7 6 88 .86
t l / 2 p  (h-l) 1.73 1.89 2 .10 1.80 2.11 1.89
Clb (ml/min.kg) 5 .78 4 .30 4 .62 4.93 4 .47 4.63
Vc (ml/kg) 4 6 6 .0 0 4 3 1 .0 0 4 9 5 .0 0 4 3 1 .8 0 5 8 2 .4 0 4 7 7 .1 0
V d ( a r e a ) ( m l /k g ) 8 6 1 .8 0 7 0 3 .0 0 8 3 8 .6 0 7 6 8 .9 0 7 5 6 .4 7 5 5 .9 0
Vdss (ml/kg) 6 8 0 .4 0 6 3 9 .6 0 7 5 3 .1 0 6 9 1 .4 0 7 3 8 .3 0 6 9 1 .9 0
2 7 2
Appendix E-30. Plasma concentrations of antipyrine in group A
(6 weeks after F. hepatica  infection)
Animal number
Time (hours) 7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
0 .083 51 .77 3 9 .3 2 4 4 .7 4 50 .1 7 46 .03 51 .9 6
0.5 32 .9 4 2 4 .3 0 3 4 .5 6 33 .2 3 2 9 .6 6 2 9 .78
1 25.81 16.20 2 1 .9 2 2 2 .6 9 19.66 2 1 .2 4
2 14.08 8.21 13.05 12 .56 15.00 12.97
3 7 .94 4.16 11.05 7.25 10.91 8.24
4 5.21 2 .56 7 .92 4 .08 7.05 5.15
6 2.07 0 .99 3.87 1.65 2.98 2.27
' 8 0.98 0 .44 2 .04 0 .80 1.88 0.97
1 2 0.25 0.11 0 .54 0 .24 0 .54 0.29
2 4 0 .00 0 .00 0 .00 0 .00 0.08 0 .00
Appendix E-31 Pharmacokinetic parameters of antipyrine in
group A (6 weeks after F hepatica infection)
Animal number
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
Cpo (pg/ml) 57 .46 4 3 .5 6 5 3 .8 0 53 .73 50.61 5 9 .5 7
AUC (lig.h/ml) 84 .29 51 .98 95 .8 9 7 6 .3 9 9 0 .9 4 7 9 .2 5
t l / 2 p  (h-l) 1.66 1.55 2 .12 1.76 2 .84 1.76
Clb (ml/min.kg) 4.93 7 .72 4 .36 5 .32 4 .46 5 .22
Vc (ml/kg) 4 3 5 .1 0 5 7 3 .9 0 4 6 4 .4 0 4 6 5 .3 0 4 9 4 .0 0 4 1 9 .7 0
V d ( a r e a ) ( m l /k g ) 7 0 8 .8 0 1034 .5 8 0 1 .8 0 8 1 0 .6 0 1096 .5 7 9 4 .8 0
Vdss (ml/kg) 6 3 1 .3 0 8 40 .6 0 7 2 3 .4 0 6 4 2 .8 0 9 1 0 .1 0 6 9 9 .1 0
2 7 3
Appendix E-32. Plasma concentrations of antipyrine in group A
(8 weeks after F. hepatica  infection)
Animal number
Time (hours) 7 85 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
0 .083 40 .7 0 50 .55 4 9 .5 0 57.61 4 6 .9 0 53 .83
0.5 29.67 29 .6 7 3 6 .3 0 3 5 .6 7 3 3 .9 8 3 6 .7 6
1 20.63 22.71 23 .45 27 .23 2 6 .5 8 2 4 .3 0
2 14.09 14.01 15.34 15 .34 16.38 18.85
3 9.09 10.07 10.46 9 .79 11.98 13.09
4 6.74 6.91- 6 .39 6 .62 8.93 12.31
6 2.72 2 .92 3.79 2.85 5 .29 6.23
8 1.43 1.65 1.57 1.68 2.77 4.18
1 2 0.41 0 .47 0.53 0 .42 0 .9 4 1.46
2 4 0 .00 0 .00 0 .00 0 .00 0 .00 0 .08
Appendix E-33 Pharmacokinetic parameters of antipyrine in
group A (8 weeks after F hepatica infection)
Animal number
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
Cpo (|J.g/ml) 43 .63 5 9 .9 4 50 .8 8 64 .5 5 4 9 .0 9 58.81
AUC (p.g.h/ml) 83 .97 9 0 .29 9 6 .6 0 9 8 .0 9 1 14 .0 0 1 34 .00
t l / 2 p  (h-l) 1.92 2.11 2 .10 1.87 2.83 2 .79
Clb (ml/min.kg) 4 .86 4.57 4.28 4.21 3 .64 3 .09
Vc (ml/kg) 5 7 3 .0 0 4 1 7 .1 0 4 9 1 .4 0 3 8 7 .3 0 5 0 9 .3 0 4 2 5 .1 0
V d ( a r e a ) ( m l /k g ) 8 1 0 .4 0 8 3 9 .0 0 7 8 4 .3 0 6 8 2 .5 0 8 9 2 .9 0 7 4 7 .2 0
Vdss (ml/kg) 7 4 2 .0 0 7 1 4 .0 0 6 6 5 .8 0 6 0 6 .6 0 7 4 6 .5 0 6 7 0 .4 0
2 7 4
Appendix E-34. Plasma concentrations of antipyrine in group A
(10 weeks after F. hepatica  infection)
Animal number
Time (hours) 7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
0.083 4 5 .3 0 39 .88 50 .0 8 4 0 .4 0 4 2 .9 6 4 7 .9 2
0.5 32 .77 26 .5 4 35 .6 7 27 .08 36 .13 29 .38
1 27 .03 23 .93 2 4 .0 0 21 .23 27 .5 7 21 .3 9
2 2 0 .22 13.12 15.95 14.20 19 .24 12 .54
3 12.54 6.72 15.85 9.36 15.47 8.28
4 9.99 3.68 12.52 6.95 11.40 5 .64
6 4 .16 2.48 5 .74 3 .54 4.56 2 .24
8 2.51 0.93 4 .50 1.72 2.56 1.22
1 2 0 .88 0.19 1.42 0 .52 0 .7 0 0 .30
2 4 0 .08 0 .00 0 .09 0 .04 0 .06 0 .04
Appendix E-35 Pharmacokinetic parameters of antipyrine in
group A (10 weeks after F. hepatica infection)
Animal number
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
Cpo (|lg/ml) 46 .13 40 .7 2 54 .09 41 .4 7 4 4 .6 0 49.71
AUC (lag.h/ml) 117 .43 73 .16 132 .38 87 .4 9 120 .80 79 .6 8
t l / 2 p  (h-l) 2.81 1.64 2.85 2.61 2 .64 2.65
Clb (ml/min.kg) 3.55 5.41 3 .12 4 .72 3.43 5 .12
Vc (ml/kg) 5 4 2 .0 613 .9 0 4 6 2 .2 0 6 0 2 .8 0 5 6 0 .6 0 5 0 2 .9 0
V d ( a r e a ) ( m l /k g ) 861 .7 7 6 5 .9 0 7 6 9 .4 0 1065 .2 7 8 4 .4 0 1175 .0
Vdss (ml/kg) 7 38 .2 7 1 7 .6 0 7 0 2 .9 0 8 9 0 .6 0 6 7 8 .2 0 8 4 7 .6 0
2 7 5
Appendix E-36. Plasma concentrations of antipyrine in group A
(12 weeks after F. hepatica  infection)
Animal number
Time (hours) 7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
0 .083 48 .83 4 9 .1 6 3 3 .7 4 5 2 .4 2 4 6 .4 4 4 6 .4 4
0.5 33 .1 2 3 0 .8 7 27 .6 9 30 .43 29.11 3 5 .8 6
1 25 .15 2 4 .1 2 23 .17 25 .41 22 .57 3 0 .9 6
2 15.45 15.33 15.90 15.77 13.52 2 3 .4 5
3 12.53 11.06 11.25 9 .46 8.44 12.23
4 8.47 7 .5 2 7.17 7 .56 5 .94 8.13
6 4.17 3 .77 3.83 3 .82 2 .89 4.21
8 2.57 2 .07 2.37 2 .17 1.43 ' 2 .39
1 2 0.85 0.55 0.71 0 .75 0.45 0.81
2 4 0 .04 0 .00 0.03 0 .00 0 .00 0 .00
Appendix E-37 Pharmacokinetic parameters of antipyrine in
group A (12 weeks after F. hepatica  infection)
Animal number
7 85 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
Cpo (|LLg/ml) 53 .29 5 5 .7 0 34 .39 60 .5 3 51 .98 4 6 .65
AUC (|ig.h/ml) 108 .10 98 .4 3 95 .7 4 100 .78 84.61 119 .4 0
t l / 2 p  (h-l) 2.51 2 .05 2 .54 2.21 1.97 2 .15
Clb (ml/min.kg) 3.81 4 .23 4.27 4 .17 4.91 3.41
Vc (ml/kg) 4 6 9 .1 0 4 4 8 .8 0 7 2 7 .0 0 4 1 3 .0 0 4 8 1 .0 0 5 3 5 .9 0
V d ( a r e a ) ( m l /k g ) 8 2 8 .6 0 7 4 9 .2 0 9 3 9 .2 0 8 0 0 .1 0 837 .2 0 6 3 8 .5 0
Vdss (ml/kg) 7 3 8 .7 0 6 9 7 .0 0 816 .3 0 7 2 7 .9 0 7 5 3 .4 0 5 8 8 .1 0
2 7 6
Appendix E-38. Plasma concentrations of antipyrine in group A
(14 weeks after F. hepat ica  infection)
Animal number
Time (hours) 7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
0 .083 4 4 .64 4 2 .8 0 4 2 .3 9 5 0 .46 4 3 .4 2 48 .0 2
0.5 29 .76 25 .0 7 27 .48 3 1 .29 33 .57 3 3 .5 4
1 24 .18 2 2 .6 2 22.81 23.21 27 .5 8 23 .67
2 15.55 13.16 14.94 13.69 24.21 13.85
3 10.37 7 .92 10.53 9.91 16.33 9.83
4 8.54 5.39 8.04 6.58 14 .04 7 .50
6 3.39 2.36 4 .39 3 .00 6.16 3.56
8 2 .09 1.27 3.01 1.78 5.98 1.78
1 2 0 .64 0.33 0 .86 0 .50 1.72 0.68
2 4 0 .04 0 .00 0 .04 0 .00 0.11 0 .00
Appendix E-39 Pharmacokinetic parameters of antipyrine in
group A (14 weeks after F. hepatica infection)
Animal number
7 8 5 7 9 0 7 9 2 8 0 0 9 9 9 1 0 0 0
Cpo (fig/ml) 4 5 .1 4 5 0 .3 4 4 7 .3 4 56.61 4 6 .6 2 5 1 .89
AUC (p.g.h/ml) 98 .34 7 7 .8 2 101.11 91.21 152.43 9 6 .1 0
t l / 2 p  (h-l) 2 .57 1.84 2.55 2 .02 2 .86 2.25
Clb (ml/min.kg) 4 .20 5.43 4.15 4 .52 2 .80 4.31
Vc (ml/kg) 5 5 3 .8 0 4 9 6 .6 0 5 2 8 .1 0 4 4 1 .6 0 5 3 6 .3 0 4 8 1 .8 0
V d ( a r e a ) ( m l /k g ) 9 3 3 .8 0 8 6 3 .2 0 9 1 8 .0 0 7 9 1 .2 0 6 9 3 .8 0 840 .1 0
Vdss (ml/kg) 7 8 7 .8 0 806 .3 0 8 5 1 .3 0 7 0 8 .3 0 6 7 7 .9 0 7 1 7 .0 0
Appendix E-40. Plasma concentrations of antipyrine in group B
(before F. hepatica  infection)
2 7 7
Animal number
T im e
(h o u r s )
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
0 .0 83 47 .49 39 .37 38.11 43.81 4 9 .2 6 38 .83
0.5 32.03 27 .0 0 23 .9 0 25.51 31 .8 7 34 .97
1 2 9 .3 2 19.96 17.53 19.04 24 .1 7 2 4 .3 0
2 15.07 13.53 8.40 11.19 16.80 15.93
3 10.59 9.73 4 .94 6 .97 10 .62 1 0 .6 2 .
4 7.71 7 .60 2.67 4 .59 7 .95 7 .29
6 4.11 3.99 1.05 1.83 3 .92 3 .59
8 1.85 2 .74 0.36 0 .98 2 .1 0 2 .16
12 0 .62 1.00 0.08 0 .25 0 .56 0 .66
2 4 0 .00 0 .00 0 .00 0 .0 0 0 .0 0 0 .05
Appendix E-41. Pharmacokinetic parameters of antipyrine in 
group B (before F, hepatica infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Cpo (|ig/ml) 51.71 4 2 .3 0 42.25 5 0 .0 6 5 5 .2 0 4 1 .8 6
AUC (lig.h/ml) 102.65 9 4 .5 2 53.31 6 8 .8 6 101 .10 99 .1 9
t l / 2 p  (h-l) 2 .18 2 .69 1.42 1.77 2 .04 2 .9 4
Clb (ml/min.kg) 4.13 4.43 7.69 6 .02 4 .12 4 .16
Vc (ml/kg) 4 8 3 .5 0 5 9 1 .0 0 5 91 .7 0 4 9 9 .4 0 4 5 2 .9 0 5 9 7 .3 0
V d ( a r e a ) ( m l /k g ) 7 8 0 .3 0 1031 .9 9 47 .10 9 2 3 .6 0 7 2 8 .2 0 1056 .3
Vdss (ml/kg) 6 7 5 .9 0 9 2 0 .9 0 822 .00 8 1 8 .4 0 6 7 8 .9 0 7 6 6 .9 0
2 7 8
Appendix E-42. Plasma concentrations of antipyrine in group B (4
weeks after F . hepatica infection)
Animal number
T im e
(h o u rs )
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
0 .0 8 3 35 .79 46 .65 4 3 .96 4 5 .3 0 39 .8 6 5 3 .1 2
0.5 2 6 .2 4 31 .47 26 .15 30 .58 29 .63 2 8 .5 2
1 16.71 21 .05 17.53 2 2 .4 4 24 .65 25 .88
2 9 .92 12.15 8 .24 16.25 14.68 17.47
3 6 .74 6.39 4 .08 10.68 9 .09 12.59
4 4.61 3.29 2.33 8.43 6 .64 9 .38
6 1.88 1.24 0 .58 4 .09 3 .29 7 .56
8 0 .92 0.71 0 .26 2.33 1.73 5 .25
1 2 0 .18 0 .16 0 .06 0 .49 0 .39 2 .1 2
2 4 0 .00 0 .00 0 .00 0 .00 0 .00 0 .1 4
Appendix E-43. Pharmacokinetic parameters of antipyrine in 
group B (4 weeks after F. hepatica  infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Cpo (|ig/ml) 51.71 5 0 .6 2 4 9 .1 0 50 .3 8 4 1 .7 2 64 .8 7
AUC (|lg.h/ml) 63 .65 69 .43 5 2 .6 4 99 .08 89.11 136 .48
t l / 2 p  (h-l) 1.73 1.57 1.34 2 .02 1.98 3 .17
Clb (ml/min.kg) 6 .50 5.75 7 .76 4 .20 4 .67 3 .12
Vc (ml/kg) 4 8 3 .5 0 4 9 3 .9 0 5 0 9 .2 0 4 9 6 .2 0 5 9 9 .2 0 3 8 5 .4 0
V d ( a re a ) (m l /k g ) 9 7 1 .2 0 7 8 3 .0 0 8 9 7 .8 0 7 3 6 .1 0 7 9 9 .4 0 8 5 7 .6 0
Vdss (ml/kg) 6 7 5 .9 0 6 5 7 .4 0 7 2 4 .2 0 6 9 8 .8 0 7 1 8 .8 0 8 0 6 .2 0
2 7 9
Appendix E-44. Plasma concentrations of antipyrine in group B (6
weeks after F. hepatica  infection)
Animal number
Time (hours) 7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
0.083 47.67 4 1 .57 45 .57 4 3 .55 38.91 5 0 .6 9
0.5 30.75 2 8 .1 5 2 3 .4 2 2 7 .5 0 2 9 .2 6 3 1 .76
1 23.03 19.97 15.82 21 .45 20 .83 2 7 .3 0
2 14.14 10.58 7.07 13.81 12.44 18.52
3 8.24 4 .46 2.85 8.27 7.85 12.73
4 5 .32 3.45 1.27 5 .89 4 .97 9 .64
6 2 .44 1.49 0 .42 2.63 2.81 5 .26
.8 1.40 0 .56 0.16 1.31 1.20 3.71
1 2 0 .39 0 .18 0.03 0 .46 0 .44 1.20
2 4 0 .00 0 .00 0 .00 0 .00 0.05 0 .09
Appendix E-45 Pharmacokinetic parameters of antipyrine in
group B (6 weeks after F hepatica infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Cpo (|ig/ml) 52 .70 4 3 .8 2 52 .6 6 48 .7 3 4 0 .5 6 6 3 .3 2
AUC (iig.h/ml) 83 .99 6 2 .9 7 4 5 .5 9 81 .6 7 7 8 .0 4 120 .38
t l / 2 p  (h-l) 1.90 1.75 1.23 1.97 2 .94 2 .92
Clb (ml/min.kg) 4.91 6.31 9.18 5 .12 5.08 3.47
Vc (ml/kg) 4 7 4 .4 0 5 7 0 .5 0 4 7 4 .7 0 5 1 3 .0 0 6 1 6 .3 0 3 9 4 .8 0
V d ( a r e a ) ( m l /k g ) 80 6 .4 0 9 5 4 .4 0 9 7 6 .1 0 8 7 4 .0 0 1292 .6 8 7 2 .6 0
Vdss (ml/kg) 7 1 4 .4 0 7 3 8 .1 0 7 4 2 .3 0 7 9 3 .5 0 9 0 0 .2 0 7 0 2 .6 0
2 8 0
Appendix E-46. Plasma concentrations of antipyrine in group B
(8 weeks after F. hepatica  infection)
Animal number
Time (hours) 7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
0.083 46 .6 4 4 8 .2 4 35 .13 4 4 .5 0 32 .9 8 55.51
0.5 29.05 3 4 .1 6 27 .3 7 2 5 .5 4 2 6 .7 6 34 .8 6
1 19.36 2 4 .7 9 20 .47 22 .8 3 23 .7 8 27 .5 9
2 9.24 13.27 11 .72 14 .06 15.06 16.77
3 6.24 12.13 6.92 9.53 8.95 12 .02
4 4.35 7.23 4.21 6 .08 5.55 9.57
6 1.85 3 .36 1.70 2.61 2 .10 5 .72
8 0 .99 2 .06 0.75 1.11 0.93 2.65
1 2 0 .26 0 .58 0.17 0.23 0.15 1.13
2 4 0 .00 0 .00 0 .00 0 .00 0 .00 0.07
Appendix E-47 Pharmacokinetic parameters of antipyrine in
group B (8 weeks after F hepatica  infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Cpo (| ig/ml) 50 .36 51 .6 3 37 .3 6 4 9 .2 8 3 5 .1 4 61 .88
AUC (jig.h/ml) 69 .02 9 8 .2 2 67 .2 9 8 1 .3 2 7 7 .5 0 120 .38
t l / 2 p  (h-l) 1.92 2 .15 1.69 1.68 1.52 2.73
Clb (ml/min.kg) 5 .89 4 .2 0 6.05 4 .9 4 5.41 3.45
Vc (ml/kg) 4 9 6 .4 0 4 8 4 .2 0 6 6 9 .2 0 5 0 7 .3 0 7 1 1 .5 0 4 0 4 .0 0
V d ( a r e a ) ( m l /k g ) 9 7 3 .9 0 7 8 0 .6 0 8 8 5 .4 0 7 1 7 .2 0 7 0 6 .5 0 8 1 3 .8 0
Vdss (ml/kg) 7 6 4 .6 0 6 8 0 .5 0 7 6 5 .3 0 6 6 5 .6 0 7 2 3 .3 0 7 2 1 .5 0
2 8 1
Appendix E-48. Plasma concentrations of antipyrine in group B
(10 weeks after F. hepatica  infection)
Animal number
Time (hours) 7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
0 .083 31.03 4 2 .8 7 4 3 .4 0 2 6 .8 2 4 6 .1 0 7 1 .7 0
0.5 30.17 29 .13 2 4 .9 4 2 3 .5 0 2 8 .9 8 36 .65
1 17.14 2 0 .3 7 15.81 19 .76 2 1 .4 0 21.91
2 10.05 8.73 6 .52 11 .56 13.33 15.06
3 7 .24 6.86 3.45 7.01 7.88 9.76
4 4.93 4.35 1.69 5 .07 5.61 7.75
6 1.70 1.76 0 .50 1.96 2 .42 3 .36
8 0.62 0 .74 0 .22 0.63 1.25 1.42
1 2 0.23 0.45 0 .05 0 .24 0 .35 0.28
2 4 0 .00 0 .00 0 .00 0 .0 0 0 .0 0 0 .00
Appendix E-49. Pharmacokinetic parameters of antipyrine in group B
(10 weeks after F. hepatica infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Cpo (|ig/ml) 33 .72 45 .51 48 .73 4 4 .6 0 5 1 .4 6 85 .4 4
AUC (jig.h/ml) 65 .03 6 9 .1 4 4 7 .0 0 6 5 .1 7 80 .08 98.01
t l / 2 p  (h-l) 2 .80 2 .17 1.34 1.78 1.86 1.75
Ulb (ml/min.kg) 6.28 5 .74 8.51 6.28 5 .16 4.15
Vc (ml/kg) 7 41 .5 0 5 4 9 .3 0 5 1 3 .0 0 5 6 0 .6 0 4 8 5 .8 0 2 9 2 .6 0
V d ( a r e a ) ( m l /k g ) 1519 .20 1 0 8 0 .5 0  9 8 6 .4 0 9 6 4 .8 0 8 3 3 .4 0 6 2 8 .7 0
Vdss (ml/kg) 867 .30 7 9 7 .9 0 7 4 7 .9 0 8 9 2 .5 0 7 4 5 .3 0 5 4 7 .8 0
2 8 2
Appendix E-50. Plasma concentrations of antipyrine in group B
(12 weeks after F. hepatica  infection)
Animal number
Time (hours) 7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
0 .083 41.03 45 .3 8 42.33 4 2 .6 7 45 .53 4 3 .2 9
0.5 29 .6 4 32.41 26 .37 29 .51 30 .68 36 .08
1 21 .37 2 2 .6 9 15.96 19.91 22 .17 29.31
2 9.45 13.83 9.02 11.43 13.24 18 .64
3 6.03 8.66 3.70 9 .64 8.84 15.63
4 3.36 6.55 1.91 5 .72 6.08 9.98
6 1.45 2.97 0.63 3 .6 0 3.15 4.71
8 0 .80 1.95 0.25 ' 1 .80 1.84 2 .14
1 2 0.28 0 .52 0.08 0 .47 0.55 0.95
2 4 0 .00 0 .00 0.00 0 .0 0 0.03 0.0.5
Appendix E-51 Pharmacokinetic parameters of antipyrine in
group B (12 weeks after F. hepatica infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Cpo (ng/ml) 44 .2 2 49.21 46 .65 4 7 .8 6 48 .13 4 4 .8 8
AUC (|ig.h/ml) 66 .34 89 .72 51 .22 83 .4 8 87 .90 120 .65
t l / 2 p  (h-l) 2 .54 2.17 1.41 2 .1 6 2.53 2.57
Clb (ml/min.kg) 6.19 4 .60 7.78 4 .96 4 .64 3.33
Vc (ml/kg) 5 6 5 .4 0 5 0 8 .0 0 5 35 .9 0 5 2 2 .4 0 5 1 9 .4 0 5 5 7 .0 0
V d ( a re a ) (m l /k g ) 1363.1 8 6 1 .6 0 9 51 .0 0 9 2 6 .4 0 1018.3 7 3 9 .9 0
Vdss (ml/kg) 7 8 7 .5 0 7 3 5 .2 0 7 3 7 .2 0 8 1 1 .3 0 81 4 .2 0 6 5 0 .2 0
2 8 3
Appendix E-52. Plasma concentrations of antipyrine in group B
(14 weeks after F. hepat ica  infection)
Animal number
Time (hours) 7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
0.083 56.31 32 .5 6 4 4 .1 2 5 8 .27 5 7 .1 9 47 .75
0.5 3 2 .96 26 .6 9 29 .23 28 .23 3 7 .4 0 3 3 .2 2
1 2 9 .0 0 2 2 .4 4 21 .43 22 .23 3 1 .8 9 2 5 .8 4
2 19.14 15.54 13.39 13.03 19 .34 17.58
3 15.42 9.55 8.97 7.78 14 .02 14.04
4 11.09 7.78 6 .40 5.35 11.18 10.74
6 5.71 4.35 3 .17 2 .54 6 .04 6.82
8 4.23 2.67 1.55 1.32 3 .94 4.95
1 2 1.84 0 .82 0 .40 0 .44 1.19 1.75
2 4 0 .00 0 .04 0 .00 0.05 0.05 0.09
Appendix E-53. Pharmacokinetic parameters of antipyrine in
group B (14 weeks after F. hepatica infection)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
Cpo (ng/ml) 66 .0 9 3 3 .3 0 4 8 .6 8 68 .5 9 6 1 .87 5 1 .1 0
AUC (jig.h/ml) 138 .76 96 .22 84 .93 8 3 .59 136 .98 135.45
t l / 2 p  (h-l) 2 .79 2.63 1.94 2.67 2.57 2.90
Clb (ml/min.kg) 3 .05 4.25 4 .85 5 .04 3.08 3.13
Vc (ml/kg) 3 7 8 .3 0 7 5 0 .8 0 5 1 3 .6 0 3 6 4 .5 0 4 0 4 .1 0 4 8 9 .2 0
V d ( a re a ) (m l /k g ) 7 3 8 .0 0 9 7 0 .8 0 8 1 5 .0 0 1164 .9 6 8 6 .5 0 7 8 4 .8 0
Vdss (ml/kg) 6 9 3 .0 0 86 3 .50 7 4 6 .0 0 9 1 4 .7 0 6 1 3 .4 0 7 3 1 .1 0
Appendix E-54. Plasma concentrations of antipyrine in group C
(8 weeks before treatment)
2 8 4
Animal number
Time
(hours )
7 8 7 791 7 9 3 7 9 4 7 9 5 7 9 6
0.083 39 .46 61 .00 38 .96 4 5 .24 4 1 .5 4 42 .53
0.5 30 .39 33.65 25 .43 27.93 24 .6 7 2 4 .9 0
1 19.61 23 .40 17.53 20 .5 2 17.05 19.60
2 13.17 14.57 11.17 12.31 8 .22 11.83
3 10.34 9.08 6.48 7 .86 4 .57 7.63
4 7.21 5.85 4 .40 5 .59 2.41 4 .65
6 3.37 2.81 1.59 2 .12 0 .73 2.15
8 2 .44 1.49 0 .95 1.22 0 .38 1.08
1 2 0 .78 0.48 0 .24 0.31 0 .07 0 .26
2 4 0 .00 0.00 0 .00 0 .00 0 .0 0 0 .0 0
Appendix E-55. Pharmacokinetic parameters of antipyrine in 
group C (8 weeks before treatment)
Animal number
7 8 7 7 9 1 7 9 3 7 9 4 7 9 5 7 9 6
Cpo (|ig/ml) 44.01 7 0 .3 2 42 .85 50 .81 46 .55 49 .0 7
AUC (|ig.h/ml) 91 .60 9 2 .19 65.23 7 6 .6 8 5 2 .4 2 7 1 .1 4
t l / 2 p  (h-l) 2 .47 1.97 1.78 1.83 1.40 1.78
Clb (ml/min.kg) 4 .60 4.47 6.27 5 .3 9 7 .80 5.85
Vc (ml/kg) 568 .0 0 3 5 5 .5 0 5 8 3 .4 0 4 9 2 .0 0 5 3 7 .0 0 5 0 9 .5 0
V d (a re a ) (m l /k g ) 984 .0 0 7 6 2 .8 0 9 6 3 .7 0 8 5 4 .9 0 9 4 6 .8 0 9 0 3 .1 0
Vdss (ml/kg) 8 6 9 .5 0 6 5 2 .2 0 8 4 7 .1 0 7 6 4 .7 0 7 8 5 .8 0 8 2 3 .7 0
2 8 5
Appendix E-56. Plasma concentrations of antipyrine in group C
(1 day prior to treatment)
Animal number
Time
(h o u rs )
7 8 7 791 7 9 3 7 9 4 7 9 5 7 9 6
0 .083 50.15 5 7 .0 4 40.13 44 .7 5 37 .92 4 6 .4 7
0.5 33 .60 35 .05 22 .82 31 .7 6 27 .66 30 .7 8
1 25 .47 21 .56 16.22 21.11 19.75 22.01
2 16.80 11.82 9.68 11 .90 11.17 13.98
3 12.73 7.56 6.87 7.91 6 .62 9 .52
4 8.48 4.96 3.42 4 .5 2 3 .69 6 .54
6 4.75 2 .22 1.60 1.70 1.19 3 .08
8 3.16 1.30 0.61 0 .85 0.45 1.17
12 0.83 0 .36 0.16 0.21 0 .09 0 .32
2 4 0 .00 0 .00 0 .00 0 .0 0 0 .00 0 .0 0
Appendix E-57. Pharmacokinetic parameters of antipyrine in 
group C (1 day prior to treatment)
Animal number
7 8 7 791 7 9 3 7 9 4 7 9 5 7 9 6
Cpo (M-g/ml) 55 .37 6 3 .84 4 6 .2 9 47 .53 40 .45 5 1 .4 0
AUC (p.g.h/ml) 112 .96 82.31 59 .0 8 7 4 .0 6 63 .27 85 .97
t l / 2 p  (h-l) 2 .30 2.01 1.63 1.74 1.40 1.80
Clb (ml/min.kg) 3.68 4.98 6.99 5.55 6 .42 4 .84
Vc (ml/kg) 4 5 1 .5 0 3 9 1 .6 0 5 4 0 .1 0 5 2 6 .0 0 6 1 8 .1 0 4 8 6 .4 0
V d (a re a ) (m l /k g ) 7 3 0 .5 0 8 6 5 .6 0 9 8 6 .7 0 8 3 8 .5 0 7 7 5 .5 0 7 5 6 .3 0
Vdss (ml/kg) 6 7 7 .8 0 6 6 8 .2 0 8 7 7 .2 0 6 8 8 .3 0 7 1 3 .1 0 6 9 2 .1 0
2 8 6
Appendix E-58. Plasma concentrations of antipyrine in group C
(2 weeks after treatment)
Animal number
T im e
(hours )
7 8 7 791 7 9 3 7 9 4 7 9 5 7 9 6
0 .083 45 .15 51 .24 4 6 .8 4 45.05 51 .3 8 37.91
0.5 32 .2 0 29.51 27 .22 28 .76 2 8 .29 25 .96
1 23 .67 20 .65 19.51 18.21 17.88 21 .28
2 17.12 10.16 9.81 9.27 8.83 11.67
3 12.56 5.11 5 .26 4.86 4 .26 6.97
4 9.50 3.18 3.38 2.78 2 .55 4 .74
6 5.45 1.29 1.31 1.21 0 .9 2 2 .42
8 2.93 0.61 0 .59 0.51 0 .33 1.31
12 0 .98 0 .16 0.11 0.15 0 .08 0.33
2 4 0 .00 0 .00 0 .00 0 .00 0 .0 0 0 .00
Appendix E-59. Pharmacokinetic parameters of antipyrine in 
group C (2 weeks after treatment)
Animal number
7 8 7 7 91 7 9 3 7 9 4 7 9 5 7 9 6
Cpo (p.g/ml) 48 .97 5 7 .8 2 5 3 .0 4 4 9 .1 8 58.51 3 9 .4 0
AUC (lig.h/ml) 113.51 6 5 .55 6 2 .4 0 5 9 .8 0 5 7 .6 0 7 3 .0 2
t l / 2 p  (h-l) 2 .40 1.60 1.51 1.70 1.42 2 .07
Clb (ml/min.kg) 3.66 6 .22 6.56 6 .74 7.03 5.63
Vc (ml/kg) 5 1 0 .5 0 4 3 2 .4 0 4 7 1 .3 0 5 0 8 .3 0 4 2 7 .3 0 6 3 4 .5 0
V d ( a r e a ) ( m l /k g ) 7 6 2 .0 0 8 6 3 .9 0 8 56 .40 9 9 3 .1 0 8 6 0 .4 0 1005 .2
Vdss (ml/kg) 7 1 5 .3 0 6 9 6 .0 0 7 2 9 .2 0 7 3 4 .6 0 6 7 6 .0 0 8 2 7 .9 0
2 8 7
Appendix E-60. Plasma concentrations of antipyrine in group C
(4 weeks after treatment)
Animal number
Time (hours) 7 8 7 7 91 7 9 3 7 9 4 7 9 5 7 9 6
0 .083 56 .9 0 5 5 .4 0 61.21 44.91 5 9 .9 0 40 .63
0.5 32 .9 4 25 .8 8 29 .21 2 8 .6 9 3 2 .1 6 2 7 .3 2
1 26.81 20 .6 8 19.25 2 0 .4 8 2 3 .3 9 21 .28
2 15.43 13.26 13.29 10.81 11.33 14.45
3 13.31 7 .10 7 .97 6 .46 7 .28 10.15
4 10.81 3 .78 5 .69 4.31 4.21 7.55
6 4.91 1.54 2 .30 1.78 1.93 4 .24
8 2 .97 0 .84 1.27 0 .72 0.93 1.96
1 2 1.53 0 .17 0.35 0 .19 0 .20 0 .50
2 4 0.08 0 .00 0 .00 0 .00 0 .00 0 .00
Appendix E-61 Pharmacokinetic parameters of antipyrine in
group C (4 weeks after treatment)
Animal number
7 8 7 791 7 9 3 7 9 4 7 9 5 7 9 6
Cpo (p.g/mi) 65 .26 69 .48 74 .0 5 4 9 .6 0 64 .9 5 45 .53
AUC (p.g.h/ml) 123.61 7 2 .0 4 81 .73 6 8 .9 6 7 7 .4 6 9 1 .3 4
t l / 2 p  (h-l) 2 .83 1.59 1.89 1.64 1.65 2 .06
Clb (ml/min.kg) 3 .40 5 .86 5 .06 5 .90 5 .28 4 .57
Vc (ml/kg) 3 8 3 .1 0 3 5 9 .8 0 3 3 7 .6 0 5 0 4 .0 0 3 8 4 .9 0 5 4 9 .1 0
V d ( a r e a ) ( m l /k g ) 8 3 2 .8 0 8 0 7 .9 0 8 2 6 .2 0 8 3 9 .0 0 7 5 5 .3 0 8 1 4 .1 0
Vdss (ml/kg) 7 4 8 .4 0 7 1 3 .3 0 7 0 3 .1 0 7 2 8 .4 0 8 9 0 .6 0 7 7 7 .7 0
E-62. Plasma concentrations of antipyrine in group C
(6 weeks after treatment)
2 8 8
Animal number
Time (hours) 7 8 7 7 9 1 7 9 3 7 9 4 7 9 5 7 9 6
0.083 48 .45 4 5 .2 9 3 7 .2 6 4 2 .9 6 4 8 .0 6 45 .65
0.5 38.21 23 .73 2 5 .2 2 2 4 .8 9 25 .83 2 6 .3 0
1 19.89 2 0 .3 9 17 .74 17.05 11.77 2 2 .5 0
2 16.29 6.85 7.07 7.05 7.13 16.77
3 10.82 4 .26 3 .29 3 .52 3 .78 12.01
4 8.46 2 .28 1.94 1.53 1.96 9 .30
6 4 .77 0 .99 0 .49 0 .6 4 0.65 5.47
8 2.73 0 .5 0 0 .26 0 .27 0 .29 2.18
1 2 0 .94 0 .09 0 .04 0 .07 0 .10 0 .84
24 0 .08 0 .0 0 0 .00 0 .00 0 .00 0.03
E-63. Pharmacokinetic parameters of antipyrine in group C
(6 weeks after treatment)
Animal number
7 8 7 7 9 1 7 9 3 7 9 4 7 9 5 7 9 6
Cpo ((ig/ml) 46.81 4 5 .9 3 3 9 .6 0 4 8 .1 6 5 4 .7 0 56.41
AUC (|ig.h/ml) 108 .20 54 .4 5 48 .08 4 8 .7 7 4 7 .6 2 105 .67
t l / 2 p  (h-1) 2 .96 1.72 1.63 1.42 1.55 2 .40
Clb (ml/min.kg) 3.85 7 .6 0 8.53 8 .32 8.11 4.03
Vc (ml/kg) 5 3 4 .1 0 5 4 4 .3 0 6 3 1 .3 0 5 1 9 .1 0 4 5 7 .0 0 4 4 3 .2 0
V d ( a r e a ) ( m l /k g ) 9 8 6 .4 0 1 129 .9 1204 .2 1 0 21 .0 1088 .6 8 3 7 .1 0
0 0
Vdss (ml/kg) 8 0 7 .8 0 7 6 0 .5 0 7 3 9 .7 0 7 7 3 .6 0 7 6 1 .5 0 7 9 8 .7 0
2 8 9
Appendix E-64. Plasma concentrations of antipyrine in group C (8
weeks after treatment)
Animal number
Time (hours) 7 8 7 791 7 93 7 9 4 7 9 5 7 9 6
0 .083 3 2 .4 4 57 .3 2 57.23 43 .1 8 41 .6 5 56.51
0.5 29.71 30 .06 30 .79 2 2 .59 2 4 .18 3 5 .5 0
1 2 3 .29 17.01 18.01 16 .54 16.87 24 .0 9
2 15.60 9.20 6.87 8.13 6 .43 17.00
3 9.83 5 .99 2.73 4 .0 0 3.95 11.40
4 7 .79 3.76 1.71 2.43 1.88 9.23
6 3.96 1.32 0 .50 1.09 0 .69 5.27
8 2 .00 0 .74 0 .22 ' 0 .48 0 .26 3.16
1 2 0 .66 0.21 0.05 0 .12 0.07 0 .69
2 4 0 .04 0 .00 0 .00 0 .00 0 .00 0 .00
Appendix E-65 Pharmacokinetic parameters of antipyrine in
group C (8 weeks after treatment)
Animal number
7 8 7 791 7 9 3 7 9 4 7 9 5 7 9 6
Cpo (|ig/ml) 34 .59 66 .07 65 .02 5 0 .1 0 4 6 .3 7 63 .47
AUC (^g.h/ml) 9 4 .5 0 65 .99 53.91 5 2 .2 2 4 8 .4 4 114 .05
t l / 2 p  (h-l) 2 .86 1.74 1.33 1.59 1.57 2.23
Clb (ml/min.kg) 4.41 6 .04 7.33 7.93 8 .42 3 .62
Vc (ml/kg) 7 2 2 .8 0 3 7 8 .4 0 3 8 4 .5 0 4 9 9 .0 0 5 3 9 .3 0 3 9 3 .9 0
V d ( a r e a ) ( m l /k g ) 1094 .4 9 1 0 .2 0 8 44 .9 0 1091 .3 1143 .5 6 9 8 .9 0
Vdss (ml/kg) 8 3 8 .5 0 6 9 9 .6 0 5 8 2 .2 0 8 8 2 .7 0 7 6 2 .0 0 6 3 7 .0 0
2 9 0
Appendix E-66. Plasma concentrations of antipyrine in group C
(10 weeks after treatment)
Animal number
Time (hours) 7 8 7 79 1 7 9 3 7 9 4 7 9 5 7 9 6
0 .083 4 5 .7 4 4 8 .99 61.78 52 .13 52 .53 55 .43
0.5 27 .37 32 .47 25 .97 24 .55 2 6 .7 8 3 4 .5 9
1 26 .2 6 23 .4 7 18.50 15.23 2 0 .9 0 2 6 .5 7
2 16.08 13.51 9 .12 7.61 9.75 19.83
3 10.31 9 .62 3.58 4 .00 3 .82 15 .04
4 7 .12 6 .40 2.56 2 .76 2.91 11.73
6 4.91 3.19 0 .96 1.14 1.04 7 .27
8 2.53 1.86 0 .44 0.53 ' 0 .46 4 .34
1 2 0.75 0 .62 0.13 0 .09 0 .08 1.30
2 4 0.05 0.06 0 .00 0 .00 0 .00 0.08
Appendix E-67 Pharmacokinetic parameters of antipyrine in
group C (10 weeks after treatment)
Animal number
7 8 7 791 7 9 3 7 9 4 7 9 5 7 9 6
Cpo (ng/ml) 5 2 .6 9 51 .55 75 .48 62 .05 61.61 6 3 .1 2
AUC (}ig.h/ml) 102 .56 9 2 .8 4 59 .62 5 4 .0 0 6 1 .0 6 138 .38
t l / 2 p  (h-l) 2 .76 2 .84 1.57 1.54 1.42 2 .74
Clb (ml/min.kg) 4.13 4 .34 7.06 7 .47 6 .89 3.03
Vc (ml/kg) 4 74 .5 4 8 5 .0 0 3 3 1 .2 0 4 0 2 .9 0 4 0 5 .8 0 3 9 6 .1 0
V d ( a r e a ) ( m l /k g ) 9 3 1 .6 0 1066.1 9 5 9 .8 0 9 9 5 .9 0 8 4 7 .8 0 7 1 8 .7 0
Vdss (ml/kg) 8 5 4 .5 0 8 1 2 .1 0 7 1 1 .6 0 7 7 5 .6 0 6 9 7 .6 0 6 7 3 .1 0
2 9 1
Appendix E-68. Mean clearance 
indices in different animal groups
Clearance
In d e x
4 weeks
Group A 0.77
Group B 1.06
Group C 0.95
6 weeks
Group A 0.85
Group B 1.14
Group C 1.05
8 weeks
Group A 0.66
Group B 1.00
Group C 0.88
10 weeks
Group A 0.68
Group B 1.20
Group C 1.18
12 weeks
Group A 0.66
Group B 1.06
Group C 1.10
14 weeks
Group A 0.68
Group B 0.78
Group C 0.96
2 9 2
Appendix E-69. Plasma concentrations of rafoxanide in group B
( in fected )
Animal number
Time (days) 7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
0 0 .00 0 .00 0 .00 0 .00 0 .0 0 0 .00
1 17.96 22 .78 14.72 13.94 20 .11 16.51
2 20 .53 22 .86 19.76 16.08 19.23 17.41
3 19.93 22 .15 20 .53 15.10 19 .82 19.34
4 20.41 19.36 2 0 .7 6 14.40 18 .07 18.29
8 17.39 14.44 14.39 12.24 14.13 15.27
1 2 13.16 11.58 11.81 9 .72 11 .60 12.95
1 9 7 .84 8.18 6 .80 7.01 7 .36 7.43
2 7 1.24 5.81 5.79 5 .09 3.11 3.97
33 2.07 4.13 2.91 3 .89 2.21 2.48
3 9 1.24 2.48 1.96 2.53 2.43 1.43
47 0 .99 1.22 1.31 1.57 0.71 0.73
5 2 0 .72 0.99 0.67 1.37 0 .52 0.43
63 0 .38 0.46 0.48 0 .82 0 .29 0.19
7 0 0 .24 0.28 0.28 0.57 0.21 0.15
7 6 0 .18 0.16 0.25 0.33 0.13 0.05
Appendix E-70. Pharmacokinetic parameters of rafoxanide group B
(infec ted)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
AUC obs(l^g-d/ml) 35 7 .68 4 0 4 .0 9 3 7 3 .0 0 3 46 .0 3 3 4 5 .0 3 350.71
AUMCobsCM'g-d^/ml) 4 8 1 6 6 5 2 3 5 8 7 3 6 5 3 9 4 9 7 7 4 9 1 5
MRT (d) 13.46 16.14 15.75 18.89 14 .42 14.02
Cmax (|ig/ml) 20 .53 22 .8 6 2 0 .76 16.08 20 .11 19.34
tmax (d) 2 .00 2 .00 4 .00 2 .00 1 .00 3.00
2 9 2
Appendix E-69. Plasma concentrations of rafoxanide in group B
(in fected )
Animal number
Time (days) 7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
0 0 .00 0 .00 0 .00 0 .00 0 .00 0 .0 0
1 17.96 2 2 .78 14.72 13.94 20.11 16.51
2 20.53 2 2 .8 6 19.76 16.08 19.23 17.41
3 19.93 22 .15 20.53 15 .10 19.82 19 .3 4
4 20.41 19.36 20 .76 14.40 18.07 18 .29
8 17.39 14 .44 14.39 12 .24 14.13 15 .27
12 13.16 11.58 11.81 9 .72 11.60 12.95
1 9 7 .84 8 .18 6.80 7.01 7.36 7 .43
2 7 1.24 5.81 5.79 5 .09 3.11 3 .97
33 2.07 4.13 2.91 3 .89 2.21 2 .48
3 9 1.24 2 .48 1.96 2.53 2.43 1.43
4 7 0.99 1.22 1.31 1.57 0.71 0 .73
5 2 0 .72 0 .99 0.67 1.37 0 .52 0 .43
63 0.38 0 .46 0.48 0 .82 0 .29 0 .19
7 0 0 .24 0 .28 0.28 0 .57 0.21 0 .15
7 6 0.18 0 .16 0.25 0 .33 0.13 0 .05
Appendix E-70. Pharmacokinetic parameters of rafoxanide group B
(infec ted)
Animal number
7 8 6 7 8 8 7 8 9 7 9 7 7 9 8 7 9 9
AUC obs(llg.d/ml) 3 57 .68 4 0 4 .0 9 3 7 3 .0 0 34 6 .0 3 34 5 .03 3 50 .71
AUMCobs(l ig.d2/ml) 4 8 1 6 6 5 2 3 5 8 7 3 6 5 3 9 4 9 7 7 4 9 1 5
MRT (d) 13.46 16.14 15.75 18.89 14.42 14 .02
Cmax (| ig/ml) 20 .53 22 .8 6 2 0 .7 6 16.08 20.11 19 .34
tmax (d) 2 .00 2 .00 4 .00 2 .00 1.00 3 .0 0
2 9 3
Appendix E-71. Plasma concentrations of rafoxanide in group C
(u n in fec ted )
Animal number
Time (days) 7 8 7 791 7 9 3 7 9 4 7 9 5 7 9 6
0 0 .0 0 0 .00 0 .00 0 .00 0 .00 0.00
1 17.83 17.15 24 .58 17.65 2 0 .6 0 15.20
2 17.59 2 0 .3 2 27.41 19.16 18.27 21 .16
3 17.59 2 2 .3 2 24 .8 7 18.25 17 .54 23 .28
4 16 .72 2 1 .38 2 2 .0 4 17.12 16 .10 19.00
8 14.27 17.11 16.11 13.11 10.85 14.72
1 2 12.79 13.62 11.52 10.36 7 .96 12.76
1 9 9 .59 8.00 7.77 6.22 4.28 7 .60
2 7 6 .52 4 .89 5 .10 3.69 2.33 5.41
33 5 .52 3.53 2.29 2.17 1.43 3.71
3 9 3 .94 1.72 1.17 1.36 0.71 2.11
4 7 2 .44 0 .89 0 .70 0.76 0.28 1.42
5 2 1.98 0.85 0 .40 0.58 0.18 1.20
63 1.12 0 .40 0.37 0.29 0.07 0.82
7 0 0 .79 0 .3 2 0 .26 0.21 0 .04 0.66
7 6 0 .54 0.23 0 .14 0.16 0.03 0.55
Appendix E-72. Pharmacokinetic parameters of rafoxanide group C
(un in fec ted)
Animal number
7 8 7 791 7 9 3 7 9 4 7 9 5 7 9 6
AUC obs(^g-d/ml) 4 4 9 .0 4 4 0 3 .0 0 3 8 9 .0 0 3 1 6 .0 0 2 5 0 .0 0 4 0 0 .0 0
AUMCobs(^g-d2/ml) 9 0 2 8 6 0 6 8 5 2 3 4 4 5 4 0 2 8 9 6 6 8 7 0
MRT (d) 20.11 15.06 13.46 14.35 11.58 17.16
Cmax (|ig/ml) 17.83 22 .3 2 27.41 19.16 2 0 .6 0 23.28
tmax (d) 1.00 3 .00 2 .00 2 .00 1.00 3.00
